{
  "doc_id": "dlcg_pal_onkogen_dreven_nsclc_v.1_admgodk_010724",
  "created_date": "2024",
  "country": "DK",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
<<<<<<< HEAD
      "text": "Klinisk\nPallie\nonko\nSkabelo\nk Retnings\neren\nogen\non v. 9.1\nslinje\nnd\nn-d\n│Kræ\nde o\ndre\næft\non\nev\nnko\nven\nol\nn i\nlog\nikk\ngis\nke\nKLINISK\nsk behand\ne-småcelle",
=======
      "text": "Clinical Pallie onko Klevelo k Directions eren anden on v. 9.1 sline nd n-d",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Version 1.0",
<<<<<<< HEAD
      "text": "GODKENDT\nFaglig godkendelse\n24. juni 2024 (DLCG)\nAdministrativ godken\n1.juli 2024 (Sekretaria\nRetningslinjer på Kræf",
=======
      "text": "Approved Professional approval 24 June 2024 (DLCG) Administrative approval 1 July 2024",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "REVISION",
<<<<<<< HEAD
      "text": "Planlagt: 1. juni 2025",
=======
      "text": "Scheduled June 1, 2025",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 1,
      "end_page": 1
    },
    {
<<<<<<< HEAD
      "heading": "INDEKSERING",
      "text": "DOLG, NSCLC, Onkog\nbehandling\nDMCG\nKE RETNINGSLINJER | KRÆFT\ndling af\net lungekræft\nndelse\natet for Kliniske\nftområdet)\ngen-dreven, pallierende\nKlinisk Retningslinje │Kræft",
=======
      "heading": "INDECTION",
      "text": "DOLG, NSCLC, Oncook Treatment DMCG KE GUIDELINES CANCER OF Lung cancer atet for Clinical FtRange) re-driven, palliative Clinical Guideline • Application",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 1,
      "end_page": 2
    },
    {
<<<<<<< HEAD
      "heading": "Indholdsfortegnelse",
      "text": "1. Anbefalinger (Quick guide) .....................................................\nPallierende 1. linje onkologisk behandling af onkogen-drev\nPallierende 2. linje onkologisk behandling af onkogen-drev\nFlow chart for behandling ..................................................\n2. Introduktion ............................................................................\n3. Grundlag ................................................................................\nPallierende 1. linje onkologisk behandling af onkogen-drev\nPallierende 2. linje onkologisk behandling af onkogen-drev\n4. Referencer .............................................................................\n5. Metode ...................................................................................\n6. Monitorering ...........................................................................\n7. Bilag .......................................................................................\nBilag 1 – Søgestrategi .......................................................\nBilag 2 - Forkortelser og forklaringer .................................\nBilag 3 - Vejledning i ansøgning om enkelt-patient ibrugtag\ntilgængelig i DK) dyre lægemidler som enten er afvist af e\n8. Om denne kliniske retningslinje ..............................................\nven ikke-sm\nven ikke-sm\nven ikke-sm\nven ikke-sm\ngning af EM\neller ikke-vu\nDLCG\nmåcellet lungekræft .....\nmåcellet lungekræft .....\nmåcellet lungekræft .....\nmåcellet lungekræft .....\nMA (og evt. FDA) godk\nurderet i MR: ................\nG\nkendte\ne (og\nKlinisk\n1. A\nPallie\nsmåc\n1. Pa\nud\nme\n2. Pa\nka\n3. Pa\nlin\n4. Pa\nbe\n5. Pa\nke\n6. Pa\nlin\ndre\n7. Pa\nam\nke\nret\n8. Pa\nlin\nNS\n9. Pa\ntilb\n10. Pa\nlin\nRetningslinje │Kræft DLCG\nAnbefalinger (Quick guide)\nerende 1. linje onkologisk behandling af onkogen-dreven ikke-\ncellet lungekræft\natienter med inkurable pulmonale adenokarcinomer og NSCLC NOS samt enkelte\ndvalgte patienter med inkurabel pulmonal planocellulært karcinom bør udredes\ned et targeteret NGS-panel indeholdende retningslinjens beskrevne varianter\natienter med klassiske aktiverende EGFR mutationer og performance status 0-3\nan tilbydes 1. linje behandling med osimertinib (A)\natienter med ALK translokation og performance status 0-3 kan tilbydes 1.\nnjebehandling med ALK-TKI (brigatinib, alectinib eller lorlatinib) (A)\natienter med ROS1 translokation og performance status 0-3 kan tilbydes 1. linje\nehandling med entrectinib, alternativt crizotinib (B)\natienter med RET translokation og PS 0-2 kan tilbydes 1. linje platinholdig\nemoterapi. Overvej selpercatinib efter godkendelse i regionale medicinudvalg. (A)\natienter med aktiverende BRAF V600E og performance status 0-2 kan tilbydes 1.\nnje behandling med kemoterapi +/- immunterapi i henhold til non-onkogen\neven NSCLC retningslinjer (A)\natienter med aktiverende MET exon 14 skipping varianter eller MET\nmplifikation og performance status 0-2 kan tilbydes 1. linje behandling med\nemoterapi +/-immunterapi i henhold til non-onkogendreven NSCLC-\ntningslinjer (A)\natienter med aktiverende KRAS G12C og performance status 0-2 kan tilbydes 1.\nnje behandling med kemoterapi +/-immunterapi i henhold til non-onkogendreven\nSCLC-retningslinjer (A)\natienter med aktiverende EGFR exon20 ins / HER2 /NTRK-varianter og PS 0-2 kan\nbydes 1. linje behandling med platinbaseret kemoterapi (A)\natienter med øvrige sjældne aktiverende EGFR-varianter og PS 0-2 kan tilbydes 1.\nnje behandling med osimertinib (B)\nKlinisk R\nPallie\nsmåc\n11. Pa\nsys\nba\n12. Pa\npro\nke\n13. Pa\npro\nbe\n14. Pa\nbe\n15. Pa\nbe\ntilb\nen\nme\n16. Pa\nam\nke\nell\ncri\n17. Pa\nbe\ntilb\nreg\n18. Pa\npe\ngo\nen\n19. Pa\n2 o\npla\nRetningslinje │Kræft DLCG\nerende 2. linje onkologisk behandling af onkogen-dreven ikke-\ncellet lungekræft\natienter med klassiske aktiverende EGFR mutationer og performance status 0-2 og\nstemisk progression (efter re-biopsi) kan tilbydes 2. linje behandling med platin-\naseret kemoterapi (A)\natienter med ALK translokation og performance status 0-2(3) og systemisk\nogression (efter rebiopsi), kan tilbydes 2.-3. linje behandling med lorlatinib eller\nemoterapi (A-B)\natienter med ROS1 translokation og performance status 0-2 og systemisk\nogression og ingen mulighed for yderligere ROS1 rettet TKI, kan tilbydes 2. linje\nehandling med platinbaseret kemoterapi (A)\natienter med RET translokation og performance status 0-1 kan tilbydes 2. linje\nehandling med selpercatinib (A)\natienter med aktiverende BRAF V600E og performance status 0-2(3) og tidligere\nehandlet med platinbaseret kemoterapi og immunterapi (hvor relevant) kan\nbydes 2. (3.) linje behandling med dabrafenib plus trametinib, alternativt\nncorafenib plus binimetinib efter godkendelse af afdelingsledelsen/ regionale\nedicinudvalg (B)\natienter med aktiverende MET exon 14 skipping mutation eller MET\nmplifikation og performance status 0-2 og tidligere behandlet med platinbaseret\nemoterapi +/- immunterapi kan tilbydes 2 (3). linje behandling med capmatinib\nler tepotinib efter godkendelse ved regionale medicinudvalg, alternativt\nizotinib (B/C)\natienter med aktiverende KRAS G12C og performance status 0-2 og tidligere\nehandlet med platinbaseret kemoterapi og immunterapi (hvor relevant) kan\nbydes 2 (3). linje behandling med sotorasib eller adagrasib efter godkendelse i\ngionale medicinudvalg (A)\natienter med aktiverende EGFR exon20 ins / ERBB2 (HER 2) / NTRK-varianter og\nerformance status 0-1 kan tilbydes 2. linje behandling i henhold til EMA\nodkendt behandling af matchet variant (amivantamab / trastuzumab-deruxtecan /\nntrectinib eller larotrectinib efter godkendelse i regionale medicinråd (A/B/B)\natienter med øvrige sjældne aktiverende EGFR-varianter og performance status 0-\nog systemisk progression (ved rebiopsi) kan tilbydes 2. linje behandling med\natin-baseret kemoterapi +/- immunterapi (A)\nKlinisk Retni\ningsl\nlinje │Kræ\næft\nFlow\nw chart for be\nehan\nDMCG\nndling",
=======
      "heading": "Contents",
      "text": "(1) Recommendations (Quick guide) ............................................ palliative 1st line oncology of oncoke drive Palliating 2nd line onkology of Oncoke Drive Flow chart for treatment ......................................................................... 2. Introduction ........................................................ 3. Basis .......................................................................... .Palliating 1st Line oncogen Drive Oncogenic Drive Palliative 2nd Line onkological Treatment of Oncogen Drive 4. References .................................................................. 5. Method .................................... MA (and possibly FDA) approved in MR: ................ G known e (and Clinical 1. A Pallie småc 1. Pa ud me 2. Pa ka 3. Pa lin 4. Pa be 5. Pa ke 6. Pa lin ere 7. Pa ek ret 8. Pa lin NS 9. Pa tilb 10. Pa lin Guideline • Kræft DLCG Recommendations (Quick guide) remaining 1st line oncologic treatment of oncogen-driven non-cell lung cancer atients with incurable pulmonary adenocarcinomas and NSCLC NOS as well as single dselected patients with incruable pulmonaial squamous carcinoma should be provided with a targetized NGS panel containing the described variants of ALK-TKI (brigatinib, alectinib or inib status 0-3 an offered 1st-line treatment with osimaterinib (A) atient translocation and performance status 0-3 can be offered 1. nje treatment with ALK. The 15th-line eaction with entrectinib, alternatively crizotinib (B) atients with RET translocation and PS 0-2 can be offered 1st-line platinum-containing emotherapy. Consider selfpercatinib after approval in regional drug selection. (A) atients with activating BRAF V600E and performance status 0-2 may be offered 1.-line treatment with chemotherapy +/- immunotherapy according to non-oncogen even NSCLC guidelines (A), atientes with activated MET exon 14 skipping variants or MET amplification and performance Status 0-2 are offered 1 st-line therapy with chemotherapy +/ -immune therapy according to the non-Oncogen-driven NSclC guideline (A). Pa 2 o pla versus bra versus abbreviated 0-2 and performance status (after re-biopsy) can be offered 2nd line treatment with platinum-based chemotherapy (A) atients with ALK translocation and performance 0-2(3) and systemic ogression (after repeat biopsy), can be provided 2nd-line treatment with RET translocation or performance (A-B) atients with ROS1 translocation, and performance progress status 0-2, and no possibility of further ROS1, directed TKI, can be available 2nd Line treatment with Platinated chemotherapy and immunotherapy (where applicable) can follow 2nd row eaction with selfpercatinib (A), atienter with activating BRAF V600E and performance Status 0-2 ((3), and previously dealt with platinum based chemotherapy, and immunotherapeutic (where relevant) may be offered after 2nd class treatment with placebo. adadrasib after approval in regional medicine committee (A) atients with activating EGFR exon20 ins / ERBB2 (HER 2) / NTRK variants and training status 0-1 can be offered 2nd line treatment according to EMA odd treatment of matched variant (amivantamab / trastuzumab-deruxtecan / ntrectinib or larotractinib after approval by regional medicine council (A/B/B) at clients with other rare activation EGFR variants and performance status 0and systemic progression (by re-biopsy) can be provided 2nd-line treatment with atin-based chemotherapy +/- immunotherapy (A). Clinical Retinigingsl line",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 2,
      "end_page": 5
    },
    {
<<<<<<< HEAD
      "heading": "2. Introduktion",
      "text": "Onkogen-dreven lungecancer er en yderst heterogen og biologisk ustabil kræftsygdom med mange forskellige\nbehandlingsmuligheder. Gruppen af patienter udgør ca. 60 % af alle patienter med pulmonale\nadenocarcinomer. Behandlingsmulighederne er komplekse og baseret på genomisk profilering af patienternes\ntumores og/eller frit tumor DNA i blod (ctDNA). Forståelsen af de molekylærbiologiske mekanismer er i rivende\nudvikling efter indførelsen af next-generation-sequencing (NGS). Udviklingen går mod en behandling,\nskræddersyet til de enkelte gen-fejl (varianter); –en EGFR mutation skal behandles helt forskelligt ud fra\nhvilken protein-ændring genfejlen (varianten) i EGFR genet medfører (f.eks. EGFR exon 19 del versus EGFR\nexon 20 insertion). På grund af denne dybere forståelse af sygdommens biologi og den afledte endnu mere\nmålrettet behandling, vil udviklingen af nye lægemidler i stigende grad blive baseret på studier med færre\npatientpopulationer. Vores klassiske vurdering af effekt på baggrund af store randomiserede fase III studier vil\nblive udfordret.\nBehandlingen af denne patientgruppe kræver derfor et tæt tværfagligt samarbejde mellem molekylærbiologer,\npatologer og onkologer i forståelsen af varianternes kliniske betydning, fortrinsvis (hvis tilgængeligt) på\nmolekylære tumor boards (MDT).\nFormål\nDet overordnede formål med retningslinjen er at understøtte en evidensbaseret kræftindsats af høj og ensartet\nkvalitet på tværs af Danmark.\nBehandlingen af onkogen-dreven NSCLC er i rivende udvikling og mange nye lægemidler godkendes årligt af\nFDA (fast-track) og ofte efterfølgende af EMA. Denne udvikling skal danske patienter også være en del af\nhvilket kalder på en samlet dansk indsats og overvågning, i tæt samarbejde med medicinrådet (MR).\nDenne retningslinje er et forsøg på at samle og årligt opdatere den nye viden og de nye godkendelser i FDA,\nEMA og MR inden for feltet.\nPatientgruppe\nRetningslinjens patientgruppe er patienter med inkurabel stadie III-IV NSCLC, hvor der ved genomisk\nprofilering af tumor, på diagnosetidspunktet, er fundet følgende varianter i generne:\nEGFR, KRAS (G12C), BRAF (V600E), MET, ERBB2, ALK, RET, ROS1 og NTRK.\nPatienter med onkogen-dreven NSCLC har generelt en bedre prognose end de øvrige patienter med NSCLC.\nPatientgruppen har ofte færre komorbiditeter og ingen eller sparsom ryganamnese (gælder ikke for KRAS\nG12C varianten) sammenlignet med den øvrige gruppe af patienter med NSCLC. Onkogen-dreven NSCLC\nkan dog forekomme hos rygere og derfor bør alle patienter med adenocarcinomer eller NSCLC NOS udredes\nmed bred genomisk profil, uafhængig af rygeanamnese. Desuden bør genomisk profilering af tumorer fra\npatienter med planocellulært karcinom i ung alder eller patienter med planocellulært karcinom kombineret med\nsparsom eller negativ rygeanamnese overvejes. Se derudover under anbefaling 1 for NGS.\nKlinisk Retningslinje │Kræft\nMålgruppe for brug af retningsli\nDenne retningslinje skal primært unders\nden primære målgruppe er klinisk arbejd\nsundhedsvæsen.\ninjen\nstøtte det kliniske arbe\ndende sundhedsprofe\nDMCG\nejde og udviklingen af den kliniske kvalitet, hvorfor\nessionelle og molekylærpatologer i det danske",
=======
      "heading": "2. Introduction",
      "text": "The treatment of all patients with pulmonary adenocarcinomas is complex and based on the genomic profiling of patients' tumors and/or free tumor DNA in blood (ctDNA). The understanding of the molecular biological mechanisms is developing rapidly after the introduction of next generation sequence (NGS). The development is directed towards a treatment, tailored to the individual gene errors (variants); the EGFR mutation must be treated quite differently from what protein-change gene error (variant) in EGFR gene causes (e.g. EGFR exon 19 del versus EGFR Exon 20 insertion). Because of this deeper understanding of disease biology and the derived even more targeted treatment, the development of new drugs will increasingly be based on studies with fewer patient populations. Our classic assessment of efficacy on the basis of large randomised phase III studies will be challenged. The main purpose of the guideline is to support an evidence-based high and uniform quality cancer interventions across Denmark. The treatment of onkogen-driven NSCLC is in rapid development and many new medicinal products are approved annually by the FDA (fast-track) and often subsequently by EMA. This development must also be part of which calls for an overall Danish effort and monitoring, in close cooperation with the Medical Council (MR). This guideline is an attempt to gather and update the new knowledge and approvals in FDA, EMA and MRI within the field. Patient group Guideline patients are patients with curable stage III-IV NSclC, where genomic tumour profiling at the time of diagnosis has been found the following variants in the genes: EGFR, KRAS (G12C), BRAF (V600E), MET, ERBB2, ALK, RET, ROS1 and NTRK. Patients with onkoken-driven NACLC have generally a better prognosis than the other patients with NSBLCCLC. Oncoke-driven NSCLC may, however, occur in smokers and therefore all patients with adenocarcinomas or NSclC NOS should be cleared with a broad genomic profile, independent of smoking history. In addition, genomic profiling of tumours from patients with squamous cell carcinoma at young age or patients with planocellular carcinoma combined with sparing or negative smoking history should be considered. See also under Recommendation 1 for NGS. Clinical Guideline",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 6,
      "end_page": 7
    },
    {
<<<<<<< HEAD
      "heading": "3. Grundlag",
      "text": "Indledning\nMan må betragte onkogen-dreven NSCLC som en sygdom i konstant molekylær udvikling i den enkelte\npatient. Behandlingsbeslutningerne bør derfor afspejle denne udvikling. Det anbefales derfor at patienter i\nprogression under TKI får foretaget en ny genetisk profilering på progredierende metastase og at denne profil\ngerne drøftes på et molekylært tumor board (hvis tilgængelig) eller med kolleger på patologisk afdeling.\nGenerelt anbefales det at behandle den enkelte patient så længe som muligt med relevante TKIer, også\nbeskrevet i ESMO og NCCN guidelines. Måden hvorpå progressionen viser sig hos patienterne under TKI\nbehandlingen har betydning for behandlingsvalget. Ved oligoprogression kan man overveje at lokalbehandle\nde metastatiske sites under fortsat TKI. Ved asymptomatisk systemisk progression kan man overveje at\nbehandle med TKI \"beyond progression\" under tættere monitorering af sygdomsaktiviteten. Ved symptomatisk\nsystemisk progression, kan en rebiopsi fra en progrederende metastase, være afgørende for det næste\nbehandlingsvalg.\nI det nedenstående gennemgås evidensen for den anbefalede behandling, målrettet den enkelte patients\ngenomiske profil over tid.\nPallierende 1. linje onkologisk behandling af onkogen-dreven ikke-\nsmåcellet lungekræft\n1. Patienter med inkurable pulmonale adenokarcinomer og NSCLC NOS samt enkelte\nudvalgte patienter med inkurabel pulmonal planocellulært karcinom bør udredes\nmed et targeteret NGS-panel indeholdende retningslinjens beskrevne varianter.\nLitteratur og evidensgennemgang\nAd. anbefaling 1\nI tråd med ESMO guidelines anbefales det, på baggrund af velundersøgte targeterede\nbehandlingsmuligheder, til patienter med NSCLC, at der udføres genetisk profilering både på\ndiagnosetidspunkt af inkurabel NSCLC og ved progression under targeteret behandling.\nEfter en national høring blandt patologer (DaLuPa) med særligt ansvar på lungecancer er der opnået\nnedenstående konsensus (april 2024).\nHvilke patienter\n1) Diagnostik af inkurabel NSCLC af typen pulmonalt adenocarcinom eller NSCLC NOS (not otherwise\nspecified) (alle patienter)\n2) Diagnostik af inkurabel planocellulært carcinom og aldrig ryger (<15 pakkeår) eller alder <50 år.\n3) Ved progression under behandling for onkogen-dreven NSCLC, udvalgte patienter (god AT, rimelig\nforventet restlevetid) med forventet behandlingskonsekvens (\"tab\" af primære onkogene\ndriver/histologisk transformation og/eller nytilkomne targeterbare resistens varianter).\n4) Ved progression under behandling for non-onkogen-dreven NSCLC - Udvalgte patienter (ganske få)\nhvor der mistænkes ny primær tumor / histologisk transformation.\nHvilke varianter\nFølgende varianter bør undersøges, i tråd med ESMO guidelines, på både diagnostisk biopsi og ved\nprogression under specielt onkogen-dreven behandling (se beskrivelser af resistensmekanismer under de\nenkelte varianters anbefalinger):\n1. EGFR varianter (alle i exon 18-21 med beskrivelse af variant)\n2. ALK fusioner (alle varianter med beskrivelse af fusionspartnere)\n3. ALK varianter øvrige\n4. ROS1 fusioner (alle varianter med beskrivelse af fusionspartner)\n5. BRAF V600E\n6. NTRK re-arrangementer\n7. MET exon 14 skipping mutationer\n8. MET varianter øvrige og amplifikationer\n9. RET fusioner (alle varianter med beskrivelse af fusionspartnere)\n10. KRAS G12C\n11. ERBB2 mutationer og amplifikationer\nHvilket materiale\nSufficient og nok materiale er nødvendigt for at sikre muligheden for fuld genetisk profilering. Dette kan være\nudfordrende for de udredende afdelinger og patienterne. Re-biopsier grundet sparsomt materiale, dvs. en lav\nandel af tumor celler i biopsien, kan inducere en forsinkelse i udredningen og der skal derfor være fokus på at\nsikre sufficient materiale fra start af udredningsforløbet.\nBiopsier af tumorvæv\nFinnålsaspirater (fx EBUS) eller histologiske biopsier (GNB/endoskopiske) med sufficient materiale til genetisk\nprofilering, bør anvendes.\nOBS: vær opmærksom på, at der kræves koagelmateriale på cytologisk materiale for, at immunhistokemisk\nanalyse for PD-L1 kan foretages.\nPleuravæske / Blod (ctDNA)\n1. Pleuravæske\nPleuravæske kan anvendes, men vær opmærksom på, at der er tilstrækkeligt antal tumorceller til genetisk\nprofilering, også RNA baseret NGS.\n2. Blod\nctDNA – circulating tumor DNA\nIndsamling af tilstrækkelige og gentagne vævsprøver kan have sin begrænsning i klinisk praksis. Derfor er en\npotentiel løsning på disse udfordringer at teste cirkulerende cellefrit tumor DNA (ctDNA) i plasma, som\nsupplement til vævsbiopsier. Påvisningen af ctDNA i plasma skyldes at kræftsygdommen udskiller ctDNA i\nblodbanen (shedding tumor), men mængden af udskilt tumor-DNA kan variere fra tumor til tumor. I henhold til\nESMO guidelines, for patienter med fremskreden onkogen-dreven NSCLC, er der validerede og tilstrækkeligt\nfølsomme ctDNA-tests, der kan bruges rutinemæssig i klinisk praksis. ctDNA-analyser kan med fordel bruges,\nnår der er behov for gentagne analyser eller når vævsbiopsier ikke er mulige eller uhensigtsmæssige.\nFortolkningen af ctDNA-resultater bør foregå i dialog med patolog og molekylær biolog.\nAnalyser på ctDNA er ikke fuldt implementeret i DK og er derfor ikke tilgængelige som standard i flere\nregioner. Dertil kan manglende fund at varianter undersøgt på ctDNA ikke anvendes til at udelukke\ntilstedeværelsen af en variant.\nAndre eksempler på begrænsninger ved ctDNA-analyserne: 1) Manglende evne til at detektere fænotypiske\nændringer (eksempel transformation til anden cancer). 2) Ikke alle NGS paneler kan identificere fusioner og\nkopiantalsændringer.\nHvilke metoder\nBrug af multiplex DNA og RNA-baserede platforme (NGS) anbefales til undersøgelse for onkogen-dreven\nNSCLC. I tilfælde af sparsomt vævsmateriale, hvor validiteten af en NGS-analysen vil være tvivlsom kan der i\nstedet anvendes immunhistokemisk- eller FISH- analyse til detektion af ALK- eller ROS1-fusion, men i fald\ndisse er positive bør der foretages rebioptering mhp. detektion af fusionspartneren ved NGS. Dertil er det\nvigtig at være opmærksom på at gen-deletioner og amplifikationer ikke kan detekteres med tilstrækkelig\nsikkerhed, hvis tumorprocenten i det foreliggende vævsmateriale er lav. I tråd med dette overvejes ved\nundersøgelse for cMET-amplifikation, immunhistokemisk undersøgelse, som i fald af høj og kraftig positivitet i\ntumorcellerne bør bekræftes af FISH-undersøgelse for cMET.\nFor ctDNA\nTSO500 eller Oncomine Lung cfDNA panelet, anvendes på de centre der analyserer ctDNA i DK. I henhold til\nESMO guidelines, kan validerede paneler bruges til at identificere targeterbare mutationer i rutinemæssig\nklinisk praksis, forudsat af begrænsningerne af assaysene tages i betragtning (for eksempel falske negative\nresultater), herunder testning for EGFR mutationer og ALK fusioner/mutationer [1a]. Testning for øvrige\nbiomarkører har evidensgrad [1b] (MET exon 14 skipping, KRAS G12C, BRAF V600E, RET), [1c] (NTRAK\n1/2/3), [2a] (MET amplifikation) og [2b] (BRBB2 og BRAF non-V600E) (1).\n2. Patienter med aktiverende klassiske EGFR mutationer og performance status 0-3\nkan tilbydes 1. linje behandling med osimertinib (A)\nLitteratur og evidensgennemgang\nAd. anbefaling 2\nEGFR muteret NSCLC ses i ca.15% af alle patienter diagnosticeret med inkurabel pulmonalt adenocarcinom,\nDe hyppigste (klassiske) EGFR varianter er EGFR exon 19 deletion (45%) og EGFR L858R (40%). De\nresterende (sjældne) EGFR varianter (5%) er hyppigst repræsenteret af EGFR exon 20 insertion varianter. De\nsjældne EGFR varianter har variabel effekt af EGFR rettet behandling (2), se anbefaling 9-10 og anbefaling\nOSIMERTINIB\na. Patienter med aktiverende klassiske EGFR varianter (EGFR exon 19 deletion og EGFR L858R) tilbydes 1.\nlinje behandling med osimertinib. Behandlingen fortsætter til systemisk progression (PD) eller uacceptabel\ntoksicitet. Osimertinib er en 3. generations irreversibel EGFR-tyrosinkinase-inhibitor (TKI), der selektivt\nhæmmer begge ovenstående EGFR varianter.\nOsimertinib er undersøgt i et dobbeltblindet fase 3, 1. linje studie FLAURA (3, 4)[1b]. Patienter med EGFR\nexon 19 deletion eller L858R blev randomiseret, 1:1, mellem standard TKI (gefitinib eller erlotinib) og\nosimertinib. Det var muligt for patienter, med EGFR T790M, i standard armen, at krydse over til osimertinib-\narmen ved progression. OS (38,6 mdr vs 31,8 mdr), PFS (18,9 mdr vs 10,2 mdr) og median varighed af\nrespons (DOR) (17,2 mdr vs 8,5 mdr) var signifikant bedre for osimertinib-armen. Den median tid til respons\nvar 6,1 uge (tidspunkt for første evaluering) og vidner om kort tid til effekt af osimertinib. Den sete mer-effekt\nfor osimertinib var ens i alle subgrupper (alder, PD-L1 status (5)[1b], EGFR variant, CNS metastaser).\nBivirkninger\nI FLAURA studiet sås ingen øget forekomst af ≥ grad 3 bivirkninger (42% versus 47%), sammenholdt med\nerlotinib/gefitinib, på trods af at osimertinib blev givet i længere tid (20,7 mdr. versus 11,5 mdr.). De hyppigste\n≥ grad 3 bivirkninger under osimertinib er udslæt/tør hud (1%) og diarre (2%).\nb. CNS metastasering\nCNS metastaser hos patienter med EGFR-muteret NSCLC er associeret med dårligere prognose (6, 7) [4].\nSeksten procent af patienterne udvikler cerebrale metastaser under behandlingen.\nPatienter med CNS metastaser bør tilbydes osimertinib. Cerebral lokal behandling, up front, bør undgås.\nI FLAURA studiet (3, 4) [1b] sås mindre CNS progression under osimertinib sammenholdt med\nerlotinib/gefitinib. PFS (15,2 mdr. vs 9,6 mdr.) var signifikant længere under osimertinib for patienter med CNS\nmetastaser.\nI AURA 3 studiet, randomiseret fase III (8)[1b], hvor patienterne blev behandlet med 2. linje osimertinib efter\nprogression på 1./2. generations EGFR TKI sås en forbedret CNS ORR (70% versus 31%), CNS PFS (11,7\nmdr. versus 5,6 mdr.) og CNS DOR (8,9 mdr. versus 5,7 mdr.) sammenholdt med kemoterapi (platin plus\npemetrexed).\nFLAURA 2 studiet undersøgte Osimertinib i kombination med kemoterapi (9)[1b]. Ubehandlede patienter med\nEGFR exon 19 deletion eller L858R blev randomiseret 1:1 i en open-label fase 3 undersøgelse mellem\nstandard osimertinib versus osimertinib plus platin-kemoterapi plus pemetrexed. PFS (16,7 mdr vs 25,5 mdr)\nog DOR (15,3 mdr vs 25,5 mdr) var signifikant bedre med kombinationen osimertinib plus kemoterapi. Effekten\nsås i alle subgrupper, men specielt for patienter med asymptomatiske og stabile CNS metastaser (PFS: 13,8\nmdr vs 24,9 mdr) og for patienter med EGFR L858R varianten (PFS: 13,9 mdr vs 24,7 mdr). De foreløbige OS\ndata blev præsenteret på ASCO 2024: OS for kombinationen= NR, for osimertinib monoterapi=38,6 mdr.\nBivirkninger grad ≥3 var 64% for kombinationen vs 27% for osimertinib. SAE (alle) var 38% i\nkombinationsarmen vs 19% i osimertinib monoterapi-armen. De hyppigste bivirkninger var\nknoglemarvspåvirkning: 71% (kombinations-arm) vs 24% (osimertinib-arm). Der var ingen forskel i graden af\npneumonitis mellem de to arme (3-4%).\nKombinationen osimertinib og kemoterapi er FDA godkendt, men ikke EMA godkendt og kan derfor aktuelt\nikke anbefales.\nBLOOM studiet (fase 1 studie) (10)[4] undersøgte effekten af højdosis osimertinib (160 mg) til patienter med\nmeningeal karcinomatose. I studiet blev patienterne behandlet med osimertinib i dobbelt dosis (160 mg) og\nman opnåede ORR 40%, DOR 8,3 mdr. og OS 11 mdr. Der blev ikke rapporteret en øget toksicitet.\nMR cerebrum screening under osimertinib (patienter uden cerebrale metastaser på diagnosetidspunkt).\nESMO og NCCN guidelines anbefaler behandling af asymptomatisk oligoprogression under fortsat osimertinib.\nMan kan derfor overveje at screene patienterne for cerebrale metastaser under behandlingsforløbet, for at\nbehandle asymptomatisk oligoprogression intracerebralt under osimertinib. Der foreligger ingen sikker evidens\n(kun retrospektive opgørelser) for at behandling af oligoprogression, intrakranielt, under osimertinib forbedrer\npatienternes OS.\nc. Ældre patienter\nÆldre patienter (≥65 år) blev inkluderet i FLAURA studiet og der var ingen forskel i effekt i subgruppe\nanalyserne i alder (≥65 år vs <65 år) (3, 4) [1b].\nDer findes et enkelt japansk fase II studie (SPIRAL) (11) [2b] der undersøger 1. linje osimertinib til patienter\n>75 år. Studiet rapporterede: ORR 78,9% og mPFS 15,9 mdr. Studiet opnåede dog ikke sit primære\nendepunkt (1 års PFS rate). Studiets beskrevne bivirkninger ≥ grad 3: udslæt 5%. Any grad pneumonitis\nEt andet, japansk fase II studie (12) [2b] viser ORR for patienter >75 år (58,3%) for 2. linje osimertinib efter\n1./2. generations TKI og EGFR T790M variant. PFS blev ikke rapporteret i artiklen. Studiet beskriver\nbivirkninger ≥grad 3: Diare: 2,8 %, udslæt 0% og pneumonitis 6 %.\nProduktresumeet for osimertinib beskriver på baggrund af ADURA, FLAURA og AURA3 studierne, en øget\nforekomst af ≥ grad 3 bivirkninger (13% vs 8%)) for patienter ≥65 år. Der var ikke forskel på typen af\nbivirkninger.\nd. Patienter med PS ≥ 2\nESMO guidelines anbefaler EGFR TKI til patienter i denne patientgruppe på baggrund af ORR, dybden af\nrespons og på baggrund af håndterbare bivirkninger (13) [5].\nDenne patientgruppe blev ikke inkluderet i FLAURA studiet. Der findes ingen 1. linje prospektive studier der\nundersøger effekten af osimertinib til denne patientgruppe.\nERLOTINIB / AFATINIB / GEFITINIB\nSom alternativ til osimertinib kan 1./2.-generations TKIerne: erlotinib eller gefitinib overvejes (f.eks. ved ikke\nhåndterbare bivirkninger til osimertinib). Afatinib er ikke en \"hyldevare\" i DK, der skal ansøges om tilladelse til\nudlevering i lægemiddelstyrelsen.\nErlotinib har vist en signifikant bedre ORR (58% versus 15%) og PFS (9,7 mdr. versus 5,2 mdr.) i et europæisk\nrandomiseret fase 3 studie (14)[1b] sammenholdt med kemoterapi (cisplatin plus docetaxel), 1. linje\nbehandling af patienter med klassisk EGFR muteret NSCLC. De hyppigste ≥ grad 3 bivirkninger til erlotinib er\nudslæt (13%), diare (5%) og forhøjet lever-aminotranferase-forhøjelse (2%).\nGefitinib har vist en signifikant bedre ORR (73,7% versus 30,7%) og PFS (10,8 mdr. versus 5,4 mdr.) i et\njapansk randomiseret fase 3 studie (15) [1b] sammenholdt med kemoterapi, 1.-linje behandling af patienter\nmed klassisk EGFR muteret NSCLC. De hyppigste ≥ grad 3 bivirkninger til gefitinib er udslæt (5,3%), nedsat\nappetit (5,3%) og forhøjet lever-aminotranferase-forhøjelse (26,5%).\nAfatinib har vist en signifikant bedre ORR (66,9% versus 23,0%) og PFS (11,0 mdr. versus 5,6 mdr.) i LUX-\nLung 6 studiet (16) [1b], et randomiseret fase 3 studie sammenholdt med kemoterapi (cisplatin plus\ngemcitabin), førstelinje behandling til patienter med klassisk EGFR muteret NSCLC. De hyppigste ≥ grad 3\nbivirkninger til afatinib er udslæt (14,6 %), diare (5,4%) og stomatitis/mucositis (5,4%).\nIngen af studierne har vist forbedret OS, formentlig grundet at et større antal patienter i kemoterapiarmen\nefterfølgende blev behandlet med de undersøgte TKIer (17-19) [1b].\nEn metaanalyse (20) [1a] sammenholdt effekten og bivirkningsprofilerne for erlotinib, gefitinib og afatinib.\nAnalysen blev baseret på 8 randomiserede studier og 82 cohorte studier. Erlotinib og gefitinib viste ens data\nfor PFS og ORR uden signifikant variation i effekt mellem etnicitet, linje behandling og forekomst af cerebral\nmetastaser. Afatinib havde den samme effekt som gefitinib og erlotinib,1. linje behandling. Gefitib blev\nbeskrevet med mere leverpåvirkning, men totalt færre ≥3 bivirkninger.\n3. Patienter med ALK translokation og performance status 0-3 kan tilbydes 1.\nlinjebehandling med ALK-TKI (brigatinib, alectinib eller lorlatinib) (A)\nLitteratur og evidensgennemgang\nAd. anbefaling 3\nALK translokeret NSCLC ses i 4-6% af alle patienter diagnosticeret med inkurabel pulmonalt adenocarcinom\n(21). Den hyppigste fusions partner er EML4 (85%). For ALK-EML4 eksisterer der 12 forskellige varianter,\nhvoraf varianterne 1 og 3 er de hyppigste. Varianterne er associeret med forskellig følsomhed over for ALK-\nTKIer og de udvikler forskellige resistensmekanismer (21).\nAlectinib og brigatinib er godkendt af MR som første linje behandling af ALK translokeret pulmonalt\nadenocarcinom. Lorlatinib er godkendt som både første og senere linje behandling. Af rent økonomiske\ngrunde og uden hensyn til ALK varianten, anbefaler MR siden 01.03.2024 brigatinib. Man skal dog være\nopmærksom på at de sjældne ALK varianter ikke er undersøgt i studierne af brigatinib og effekten for disse\nvarianter kan derfor være usikker.\nALECTINIB\nAlectinib er en 2. generations ALK-TKI og blev sammenlignet med crizotinib i fase 3 ALEX studiet hos\nbehandlings naive patienter (22) [1b]. Studiet har vist større effekt af alectinib med hensyn til 12-måneders\nevents-fri rate, 68,4 % med alectinib vs. 48,7 % med crizotinib. PFS var 25.7 mdr for alectinib og 10.4 mdr for\ncrizotinib. Intrakraniel respons rate var 81% for alectinib versus 50% for crizotinib. Opdateret analyse (23)[1b]\nefter længere follow-up viste median PFS 34.8 mdr for alectinib versus 10.9 mdr for crizotinib. Intrakraniel\nrespons - målt hos en mindre gruppe af patienter med målbare hjernemetastaser - var 81% for alectinib og\n50% for crizotinib. De hyppigst rapporterede bivirkninger var kvalme (15.8 % med alectinib versus 49.7 % med\ncrizotinib), øget alanintransaminase niveau (33.1 % med alectinib versus 17.1 % med crizotinib) og diarré\n(13.2 % med alectinib versus 46.4 % med crizotinib). Bivirkninger, som førte til behandlingsophør var: ALAT\nforhøjelse (1.3% med alectinib og 6.0% hos crizotinib) samt pneumonitis (0.7% med alectinib og 3.3% med\ncrizotinib)\nBRIGATINIB\nBrigatinib er en 2. generations ALK-TKI, sammenlignet med crizotinib i et fase 3 studie, 1. linje (24)[1b].\nMedian PFS var 24.0 mdr for brigatinib og 11.0 mdr for crizotinib. De hyppigste bivirkninger var diarre (52%\nmed brigatinib og 56% for crizotinib), øget kreatinin kinase (46% med brigatinib og 17% med crizotinib), hoste\n(35% med Brigatinib og 20% med crizotinib), hypertension (32% med Brigatinib og 8% med crizotinib) og\nkvalme 30% for brigatinib og 58% for crizotinib). 3-års PFS-raten var 43% for brigatinib og 19% for crizotinib.\nBrigatinib viste intrakraniel aktivitet: median intrakraniel DOR var 33.2 mdr. for brigatinib og 13.8 mdr. for\ncrizotinib (25) [1b]. Intrakraniel respons - målt hos en mindre gruppe af patienter med målbare\nhjernemetastaser – var 77.8% for brigatinib og 26.1% for crizotinib.\nLORLATINIB\nLorlatinib er en 3. generation ALK-TKI. Fase 3 Crown studiet sammenlignede lorlatinib med crizotinib i første\nlinje. Studiet viste: median PFS for lorlatinib var NR og median PFS for crizotinib var 9.3 mdr (26) [1b]. Der\nblev observeret en signifikant intrakraniel ORR 82% for lorlatinib versus 23% for crizotinib. 3-års PFS var 64%\nfor lorlatinib og 19% for crizotinib. Hos patienter uden hjernemetastaser havde én (1 %) i Lorlatinib-gruppen,\nog 25 (23 %) i crizotinib-gruppen intrakraniel progression. De hyppigste bivirkninger under behandling med\nlorlatinib var hyperkolesterolæmia 82.4% (13.9% grad 3), hypergliceridemia 60.7% (13.2% grad 3), ødem\n51.2% (2.4% grad 3), perifer neuropati 43.7 % (2.4% grad 3) samt kognitiv påvirkning 23.1% (1.7% grad 3)\n(27)[1b]. Behandling med statiner anbefales ved første tegn på forhøjet kolesterol og/eller triglyceridniveauer.\nPravastatin eller rosuvastatin bør være første valg, baseret på deres lave involvering med CYP450-\nenzymsystemet. Ved manglende effekt kan tillæg af fibrater være nødvendig.",
=======
      "heading": "3. Basis",
      "text": "The treatment decisions should therefore reflect this development. Therefore, it is recommended that patients in progression during TKI have a new genetic profiling on progressive metastasis and that this profile be discussed on a molecular tumor board (if available) or with colleagues in pathological ward. In general, it should be recommended to treat the individual patient for as long as possible with relevant TKIs, also described in ESMO and NCCN guidelines. The way in which progression appears in patients during the TKI treatment has an impact on the choice of treatment. In case of oligoprogress, a biopsy from a prognostic metastase may be considered, determining the next treatment selection. In the case of asymptomatic systemic progression, consideration may be given to treatment with TKI \"beyond progression\" during closer monitoring of disease activity. In line with the ESMO guidelines, it is recommended that genetic profiling be performed both at the time of diagnosis of incurable NSCLC and at progression during targetated therapy. Following a national consultation among pathologists (DaLuPa) with special responsibility for lung cancer, the following consensus (April 2024) has been reached (April 2024). Diagnostics of inecutable NSclC of the type pulmonary adenocarcinoma or NSCLENOS (not crosswise specified) (all patients) (2) Diagnosis of inkurable planocellular carcinoma and never smokes (<15 package years) or age < 50 years. 3) In progression for on-on-coke primary therapy (no otherwise specified) patients (april 2024). The following variants should be studied, in line with the ESMO guidelines, on both diagnostic biopsy and on progression under specially oncogen-driven treatment (see descriptions of resistance mechanisms under each variant's recommendations): 1. EGFR variants (all in exon 18-21 with description of variant) 2. ALK fusions (all variants with descriptions of fusion partners) 3. ALK variants other 4. ROS1 mergers (all variations with description by fusion partner) 5. BRAF V600E 6. NTRK re-arrangements 7. MET exon 14 skipping mutations 8. MET variants others and amplifications 9. RET mergers ( all variants with description for fusion partners). 10. KRAS G12C 11. ERBB2 mutations and amplications Which material Sufficient and enough material is necessary to ensure the possibility of full genetic profiling. This may be the case of the cancerous agents. This is why a potential solution to these challenges is to test circulating cell free tumor DNA (ctDNA) in plasma, as a supplement to tissues of tumour tissue is due to the tumour tumour tissue tissue to tissue tissue tissue. On the basis of the tumor tumor tissue tissue, the tissue tissue is exposed to the tumors' tissue tissue and the tissue cell tissue tissue remains intact. On a low proportion of tumor cells in the biopsy may induce a delay in the analysis and therefore focus on ensuring sucient material from the start of the study. Biopsies of tumour tissues Finneel aspirates (e.g. EBUS) or histologic biopsies (GNB/endoscopic) with Sucient material for genetic profiling should be used. OBS: be aware of the need for clot material on cytological material for immunohistochemical analysis for PD-L1 can be performed. Pleura fluid / Blood (ctRNA) 1. Pleural fluid Pleurian fluid Pleuar fluid can be used, but be aware that there is sufficient number of tumour cells for genetic profile testing, also RNA in plasma. The detection of ctDNA in plasma is due to the fact that the cancer disease secretes ct DNA into the bloodstream (shedding tumor), but the amount of secreted tumor DNA may vary from tumor to tumor. According to ESMO guidelines, for patients with advanced oncogen-driven NSCLC, there are validated and sufficiently sensitive ctRNA tests that can be used routinely in clinical practice. ct=1 analyses can be usefully used when repeated analyses are needed or when tissue biopsy is not possible or inappropriate. The interpretation of ctsDNA results should be done in dialogue with pathologist and molecular biologist. Analysis of cthDNA is not fully implemented in DK and is therefore not available as standard in several regions. For this reason, lack of findings that variants examined on ct RNA cannot be used to exclude the presence of a variant. Other examples of limitations on cts DNA analyses: 1) Inability to detect phenotypic changes (example transformation to other cancer). 2) Not all NGS panels can identify fusion and copy number changes. The use of multiplex DNA and RNA based platforms (NGS) is recommended for testing for oncogen-driven NSCLC. In the case of sparing tissue material, where the validity of an NGS analysis will be questionable, immunohistochemical or FISH analysis may be used instead for the detection of ALK or ROS1 fusion, but in the event these are positive, the rebiopulation should be carried out with respect to detection of the fusion partner by NGS. In addition, it is important to note that gene deletions and amplifications cannot be detected with sufficient certainty if the tumour percentage of the available tissue material is low. In line with this consideration, the examination for cMET amplification, immunohistochemical examination, which in case of high and strong positivity of the tumor cells should be confirmed by the FISH study for the cMET. For ctDNA TSO500 or Oncomine Lung cfDNA panel, is applied to the centers analys ctose in DK. According to ESMO regulants, validated panels can be used in the maristable practices [tories]. The remaining patients with activating classical EGFR mutations and performance status 0-3 can be offered 1st line treatment with osimertinib (A) Literature and evidence review Ad. Recommendation 2 EGFR mutated NSCLC is seen in approximately 15% of all patients diagnosed with incurable pulmonary adenocarcinoma, the most frequent (classical) EGFR variants are EGFR exon 19 deletion (45%), and EGFR L858R (40%). Treatment for short duration of treatment is continued for systemic progression (PD) or unacceptable toxicity. Osimertinib is a 3rd generation irreversible EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits both above EGFR variants. Osimertinib has been studied in a double-blind phase 3, 1st-line study FLAURA (3.4)[1b]. Patients with EGFR exon 19 deletion or L858R were randomised, 1:1, between standard TKI (gefitinib or erlotinib) and osimitinib. It was possible for patients with EGF R T790M in the standard arm to cross over to the osimetinib arm at progression. OS (38.6 months vs 31.8 months), PFS (18.9 months vs 10.2 months vs 10.2 months) and median duration of response (DOR) (17.2 months vs 8.5 months) was significantly better for the osimateinib arm. The median time to response was 6.1 weeks (time of first evaluation) and mean duration of responses (DORS vs 8.5 ms 8.5 months). The seen mer effect for osimertinib was similar in all subgroups (age, PD-L1 status (5)[1b], EGFR variant, CNS metastases). The PFS (15.2 months vs. 9.6 months) was significantly longer during osimertinib for patients with CNS metastases. In the AURA 3 study, randomised Phase III (8)[1b], where patients were treated with 2nd line osimitinib after progression of 1.2 generation EGFR TKI was seen an improved CNS ORR (70% versus 31%), CNS PFS (11.7 months versus 5.6 months) and CNS DOR (8.9 months  vs. 5.7 months) compared to chemotherapy (platin plus pemetrexed). FLAURA 2 study investigated Osimertinib in combination with chemotherapy (9)[1b]. Untreated patients with EGFR exon 19 deletion or L858R were randomised 1:1 in an open-label phase 3 study between standard osimatertinib versus osimimitinib plus platinum chemotherapy plus pemtrexed. PFS (16,7 months vs 25,5 months) with DOR (15,3 months vs Stable CNS metastases (PFS: 13.8 months vs 24.9 months) and for patients with EGFR L858R variant (PFs: 13.9 months vs. 24.7 months). The preliminary OS data were presented on ASCO 2024: OS for the combination= NR, for osimitinib monotherapy=38.6 months. Adverse reactions grade ≥ 3 were 64% for the compound vs. 27% for osimertinib. SAE (all) was 38% in the combination arm vs. 19% in the osimetinib monapotherapy arm. The most frequent adverse events were bone marrow effects: 71% (co-arm) vs. 24% (osimertimatinib arm). There was no difference in the degree of pneumonia between the two arms (3-4%). The study did not achieve its primary endpoint (1 year PFS rate). The study describes adverse reactions ≥ degree 3: Diare: 2.8 percent, rash 0% and pneumonitis 6%. The Summary of Product Characteristics for osimertinib describes on the basis of the ADURA, FLAURA and AURA3 studies, an increased incidence of ≥ grade 3 adverse events (13% vs 8%)) for patients ≥ 65 years of age. There was no difference in type of adverse reactions. d. Patients with PS ≥ 2 ESMO guidelines recommend EGFR TKI for patients in this patient group based on ORR, the depth of response and based on manageable adverse reactions (13) [5]. This patient group was not included in the FLAura study. There are no 1st line prospective studies investigating the efficacy of osimateinib in this group of patients. ERLOTINIB/ AFATINIB/ GEFITINIB As an alternative to osimertinib, 1-2. generation TKIs: erlotinib or gefitinib is considered (e.g. by non-handlermatable adverse events shown to osimitinib). In a European randomised phase 3 study (14)[1b] compared to chemotherapy (cisplatin plus docetaxel), first line treatment of patients with classical EGFR mutated NSCLC. The most frequent ≥ grade 3 adverse events to erlotinib were rash (13%), diarrhoea (5%), and elevated liver aminotranferase elevation (2%). Gefitinib showed significantly better ORR (73.7 versus 30.7%) and PFS (10.8 months versus 5.4 months) in a Japanese randomised phase three study (15) [1b], compared with chemotherapy, first line therapy, first-line treatment in patients with classic EGFRmuted NSclC. The most frequent grade 3 adverse reactions to aflatinib are rash (14.6%), diarrhoea (5.4%) and stomatitis/mucositis (5.4%). None of the studies has shown improvement in the OS, probably due to a higher number of patients in the chemotherapy arm being subsequently treated with the studied TKIs (17-19) [1b]. A metaanalysis (20) [1a] compared the efficacy and adverse events profiles of erlotinib, gefitinib and apostinib. The analysis was based on 8 randomised studies and 82 cohort studies. Erlotinib and geptinib showed similar data for PFS and ORR with no significant variation in efficacy between ethnicity, line treatment and incidence of cerebral metastases. Aflatinib had the same effect as gefitimatinib and erlotinib,1. line treatment. Gefitib was described with more liver effects, but totally less ≥ 3 adverse events. 3. Patients with ALK translocation and performance status 0-3 can be offered 1st line treatment with ALk-TKI (brigatinib, alectinib or lorlatinib). The most frequent fusion partner is EML4 (85%). The intracranial response rate was 81% for alectinib versus 50% for crizotinib. Updated analysis (23)[1b] after longer follow-up showed median PFS 34.8 months for alicetinib  vs 10.9 months for crizotinib. Intracranial response - as measured in a small group of patients with measurable brain metastases - was 81%) for alectinib and 50% forcrizotimatinib. The most frequently reported adverse events were nausea (15.8 percent with alectaparin versus 49.7 percent with crizothinib), increased alanine transaminase levels (331.1 percent with alectamine versus 17.1 % with crizottinib) and diarrhoea (13.2 percent with anlectinib vs 46.4% with crisotinib). The most frequent adverse events were diarrhoea (52% with brigatinib and 56% for crizotinib), increased creatinine kinase (46% with brigatinib and 17% with crizothinib), cough (35% with Brigatinib, and 20% with crizotinib), hypertension (32% with Brigathinib and 8% with crizzotinib) and nausea 30% for brigathinib and 58% for crizoteinib). The 3-year PFS rate was 43% for brIGATinib and 19% for crizzotinib. Brigatimatinib showed intracranial activity: median intracranial DOR was 33.2 months for brigatainib and 13.8 months for crizontinib (25) [1b]. The study showed: The median PFS for lorlatinib was NR and median PFs for crizotinib was 9.3 months (26) [1b]. A significant intracranial ORR 82% was observed for lorlateinib versus 23% for crizotinib. 3-year PFS was 64% for lorlatinib and 19% for crizonatinib. In patients without brain metastases, one (1 %) in the Lorlatinib group, and 25 (23 %) of the crizottinib group was intracranial progression. The most frequent adverse events during treatment with lorlateinib were hypercholesterolaemia 82.4% (13.9% grade 3), hypergliceridemia 60.7% (13.2% grade 3) and oedema 51.2% (2.4% grade 3), peripheral neuropathy 43.7 % (2.4% degree 3) and cognitive influence 23.1% (1.7% grade 3) (27)[1b]; treatment with statins is recommended at first signs of elevated cholesterol and/or triglycerate levels. Pravastatin or rosuvastatinvastatin should be the first choice based on their lack of CYP.",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 8,
      "end_page": 14
    },
    {
<<<<<<< HEAD
      "heading": "BRIGATINIB VERSUS ALECTINIB VERSUS LORLATINIB",
      "text": "Brigatinib og alectinib er generelt ligestillet, men med lidt forskellig bivirkningsprofil og effekt afhængig af\nvariant. For EML4-ALK variant 3 ses ORR for brigatinib 91% versus 68% for alectinib (23)[1b]. Ydermere, hos\ncirka 10 % af patienter med andre end EML4 fusion partneren (for eksempel STRN, PLEKHH2, KANK1), er\nder kun rapporteret respons for alectinib (28-30)[4].\nDerudover bør patientens præferencer også tages i betragtning –under alectinib skal der indtages 4 tabletter 2\ngange i døgnet; for brigatinib skal der indtages 1 tablet 1 gang i døgnet.\nLorlatinib (31) [2b] er især forbundet med signifikant længere PFS hos patienter med EML4-ALK variant 3. I\nmodsætning til andre ALK-TKIer, har ko-mutation i TP53 mindre indflydelse på effekten af lorlatinib (32)[1b]. I\npatientgruppen med EML4-ALK variant 3 og koeksisterende TP53 mutation ses en mPFS 20 mdr. under\nlorlatinib. Derfor kan man overveje lorlatinib til patienter med massiv spredning til CNS, EML4-ALK variant 3 og\nko-eksisterende TP53, som 1. linje behandling.\nPatienter med PS ≥ 2\nPatienter i PS3 var ikke inkluderet i fase 3 studierne (ALEX, ALTA-1L og CROWN). Sparsomme real-world\ndata viser at disse patienter også profiterer af ALK-TKI, dog er effekten formentlig mindre end hos patienter i\nPS 0-2 (33)[2b].\nTil patienter med PS ≥ 2 anbefaler ESMO og NCCN guidelines, ALK TKI. Det er vurderet, at data fra EGFR\nstudier, der har vist høj ORR, håndterbare bivirkninger og bedring af PS, kan extrapoleres til andre onkogene\ndrivere (13)[5].\nÆldre patienter\nÆldre patienter over 65 år kan behandlingen, ifølge produktresumeerne for ALK-TKIerne gives uden justering\naf dosis.\n4. Patienter med ROS1 translokation og performance status 0-2(3) kan tilbydes 1. linje\nentrectinib, alternativt crizotinib (B)\nLitteratur og evidensgennemgang\nAd. anbefaling 4\nTil patienter med ROS1 translokeret NSCLC og cerebrale metastaser overvejes entrectinib i 1. linje i tråd med\nNCCN guidelines. Til patienter uden cerebrale metastaser er crizotinib et alternativ til entrectinib.\nENTRECTINIB\nEntrectinib er godkendt af MR og ligestillet med crizotinib til 1. linje behandling af ROS1 translokeret NSCLC\npå baggrund af en integreret analyse af tre fase 1-2 studier (34)[2b]. ORR var 77% og median DOR var 24,6\nmdr. mPFS var 19,0 mdr. De hyppigste AEs grad 3-4 var vægtøgning (8%) og neutropeni (4%).\nCNS metastasering\nI et retrospektivt studie, der undersøgte patienter med ROS1 translokeret NSCLC i behandling med crizotinib,\nhavde 36% hjernemetastaser på diagnosetidspunktet (35)[4]. For 47% af patienterne var CNS den første og\neneste lokalisation for progression. Entrectinib har formentlig en bedre effekt i CNS end crizotinib (36)[4].\nREPOTRECTINIB\nRepotrectinib anbefales som mulig behandling, specielt for patienter med cerebrale metastaser, i ESMO og\nNCCN guidelines. Repotrectinib er ikke EMA godkendt. Se desuden under retningslinjens anbefaling 13.\nCRIZOTINIB\nI en opdateret analyse af fase 1 studiet PROFILE 1001 (37)[2b] undersøgte man effekten af crizotinib til ROS1\ntranslokeret NSCLC patienter. ORR var 72% og median DOR 24,7 mdr. mPFS var 19,3 mdr og mOS 51,4\nmdr. Dette førte til godkendelse af crizotinib til ROS1 translokeret NSCLC. De hyppigste AEs grad 3 var\nhypofosfatæmi (15%), neutropeni (9%), transaminase stigning (4%) og opkastninger (4%).\nÆldre patienter\nÆldre patienter over 65 år kan tilbydes behandlingen Ifølge produktresumeerne for entrectinib og crizotinib,\nkan behandlingen gives uden justering af dosis.\nPatienter med PS ≥ 2\nTil patienter med PS ≥ 2 anbefaler ESMO og NCCN guidelines ROS1 TKI. Det er vurderet, at data fra EGFR\nog ALK studier, der har vist høj ORR, håndterbare bivirkninger og bedring af PS, kan extrapoleres til andre\nonkogene drivere (13)[5].\n5. Patienter med RET translokation og PS 0-2 kan tilbydes 1. linje platinholdig\nkemoterapi (B). Overvej selpercatinib efter godkendelse i regionale medicinudvalg\n(A)\nLitteratur og evidensgennemgang\nAd. anbefaling 5\nPatienter med aktiverende RET translokation kan tilbydes 1. linje behandling med platindublet kemoterapi, da\nselpercatinib endnu ikke er godkendt før platinbaseret kemoterapi af MR.\nSelpercatinib er i en interim analyse af fase 3 studiet LIBRETTO-431 vurderet overfor platinbaseret kemoterapi\n+/- pembrolizumab i 1. linje hos patienter med avanceret RET-translokeret NSCLC (38)[1b]. Studiet viser en\nfordobling (24,8 versus 11,2 måneder) af median progressionsfri overlevelse for selpercatnib versus\nplatinbaseret kemoterapi +/- pembrolizumab. Selpercatinib ORR er 84% versus kemoterapi, 65%. Den\nintrakranielle ORR er 82% versus kemoterapi+/-immunterapi, 58%. Mere end en tredjedel af patienterne opnår\nkomplet respons intrakranielt.\nDe hyppigste RET fusionspartnere var KIF5B (45% af patienterne) og CCDC6 (10% af patienterne) og der var\nlængere PFS ved selpercatinib behandling sammenlignet med kemoterapi uanset fusionspartner.\nSelpercatinib er anbefalet som 1. linje behandling i ESMO og NCCN guidelines. På baggrund af LIBRETTO-\n431 studiet kan man overveje at ansøge det regionale medicinudvalg om tilladelse til 1. linje selpercatinib.\nBivirkninger\nDe hyppigste bivirkninger ved selpercatinib var forhøjet ASAT/ALAT, hypertension, diarré, ødem, mundtørhed,\nforhøjet bilirubin og forlænget QTc interval. Alvorlig og livstruende pneumonitis kan forekomme. Hyppigheden\naf grad 3 og derover bivirkninger var hyppigere for selpercatinib end for kemoterapi (70% vs 57%).\nIMMUNTERAPI MONOTERAPI\nImmunterapi monoterapi bør undgås til denne patient gruppe. Da RET varianten er sjælden er der\nbegrænsede data tilgængelige. I IMMUNOTARGET studiet er ALK, ROS1 og RET analyseret som en samlet\ngruppe og der er for denne gruppe ikke set effekt af immunterapi som monoterapi (39).\nÆldre patienter\nBehandling med selpercatinib har vist effekt uafhængigt af alder og er generelt veltolereret hos patienter ≥65\når. Frekvensen af rapporterede bivirkninger er dog højere for stigende aldersgrupper; ≥65-74 år (58.0%), 75-\n84 år (62.5%) og ≥85 år (100.0%). Der er begrænsede data for patienter ≥75 år.\nPatienter med PS ≥ 2\nTil patienter med PS ≥ 2 anbefaler ESMO og NCCN guidelines, RET TKI. Det er vurderet, at data fra EGFR og\nALK studier, der har vist høj ORR, håndterbare bivirkninger og bedring af PS, og kan derfor extrapoleres til\nandre onkogene drivere (13)[5].\nPatienter i PS 0-2 blev inkluderet i LIBRETTO-001 og LIBRETTO-431 studierne, men meget få patienter var\nPS 2. Der foreligger ikke oplysninger om hvorvidt disse patienter har oplevet flere SAE.\n6. Patienter med aktiverende BRAF V600E og performance status 0-2 kan tilbydes 1.\nlinje behandling med kemoterapi +/- immunterapi i henhold til non-\nonkogendreven NSCLC retningslinjer (B)\nLitteratur og evidensgennemgang\nAd. anbefaling 6\nPatienter med aktiverende BRAF V600E kan tilbydes 1. linje behandling med kemoterapi +/- immunterapi eller\nimmunterapi monoterapi i henhold til non-onkogendreven NSCLC retningslinjer.\nMan kan overveje at tilbyde 1. linje BRAF-/MEK rettet behandling (dabrafenib plus trametinib eller encorafinib\nplus binimetinib), til udvalgte patienter (ikke egnet til kemoterapi og/eller immunterapi) efter godkendelse af\nafdelingsledelsen og evt. det regionale medicinudvalg. Prisen på nogle BRAF-/MEK inhibitorer er faldet til et\nniveau hvor det ikke altid er nødvendigt at ansøge det regionale medicinudvalg.\nBRAF/MEK rettet behandling er anbefalet som 1. linje behandling i ESMO og NCCN guidelines.\nI et fase 2 studie blev effekten af dabrafenib plus trametinib undersøgt i BRAF V600E muterede NSCLC\npatienter, der ikke tidligere havde modtaget behandling (kohorte C) (40)[2b]. I studiet var ORR 64% og median\nDOR 10,4 mdr. mPFS var 10,9 mdr. og mOS 24,6 mdr. De hyppigste grad 3-4 AEs var pyreksi (11%), ALAT\nstigning (11%), hypertension (11%) og opkastninger (8%).\nI en opdateret 5-års opgørelse (41)[2b] var mPFS uændret 10,8 mdr. og mOS var 17,3 mdr. for denne kohorte\naf patienter. Forfatterne konkluderede, at behandling med dabrafenib plus trametinib har betydelig klinisk\neffekt og en tolerabel bivirkningsprofil uagtet om gives i 1. linje (kohorte C) eller i senere linjer (kohorte B).\nEffekten af encorafenib og binimetinib for BRAF V600E muterede NSCLC patienter blev undersøgt i fase 2\nstudiet PHAROS (42)[2b]. Både ikke-tidligere behandlede patienter og patienter, der havde modtaget 1. linje\nbehandling med platinbaseret kemoterapi plus/minus immunterapi var inkluderet. Man fandt ORR på 75% og\nmedian DOR kunne ikke estimeres (data umodne) for den behandlingsnaive gruppe vs ORR på 46% og\nmedian DOR 16,7 mdr. for gruppen af tidligere behandlede patienter. mPFS kunne ikke estimeres (umodne\ndata) for de behandlingsnaive og var 9,3 mdr. for de tidligere behandlede. De hyppigste grad 3 AEs var ASAT\nstigning (7%) og ALAT stigning (5%).\n7. Patienter med aktiverende MET exon 14 skipping varianter eller MET\namplifikation performance status 0-2 kan tilbydes 1. linje behandling med\nkemoterapi +/-immunterapi i henhold til non-onkogen-dreven NSCLC\nretningslinjer (B)\nLitteratur og evidensgennemgang",
      "start_page": 15,
      "end_page": 18
    },
    {
      "heading": "Ad. anbefaling 7",
      "text": "Data for NSCLC-patienter, med METex14, behandlet med kemoterapi er begrænset. I en retrospektiv\nundersøgelse, var data tilgængelige fra 20 NSCLC-patienter, som havde modtaget forskellige typer\nkemoterapi og opnåede en PFS på 4,0 måneder og et OS på 9,5 måneder. Tolv af de 20 patienter, der fik\nPemetrexed-baseret kemoterapi havde en ORR på 33,3 % (43)[2b]. I en anden retrospektiv undersøgelse, 3\naf 11 patienter med NSCLC behandlet med kemoterapi opnåede en partiel respons (44)[2b]. Da disse data\nikke er head-to-head sammenlignende, bør de fortolkes med forsigtighed og kan kun give en svag idé om,\nhvad der kan opnås med kemoterapi hos NSCLC-patienter med METex14.\nTepotinib eller Capmatinib (grundet deres intrakranielle effekt) kan overvejes i 1. linje til patienter med\ncerebrale metastaser efter godkendelsen af regionale medicinudvalg (45-48) [2b].\nVISION er et fase 2 ikke-randomiseret studie hvor tepotinib viste ORR 56,1% for patienter med cerebrale\nmetastaser, herunder for behandlingsnaïve 64.3%, og for tidligere behandlede 48.3%.\nTepotinib krydser blod-hjerne-barrieren og er aktiv i CNS (49) [2a].\nCrizotinib kan, ligeledes, overvejes i 1. linje til patienter unfit for kemoterapi (se anbefaling 16).\nIMMUNTERAPI MONOTERAPI\nNSCLC-patienter med METex14 ser ud til at respondere mindre på immunterapi, men de rapporterede\nsvarprocenter er inkonsistente (39). I henhold til NCCN guidelines 2024\nanbefales immunterapi som hovedregel ikke, ej heller til patienter med høje PD-L1-niveauer.\n8. Patienter med aktiverende KRAS G12C og performance status 0-2 kan tilbydes 1.\nlinje behandling med kemoterapi +/-immunterapi i henhold til non-onkogendreven\nNSCLC retningslinjer (A)\nLitteratur og evidensgennemgang\nAd. anbefaling 8\nPatienter med NSCLC og aktiverende KRAS G12C variant kan tilbydes 1. linje behandling med kemoterapi +/-\nimmunterapi i henhold til non-onkogendreven NSCLC retningslinjer.\nImmunterapi monoterapi er en mulighed til denne patientgruppe. I de retrospektive opgørelse af patienter med\nonkogen-dreven NSCLC behandlet med immunterapi monoterapi IMMUNOTARGET (39)[2b] og i Keynote 042\nstudiet (50) [1b] var der ingen forskel på ORR og mPFS mellem patienter med KRAS mutation og KRAS wild\ntype. Immunotarget: 271 patienter med KRAS mutationer inkluderet. Man fandt ORR var 26% og mPFS var\n2,5 mdr. mOS var 13,5 mdr. Keynote 042: mPFS 12 mdr for patienter med KRAS mutation.\n9. Patienter med aktiverende EGFR exon20 ins / ERBB2 (HER2) /NTRK varianter og\nPS 0-2 kan tilbydes 1. linje behandling med platinbaseret kemoterapi (B)\nLitteratur og evidensgennemgang\nAd. anbefaling 9\nEGFR exon 20 insertioner\nPatienter med NSCLC og aktiverende EGFR exon 20 insertion kan tilbydes 1. linje behandling med platin-\ndublet kemoterapi som anbefalet i ESMO (13)[5] og NCCN guidelines 2024 (51)[5]. Man kan overveje platin-\nkemoterapi plus pemetrexed som fortrukne behandling på baggrund af bedre ORR (41% versus 19%) dog i\nsmå retrospektive opgørelser (52)[4]. Immunterapi monoterapi er ikke undersøgt i denne patientgruppe, men\npå baggrund af realworld-data og retrospektive opgørelser (53, 54)[4] bør immunterapi nok undgås.\nSamlet set udgør EGFR exon 20 ins, 4-12% af alle EGFR varianter. De er en heterogen gruppe, med\nvarierende effekt af EGFR rettet TKI (55, 56). De specifikke EGFR exon 20 insertion varianter: p.V769_D770\ninsX. (24,6%), p.D770_N771 insX (25,5%) og p.H773_V774 insX (22,6%) er typisk resistente overfor de\nklassiske EGFR TKIer. Platin-baseret kemoterapi til denne type varianter har effekt, men den er begrænset:\nORR 23-29% og PFS 3,4-6,9 mdr. (57)[3a]. Der er et stort behov for nye behandlingsmuligheder til denne\npatientgruppe.\nVarianten EGFR p.A763_Y764insFQEA (4-6% af alle EGFR exon 20 ins varianter) for et protein beliggend\nhelix regionen har en lignende struktur som de klassiske EGFR varianter og er den eneste EGFR exon20\ninsertion, som responderer på 1. 2. og 3. generation EGFR-TKI (58)[4]. Case rapports har vist effekt af EG\nTKIer, også osimertinib (ORR 50%) (58, 59) [4]. På den baggrund kan man overveje at tilbyde 1. linje\nosimertinib til denne variant under tæt responsmonitorering.\nERBB2(HER2) mutation\nFor beskrivelse af ERBB2 varianter / HER2 –se anbefaling 18.\nDer ingen, i EMA, godkendte HER-rettede TKI, antistoffer eller ADCer, som 1. linje behandling af ERBB2\n(HER2) muteret / amplificeret / eller for overekspression af HER2 receptoren i NSCLC. Derfor behandles,\ndenne patientgruppe, i henhold til anbefaling for pallierende 1. linje behandling til patienter med non-onkog\ndreven pulmonalt adenocarcinom. I henhold til ESMO konsensus rapport for HER2 NSCLC (60)[5] ses\nbegrænset effekt af kemoterapi +/- immunterapi til denne patientgruppe og patienterne bør derfor tilbydes\ninklusion i danske studier, hvis muligt.\nNTRK fusion\nPatienter med NSCLC og NTRK fusion kan tilbydes 1. linje behandling med platin-dublet kemoterapi som\nanbefalet i ESMO guidelines (13) [5].\nMan kan overveje at tilbyde NTRK-rettet behandling i 1. linje, til udvalgte patienter (ikke egnet til kemoterap\nmed spredning til CNS) efter godkendelse i regionale medicinudvalg. I NCCN guidelines 2024 er NTRK-ret\nbehandling den foretrukne første linje behandling (51) [5].\nNTRK fusioner er sjældne (<0,1% af NSCLC) og der er derfor begrænsede data. Der foreligger ikke data p\nførste linje NTRK-rettet behandling med entrectinib og larotrectinib. Begge behandlinger er godkendt af EM\nNTRK fusioneret NSCLC, på baggrund af basket trials.\nEntrectinib er undersøgt i fase 1 og 2 basket-studierne ALKA-372, STARTRK-1 og STARTRK-2 og opdater\ndata fra disse studier er publiceret i 2022 (61)[2b]. Ud af 121 inkluderede patienter, havde 22 NSCLC. ORR\nvar 64% med mDOR på 19,9 måneder og mPFS på 14,9 måneder. Entrectinib var i studiet effektivt\nintrakranielt med ORR på 63,6% hos patienter med CNS metastaser ved baseline (blandede diagnoser).\nLarotrectinib er undersøgt i NTRK-fusioneret NSCLC ved poolede resultater fra 2 fase 1/2 basket trials (20\npatienter) (62)[2b]. ORR var 73%, mDOR var 33,9 måneder, PFS 35,4 måneder og OS 40,7 måneder. 10/2\npatienter havde CNS metastaser ved baseline og hos disse patienter var den intrakranielle ORR 63%.\nSe i øvrigt under anbefaling 18.\nde i\nGFR\ngen-\npi,\nttet\npå\nMA til\nrede\nR\n10. Patienter med aktiverende øvrige sjældne EGFR varianter og PS 0-2 kan tilbydes 1.\nlinje behandling med osimertinib (B)\nLitteratur og evidensgennemgang\nAd. anbefaling 10\nPatienter med sjældne EGFR varianter kan tilbydes 1. linje osimertinib i henhold til ESMO og NCCN\nguidelines. Afatinib er også anbefalet af de to guidelines, men er ikke tilgængelig i DK uden forudgående\nansøgning ved lægemiddelstyrelsen.\nDe sjældne EGFR varianter udgør 10-14% af alle EGFR varianter. De hyppigste af de sjældne EGFR varianter\ner EGFR exon 20 insertion (5%) (se separat anbefaling 9), EGFR exon 18 G719X, EGFR exon 20 S768I og\nEGFR exon 21 L861Q. Cirka 14% af de sjældne EGFR varianter ses sammen med en anden samtidig EGFR\nvariant (63) uden at det ser ud til at have betydning for effekten af osimertinib.\nDer foreligger 3 fase II studier der undersøger effekten af EGFR rettet TKI (osimertinib eller afatinib) til\novenstående sjældne varianter. Patientantallet er begrænset pga. de sjældne forekomster og et af studierne\nmåtte ophøre inklusionen grundet for langsom rekruttering.\nSingle-arm fase II studierne (64, 65) [2b] undersøgte effekten af osimertinib til 17 og 37 patienter med EGFR\nvarianterne: EGFR exon 18 G719X, EGFR exon 20 S768I og EGFR exon 21 L861Q. Studierne viste følgende\neffektdata: ORR 47-50%, PFS 8,2-10,5 mdr., DOR 8,7-11,2 mdr. og OS 13,8 mdr.\nUNICORN studiet er ligeledes et fase II (66) [2b], single-arm studie, der undersøgte effekten af osimertinib til\n40 patienter med sjældne EGFR varianter med lignende effekt, ORR 55%, PFS 9,4 mdr. og DOR 22,7 mdr. En\nfjerdel af patienterne havde cerebrale metastaser: Intra-kraniel ORR: 100%. Effekten beskrives afhængig af\nEGFR varianten: G719: PFS 5,1 mdr., L861Q: PFS 22,7 mdr., S768I: PFS 9,4 mdr. Subgruppe analyserne er\ndog baseret på få patienter og dermed usikre.\nDer er desuden foretaget en post-hoc analyse af LUX-lung 2/3/6 studierne (fase II og randomiseret fase III)\nsom undersøgte effekten af afatinib til patienter med EGFR muteret NSCLC. Post-hoc analysen viste for\npatienter med de sjældne varianter (EGFR exon 18 G719X, EGFR exon 20 S768I og EGFR exon 21 L861Q)\nORR 56%-100%, PFS 10,7 mdr. og OS 19,4 mdr.\nBivirkningerne beskrevet i ovenstående osimertinib studier stemte overens med bivirkningerne under\nosimertinib til patienter med de klassiske EGFR varianter.\nPallierende 2. linje onkologisk behandling af onkogen-dreven ikke-\nsmåcellet lungekræft\n11. Patienter med aktiverende klassiske EGFR mutationer og performance status 0-2 og\nsystemisk progression (efter re-biopsi) kan tilbydes 2. linje behandling med platin-\nbaseret kemoterapi (A)\nLitteratur og evidensgennemgang\nAd. anbefaling 11\nAlle patienter med EGFR muteret lungecancer vil på et tidspunkt udvikle resistens overfor 1. linje osimertinib.\nMåden hvorpå sygdommen udvikler resistens er forskellig fra patient til patient (66). Det anbefales, som i\nESMO guidelines, at behandle resistensudviklingen på baggrund af progressionsmønstret og symptomer. Man\nskal være opmærksom på at sygdommen til tider kan have et rapidt progredierende forløb i forbindelse med\nresistensudvikling. Omvendt kan udvalgte patienter fortsat have klinisk effekt af osimertinib på trods af\nbilleddiagnostisk progression (behandling beyond progression).\nASYMPTOMATISK PROGRESSION\nDet anbefales som i ESMO og NCCN guidelines at fortsætte osimertinib under tæt monitorering.\nOLIGOPROGRESSION\nEn femtedel af patienter oplever progression i enkelte metastaser (≤3) under osimertinib -oligoprogression\nI henhold til ESMO og NCCN guidelines kan man overveje at tilbyde patienterne lokalbehandling mod\noligoprogredierende sites under osimertinib.\nSYSTEMISK PROGRESSION\nGodt halvdelen af patienterne som progredierer under osimertinib oplever systemisk progression (>3\nprogredierende metastaser) (69). Resistensmekanismerne under osimertinib er mange. Det anbefales at\nudvalgte patienter (relevant restlevetid, AT og performance status) med systemisk progression får foretaget en\nre-biopsi (gerne fra progredierende metastase) for at udelukke transformation til anden histologi (SCLC eller\nplanocellullært karcinom). Biopsien bør desuden analyseres med et bredt NGS panel for at undersøge for\nerhvervede targeterbare resistensmutationer.\na. Histologisk transformation\nFemten procent af patienterne i progression udvikler en histologisk transformation til SCLC. Specielt patienter\nmed co-mutationer i TP53 og RB1 har en øget risiko for denne transformation (67)[3a]. Behandlingen vil i dette\ntilfælde være carboplatin og etoposid.\nVed histologisk transformation til planocellulært carcinom behandles patienten efter vanlige 1. linje\nretningslinjer for denne patientgruppe.\nb. Targeterbare resistensmekanismer\nPatienter med erhvervede resistensvarianter bør tilbydes inklusion i post-EGFR-TKI-protokoller, hvis muligt.\nLangt de fleste patienter med systemisk progression bør tilbydes platinbaseret kemoterapi.\nSåfremt der ved rebiopsi findes targeterbare resistensmekanismer kan man overveje at behandle\nresistensmekanismerne som monoterapi eller under fortsat osimertinib (kombinations-TKI). På baggrund af\nden begrænsede evidens (se nedenstående) for effekt, kan denne behandling ikke anbefales uden for kliniske\nforsøg.\nResistens-mekanismerne under osimertinib er opsummeret i 3 review-artikler fra 2023 (67-69) og desuden\nundersøgt i AURA 3 studiet (70)[1b]. De hyppigste targeterbare varianter som er associeret med\nresistensudvikling under osimertinib er off-target varianter, altså genetiske ændringer for proteiner uden for\nEGFR signalvejen.\nI denne anbefaling beskrives kun varianter undersøgt i kliniske studier. MET amplifikation, som resistens-\nmekanisme, er bedst undersøgt. Se desuden under anbefaling 18 (HER2/ERBB2).\nMET amplifikation\nMET amplifikation er årsag til 7-15% af resistensmekanismerne (70-72).\nINSIGHT studiet (71) [2b] undersøgte effekten af gefitinib plus tepotinib over for kemoterapi til patienter i\nprogression under 1. linje 1./2. generations EGFR-TKI (14 patienter med MET amplifikation): ORR 67% vs\n43%, PFS 16,6 mdr. versus 4,2 mdr. og OS 37,3 mdr. vs 13,1 mdr. De rapporterede hyppigste grad 3 eller der\nover bivirkninger var: Diare (8,3%) og amylase/lipase forhøjelse (33,3%).\nTATTON studiet (fase 1b studie) (72) [3b] undersøgte effekten af kombinationen osimertinib plus MET\ninhibitoren savolitinib til samme patient population (B1: patienter i progression på 3. generations TKI) og viste\nORR på 33%, PFS på 5,5 mdr. og DOR 9,5 mdr. Over halvdelen af patienter oplevede grad ≥3 bivirkninger.\nDe hyppigste bivirkninger (alle grader) var kvalme (52%) og perifere ødemer (36%). Savolitinib er ikke EMA\ngodkendt.\nMD Andersson Cancer Center publicerede, i 2023, en samlet case report for patienter der modtog MET rettet\nbehandling (crizotinib, capmatinib, savolitinib eller tepotinib) plus osimertinib efter progression på osimertinib\n(dvs. 2-3. linje) (73) [4]. ORR var 47% og median tid i behandling var 27 måneder for 17 patienter med\nevaluerbar sygdom. I dette studie blev der retrospektivt rapporteret acceptabel toksitet, dog blev der\nrapporteret en øget opmærksomhed på pneumonitis specielt hos patienter der tidligere har modtaget\nimmunterapi.\nReal-world data af danske patienter (case series) viser at kombination af EGFR-TKI med Crizotinib kan\nresultere i PFS mellem 3-19 mdr. afhængig af øvrige molekylære ko-alterationer (74) [4].\nMARIPOSA-2 studiet (75) [1b] er et fase III, 3-armet studie, der undersøger effekten af amivantamab\n(bispecifikt antistof rettet mod både EGFR og MET) plus lazertinib (EGFR inhibitor) plus platin kemoterapi\nversus kemoterapi alene eller kemoterapi plus amivantamab, 2. linje behandling efter osimertinib. Studiet viste\nsignifikant bedre ORR (64%/63% vs 36%) i amivantamab armene vs kemoterapi armen. Det samme gjorde sig\ngældende for både PFS (6,3/8,2 mdr versus 4,2 mdr) og CNS PFS (12,8/12,5 mdr versus 8,3 mdr). Der blev\nset flere bivirkninger i amivantamab-armene sammenholdt med kemoterapi: SAE (alle) 32-52% vs 20%.\nBivirkninger grad ≥3: 72-92% vs 48%. De hyppigste bivirkninger var knoglemarvspåvirkning. En øget risiko for\nVTE blev observeret for amivantamab armene 10%-22% vs 5%. Behandlingen ophørte hos 10-22% vs 4% af\npatienterne.\nKombinationsbehandlingen amivantamab/kemoterapi er ikke EMA godkendt.\nAmivantamab monoterapi er ikke godkendt, af EMA, til klassiske EGFR varianter eller MET varianter\n(begrænset evidens) og kan derfor ikke anbefales som 2. linje behandling til de klassiske EGFR varianter\nudenfor kontrollerede forsøg.\nc. Kemoterapi under fortsat osimertinib\nDer foreligger ingen prospektive studier der undersøger effekten af fortsat osimertinib tillagt kemoterapi ved\nresistensudvikling under osimertinib.\nEt enkelt studie har undersøgt fortsat gefitinib ved progression tillagt kemoterapi: IMPRESS studiet (fase II)\n(76)[2b] undersøgte effekten af gefitinib tillagt kemoterapi ved progression under 1. linje gefitinib over for\nkemoterapi alene. Studiet viste ingen forbedret PFS eller OS ved kombinationen. Studiet viste flere ≥3\nbivirkninger: 51% versus 25%.\nFLAURA 2 studiet (9) [1b] undersøgte effekten af Osimertinib i kombination med kemoterapi, 1. linje\nbehandling. Ubehandlede patienter med EGFR exon 19 deletion eller L858R blev randomiseret 1:1 i en open-\nlabel fase 3 studie mellem standard osimertinib versus osimertinib plus platin-kemoterapi plus pemetrexed.\nOsimertinib i kombination med kemoterapi 1. linje er signifikant bedre for PFS (25,5 mdr. versus 16,7 mdr.) og\nDOR (25,5 mdr. versus 15,3 mdr.). Effekten sås i alle subgrupper, men specielt for patienter med\nasymptomatiske og stabile CNS metastaser (PFS: 13,8 mdr vs 24,9 mdr) og for patienter med EGFR L858R\nvarianten (PFS: 13,9 mdr vs 24,7 mdr). De foreløbige OS data blev præsenteret på ASCO 2024: OS for\nkombinationen= NR, for osimertinib monoterapi=38,6 mdr. Bivirkninger grad ≥3 var 64% for kombinationen vs\n27% for osimertinib. SAE (alle) var 38% i kombinationsarmen vs 19% i osimertinib monoterapi-armen. De\nhyppigste bivirkninger var knoglemarvspåvirkning: 71% (kombinations-arm) vs 24% (osimertinib-arm). Der var\ningen forskel i graden af pneumonitis mellem de to arme (3-4%).\nEn ESMO expert concensus rapport fra 2022 (2) [5] anbefaler kombinationen osimertinib plus kemoterapi til\npatienter med ekstra-kraniel progression under osimertinib og samtidig stabile asymptomatiske cerebrale\nmetastaser.\nKombinationen Osimertinib plus kemoterapi er ikke EMA godkendt.\nPå DOLG mødet den 11/6 2024 blev tillæg af kemoterapi til osimertinib i forbindelse med progression under\nosimertinib drøftet. Det blev besluttet, på baggrund af manglende evidens, ikke at anbefale kombinationen\nsom 2. linje behandling. Derfor kan det ikke anbefales at fortsætte osimertinib under tillæg af kemoterapi, ved\nprogression på osimertinib. DOLG anbefaler, i henhold til NCCN guidelines, til udvalgte patienter, der\nprogredierer intracerebralt under 2. linje kemoterapi, at overveje tillæg af osimertinib som reinduktion.\ne. Immunterapi til patienter med EGFR muteret sygdom\nAktuelt er der ingen sikker evidens for at kombinationen kemoterapi plus immunterapi, 2. linje behandling efter\nEGFR TKI er bedre end kemoterapi alene. Meget tyder på at immunterapi i kombination med EGFR TKI eller\nsekventielt (EGFR TKI efter immunterapi) resulterer i alvorlige bivirkninger, specielt interstitiel lungesygdom og\nleverpåvirkning. Derfor kan immunterapi hverken i kombination eller som monoterapi til EGFR muteret NSCLC\nikke anbefales som næste linje behandling efter osimertinib.\nImmunterapi kombineret med kemoterapi\nDer foreligger 4 fase III studier der undersøger effekten af kemoterapi i kombination med PD-L1 inhibitor, 2.\nlinje behandling efter progression under EGFR TKI: IMpower 150, Orient-31, CheckMate 722 og Keynote-789.\nIngen af studierne har vist en signifikant forbedret ORR, PFS eller OS ved at kombinere immunterapi med\nkemoterapi hos patienter i progression efter EGFR TKI.\nIMpower 150 (77) [1b] er et fase 3, 3-armet studie: Atezolizumab plus bevacizumab plus platin-dublet\nkemoterapi (ABP) versus atezolizumab plus platin-dublet (AP) versus bevacizumab plus platin-dublet (BP). I\nen subgruppe analyse for 124 patienter (78 patienter, tidligere EGFRTKI) med EGFR varianter fandt man\ningen forskel i effekt mellem atezolizumab plus platin-dublet (AP) versus bevazizumab plus platin-dublet (BP).\nOS var numerisk bedre i Atezolizumab plus bevacizumab plus platin-dublet kemoterapi (ABP) 27,8 versus\n18,1 mdr. (AP) versus 14,9 (BP). Studiet havde ikke power til disse subgruppe analyser.\nKombinationen ABP anbefales i ESMO guidelines, men ikke af NCCN guidelines.\nOrient-31 (78) [1b] er et kinesisk fase III, 3-armet studie, der undersøger effekten af VEGF inhibitor plus PD-1\ninhibitor plus kemoterapi over for kemoterapi alene eller kemoterapi plus immunterapi. Der var ingen\nsignifikant forskel i OS mellem de 3 behandlingskombinationer.\nChekmate-722 (79) [1b] er et fase III, 2-armet studie der undersøgere effekten af nivolumab plus platin-dublet\nkemoterapi over for platin-dublet kemoterapi hos 270 patienter. Studiet måtte stoppe før fuld inklusion af\nberegnede antal patienter (500) pga. corona-pandemien. Studiet viste ingen signifikant forskel i ORR (31%\nversus 27%), PFS (5,6 mdr. versus 5,4 mdr) eller OS (19,4 mdr. versus 15,9 mdr.).\nKeynote-798 (LBA ASCO 2023) [1b] er et fase III, 2-armet studie der undersøgte effekten af pembrolizumab i\nkombination med platin-dublet kemoterapi over for platin-dublet kemoterapi alene. Studiets resultater blev\npræsenteret på ASCO 2023 for 492 patienter. Studiet fandt ingen signifikant forskel i ORR, PFS eller OS. Den\nmanglende effekt var uafhængig af PD-L1 status.\nImmunterapi kombineret med EGFR TKI\nKombinationen EGFR TKI plus immunterapi er undersøgt i en række fase I/II studier (80-85) [3b]. Alle\nstudierne rapporterede betydelige bivirkninger, specielt interstitiel lungesygdom / pneumonitis, leverpåvirkning\nog gastrointestinale bivirkninger. Studierne stoppede før tid pga. den sete øget toksitet. Derfor anbefales det\nikke at kombinere immunterapi med TKIs.\nImmunterapi monoterapi\nImmunterapi monoterapi til patienter med EGFR TKI resistens kan som hovedregel ikke anbefales pga.\nmanglende evidens for effekt.\nEt fase II studie (86) [2b], undersøgte effekten af pembrolizumab til TKI naïve patienter med avanceret EGFR\nmuteret NSCLC, PD-L1 ≥ 1% (≥50 % hos 74% af patienterne). Studiet stoppede tidligt pga. manglende effekt.\nEt randomiseret fase II studie (87) [2b] undersøgte effekten af nivolumab over for platin-dublet kemoterapi til\npatienter resistente overfor EGFR TKI. Hundrede-to patienter blev inkluderet og studiet viste signifikant\nforbedret PFS til fordel for kemoterapi-armen (PFS 1,7 mdr. (nivo) versus 5,6 mdr. (kemo)) uafhængig af PD-\nL1 status. Der var ingen forskel i OS.\nIMMUNOTARGET (39) [2a] studiet er en retrospektiv opgørelse af immunterapi monoterapi til patienter med\nonkogen-dreven NSCLC (125 patienter med EGFR mutation). I dette studie beskrives ORR 12%, PFS 2,1\nmdr. og OS 10,0 mdr. for patienter med EGFR muteret NSCLC. Der var ingen korrelation til rygestatus eller\ntidligere behandling. Af patienter med EGFR mutation udtrykte 3,5% PD-L1 ≥50%. PFS var associeret med\nPD-L1 status: PD-L1 ≥1%: 2,8 mdr. versus PD-L1< 1%: 1,7 mdr.\n12. Patienter med ALK translokation og performance status 0-2(3) og systemisk\nprogression (efter rebiopsi), kan tilbydes 2.-3. linje behandling med lorlatinib eller\nkemoterapi (A/B)\nLitteratur og evidensgennemgang\nAd. anbefaling 12\nAlle patienter vil på sigt udvikle resistens overfor ALK TKI (21) [1a]. Resistensmekanismerne klassificeres efter\nom de skyldes en ændring i selve ALK genet (on-target) eller om de skyldes en ændring i gener associeret\nmed signalvejene uafhængige af ALK (off-target) eller histologisk transformation (88)[2b].\nVed progression på 3. generations ALK-TKI, lorlatinib skal der tages de samme forbehold som ved\nprogression under EGFR-TKI, se desuden anbefaling 11.\nOLIGOPROGRESSION\nLokal ablativ behandling (kirurgi eller strålebehandling) ved oligo-progression, kan overvejes tilbudt under\nsamtidig fortsat ALK-TKI (89-91)[2b].\nSYSTEMISK PROGRESSION\nOn-target resistensmekanismer\nOn-target resistensmekanismerne opstår som både enkelt-mutationer og som flere mutationer udviklet\nsamtidig (compound mutations) i ALK genet. Disse erhvervede mutationer er distinkte for hver ALK-TKI, også\ninden for samme generation af ALK-TKI. Det kan derfor, i udvalgte tilfælde, give mening af skifte mellem\nsamme generations ALK-TKI i forbindelse med resistensudvikling (f.eks. mellem brigatinib og alectinib (2.\ngenerations TKI). Det er dog afgørende at foretage en ny genetisk profilering af progredierende metastaser\n(alternativt ctDNA) for at kortlægge resistensvarianterne (21, 91)[1a, 2b].\nLorlatinib blev udviklet for at overkomme de hyppigste ALK resistens varianter opstået under 1.-2. generations\nALK-TKI. On-target resistensmekanismer udviklet under lorlatinib er ofte karakteriseret ved tilstedeværelse af\nflere forskellige mutationer (compound varianter) i ALK genet (hyppigst G1202R + L1196M og G1202R +\nF1174C/L), formentlig på baggrund af den sekventielle behandling med ALK-TKI. Compound varianter er\nsvære at behandle og de ovenstående beskrevne varianter er resistente over for alle de godkendte ALK TKIer.\nPatienterne bør derfor tilbydes inklusion i kliniske forsøg (hvis tilgængelige) eller platin-dublet kemoterapi\n(21)[2a]. ved progression under lorlatinib.\nOff-target resistensmekanismer\nGodt halvdelen af patienterne som udvikler resistens overfor 2. generations ALK-TKI har ingen nytilkomne\nALK varianter i progressionsbiopsien. Der er beskrevet multiple off-target resistensmekanismer som aktiverer\nALK-uafhængige signalveje under ALK-TKI. Der foreligger case-rapports som beskriver respons ved at\ntillægge crizotinib til fortsat lorlatinib ved erhvervet MET amplifikation (21, 89)[1a, 2b]. Flere studier, der\nundersøger effekten af kombineret TKI, er på vej. TKI kombinationerne kan,før der foreligger yderligere\nevidens, ikke anbefales udenfor kliniske forsøg.\nHistologisk transformation\nHistologisk transformation til småcellet lungecancer og planocellulært karcinom er beskrevet under behandling\nmed både lorlatinib, alectinib og brigatinib, om end det sjældent ses. Den histologiske transformation skal\nbehandles i henhold til retningslinjerne for non-onkogen-dreven NSCLC eller SCLC.\nIMMUNTERAPI MONOTERAPI\nSom for patienter med EGFR-mutationer, findes der ingen sikre data, der understøtter anvendelsen af\nimmunterapi hos patienter med ALK-fusion (92)[2b].\nI et retrospektivt studie af 42 inkurable patienter med NSCLC og ALK-translokation, der modtog immunterapi\nuden forudgående ALK-TKI, blev der vist en meget kort PFS (2,3 mdr.). Hos patienter, der modtog\nimmunterapi uden forudgående ALK-TKI, var den 3,9 mdr., og hos patienter, der modtog immunterapi efter en\nALK-TKI, var den 1,5 mdr. (93)[2b].\n13. Patienter med ROS1 translokation og performance status 0-2 og systemisk\nprogression og ingen mulighed for yderligere ROS1 rettet TKI, kan tilbydes 2. linje\nbehandling med platinbaseret kemoterapi (A)\nLitteratur og evidensgennemgang\nAd. anbefaling 13\nPlatinbaseret kemoterapi +/- immunterapi anbefales til patienter med ROS1 translokeret NSCLC uden\nmulighed for yderligere ROS rettet TKI.\nImmunterapi monoterapi kan som hovedregel ikke anbefales til patienter med ROS1 translokation pga.\nmanglende evidens for effekt. I den retrospektive opgørelse af patienter med onkogen-dreven NSCLC\nbehandlet med immunterapi monoterapi IMMUNOTARGET (39)[2b] var kun 7 patienter med ROS1\ntranslokation inkluderet. For de fleste patienter i studiet var der ikke effekt af immunterapi monoterapi.\nREPOTRECTINIB\nRepotrectinib er en ROS1 rettet behandling, som endnu ikke er EMA godkendt. I fase 2 delen af TRIDENT-1\nstudiet var ORR, for patienter med ROS1 translokation ikke tidligere behandlet med ROS1 TKI, 79% og mPFS\nvar 35,7 mdr. (94)[2b]. For patienter tidligere behandlet med ROS TKI var ORR 38% og mPFS var 9,0 mdr.\nIntra-kraniel ORR, for de tidligere TKI behandlede patienter, var 38%.\nNiogtyve procent af patienterne oplevede grad ≥3 AEs, de hyppigste var anæmi (4%) og forhøjet\nkreatinkinase (4%). Konklusionen på studiet var, at repotrectinib havde effekt ved ROS1 translokeret NSCLC\nuafhængig af om der tidligere var behandlet med ROS1 TKI og uafhængig af cerebral metastasering.\n14. Patienter med RET translokation og performance status 0-1 (2) kan tilbydes 2. linje\nbehandling med selpercatinib (A)\nLitteratur og evidensgennemgang\nAd. anbefaling 14",
      "start_page": 18,
=======
      "heading": "BRIGATINIB VERSUS ALECTINIB Versus LORLATINIB",
      "text": "For EML4-ALK variant 3, ORR for brigatinib is 91% versus 68% for alectinib (23)[1b]. In addition, in approximately 10 percent of patients with other than EML4 fusion partner (e. g. STRN, PLEKHH2, KANK1), response to alectinib (28-30)[4] has only been reported. Additionally, the patient's preferences should also be taken into consideration under alectimatinib variant 3. Unlike other ALK-TKIs, co-mutation in TP53 has less influence on the effect of lorlatinib (32)[1b] in the patient group with EML-4-ALK version 3 and co-existing TP53 mutation is seen in a mPFS in patients with 2xivating. Patients with PS ≥ 2 patients in PS3 were not included in the Phase 3 studies (ALEX, ALTA-1L and CROWN). Spacious real-world data show that these patients also benefit from ALK-TKI, however, the efficacy is probably less than in patients with PS 0-2 (33)[2b]. For patients with PS ≥ 2 recommend ESMO and NCCN guidelines, ALK TKI. It is assessed that data from EGFR studies that have shown high ORR, manageable adverse reactions and improvement of PS can be extrapolated to other oncogenic drivers (13)[5]. Elderly patients Elderly patients over 65 years of age may be treated, according to the ALK/TKI SPCs, without adjustment of dose. 4. Patients with ROS1 translocation and performance status 0-2(3) may be offered 1. line entrectinib, alternative crizotinib (B) Litterature and evidence review Ad. recommendation 4 In patients with ROS1 trans-analysis patients with NSCLinib to patients with a placeboC is considered. The most frequent AEs grade 3-4 were weight gain (8%) and neutropenia (4%). CNS metastasisation In a retrospective study of patients with ROS1 translocated NSCLC on treatment with crizotinib, 36% had brain metastases at the time of diagnosis (35)[4]. For 47% of patients, CNS was the first and only locating for progression. Entrectinib probably had a better effect in CNS than crizothinib (36)[5]. REPOTRECTINIB Repotrectinib is recommended as possible treatment, especially for patients with cerebral metastasis, in ESMO and NCCN Guidelines. Repotrectinib is not EMA approved by the study. ORR was 72% and median DOR 24.7 months mPFS was 19.3 months and mOS 51.4 months. This led to the approval of crizotinib to ROS1 translocated NSCLC. The most frequent AEs grade 3 were hypophosphataemia (15%), neutropenia (9%), transaminase increase (4%) and vomiting (4%). Elderly patients Elderly patients over 65 years of age may be offered treatment According to the Summary of Product Characteristics for entrectinib and crizothinib, treatment can be given without dose adjustment. Patients with PS ≥ 2 For patients with PS≥ 2 recommend ESMO and NCCN guidelines ROS1. Patients with RIGHT Translocation and PS 0-2 are assessed to be available on the first line of platinum-containing chemotherapy (B). Consider self-resistant adverse reactions and improvement of PS can be extrapoled to other oncogenic drivers (13)[5]. The most frequent RET fusion partners were KIF5B (45% of patients) and CCDC6 (10% of patients), 82% versus chemotherapy +/- immunotherapy, 58%. More than one third of patients achieve complete response intracranial. On the basis of the LIBRETTO-431 study, the regional medical committee may be considered for authorisation of the first line Selpercatinib. Adverse reactions The most frequent adverse events of the Selpercateinib were increased AST/ALT, hypertension, diarrhoea, oedema, dry mouth, increased bilirubin and prolonged QTc interval. Severe and life-threatening pneumonitis may occur. The incidence of grade 3 and higher adverse reactions was more frequent for self-percatimatinib than for chemotherapy (70% vs 57%). IMMUNTERAPY MONOTERAPI Immunotherapy monotherapy should be avoided in this patient group. Since the RET variant is rare, limited data are available. The IMMUMEATARGET study is ALK, ROS1 and RET analysed as an overall group and for this group no efficacy of immunotherapy as monotherapy has been observed (39). Elderly patients treatment with self-Percatinib has shown efficacy independent of age and is generally well tolerated in patients ≥ 65 years. The frequency of reported adverse events is higher for increasing age groups; ≥ 65-74 years (58 years ≥ 75. Patients with active BRAF V600E and performance status 0-2 can be offered first line treatment with chemotherapy +/- immunotherapy or immunotherapy monotherapy according to non-oncogenic NSCLC guidelines (B) Literature and evidence review Ad. recommendation 6 Patients with activating BRAFV600E can be provided 1st line treatment by chemotherapy+/- immunotherapy or immunotherapies according to Non-oncogenous NACLC Guidelines (B).",
      "start_page": 15,
      "end_page": 17
    },
    {
      "heading": "Clinical guideline • Require DLCG departmental management and possibly the regional medicine committee.",
      "text": "In a phase 2 study, the efficacy of dabrafenib plus trametinib was studied in BRAF/MEK directed treatment as first-line treatment in ESMO and NCCN guidelines. In the study, ORR was 64% and median DOR 10.4 months mPFS was 10.9 months and mOS 24.6 months. The most frequent grades 3-4 AEs were pyrexia (11%), ALT increase (11%) and vomiting (8%). In an updated 5-year inventory (41)[2b] mPFs were 10.8 months and MOS were 17.3 months for this cohort of patients. The authors concluded that treatment with dabraphenib plus tranmetinib had significant clinical efficacy and a tolerable adverse reaction profile was not observed in the 1st line (cohorte C) and MOS were 17.2 months for these cohorts. Both non-previously treated patients and patients who had received first-line treatment with platinum-based chemotherapy plus/minus immunotherapy were included. ORR of 75% and median DOR could not be estimated (unripened data) for the treatment naïve group vs. ORRR of 46% and median DOR of 16.7 months for the group of previously treated patients. mPFS couldn't be estimated for the treated naïves and was 9.3 months for those previously treated. The most frequent grade 3 AEs were AST increase (7% and ALT increase (5%). 7. Patients with activating MET exon 14 skipping variants or MET amplification performance status 0-2 can be offered 1st line treatment with chemotherapy +/-immune therapy according to non-oncoken-driven NSCLC guidelines (B) Literature and evidence review",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "Ad. Recommendation 7",
      "text": "In a retrospective study, data were available from 20 NSCLC patients who had received different types of chemotherapy and achieved a PFS of 4.0 months and an OS of 9.5 months. Twelve of the 20 patients receiving Pemetrexed-based chemotherapy had an ORR of 33.3 % (43)[2b]. In another retrospective study 3 of 11 patients with NSclC treated with chemotherapy achieved a partial response (44)[2 b]. As these data are not head-to-head comparison, these data should be interpreted with caution and can only give a weak idea of what can be achieved with chemotherapy in NSCLEC patients with METex14. Tepotinib or Capmatinib (due to their intracranial effect) may be considered in the first line of patients with cerebral metastases following the approval of regional drug committees (45-48) [2b] VISION is a phase 2 non-reverse treatment with bone marrow in patients. Crizotinib was also considered in line 1 for patients unfit for chemotherapy (see recommendation 16). IMMUNTERAPI MONOTERAPI NSCLC patients with METEX14 appear to respond less to immunotherapy, but the reported response rates are inconsistent (39). According to NCCN guidelines 2024, immunotherapy is not recommended as a general rule, nor for patients with high PD-L1 levels. 8. Patients with activated KRAS G12C and performance status 0-2 can be offered 1st-line chemotherapy +/-immune therapy according to non-oncogen-driven NSclC guidelines. Immunotherapy monotherapy is an option for this patient group. In the retrospective inventory of patients with oncogen drive G12c variant can be provided 1st line chemotherapy plus/immunotherapy according to Non-onkogen Drive NS CLC guidelines . Immunotarget: 271 patients with KRAS mutations included. ORR was found to be 26% and mPFS was 2.5 months for mOS was 13.5 months for Keynote 042: mPFs 12 months for patients with CRAS mutation. 9. Patients with activated EGFR exon20 ins/ ERBB2 (HER2) /NTRK variants and PS 0-2 can be offered 1st line treatment with platinum-based chemotherapy (B) Literature and evidence review Ad. Recommendation 9 EGFR Exon 20 inserts Patients with NSCLC and activating EGFR EXON 20 insertion may be offered on the first line treatment of platinum-dubled chemotherapy as recommended in ESMO (13)[5] and NCCN guidelines 2024 (51)[5]. The specific EGFR exon 20 insertion variants: p.V769_D770 insX. (24.6%), p.D777_N771 insx (25.5%) and p.H773_V774 ins X (22.6%) are typically resistant to the classic EGFR TKIs. Platin-based chemotherapy for this type of variant has an effect, but it is limited: ORR 23-29% and PFS 3.4-6.9 mdr. (57)[3a]. There is a great need for new treatment options for this patient group. Variant EGFR p.A763_Y764insFQEA (4-6% of all EGFR Exon 20 ins variants) for a protein beliggend helix region has a similar structure to the classical EGFR variants and is the only description of EGFRexon20insfQEA (46% of each EGFR EXON 20 INS variant). On the basis of the above, it can be considered to offer first line osimertinib to this variant under close response monitoring. ERBB2(HER2) mutation For description of ERBB 2 variants / HER2 see recommendation 18. No one, in EMA, approved HER-directed TKI, antibodies or ADCs, as first line treatment of ERB2 (HER2) mutated / augmented / or for overexpression of HER2 receptor in NSCLC. Therefore, this patient group is treated, according to recommendation for palliative 1st line treatment in patients with non-oncooked pulmonary adenocarcinoma. According to the ESMO consensus report for HER2 NSclC (60)[5] limited efficacy of chemotherapy +/ immunotherapy to this patient population and therefore patients should be offered inclusion in Danish studies if possible. NTRK fusion Patients with NSCLEC and NTRK fusion can be offered 1. line treatment with platinum-dubled chemotherapy as recommended in ESMO guidelines (13) [5]. NTRK mergers were rare (< 0.1% of NSCLC) and therefore limited data are available. There are no data available on the first line NTRK-oriented treatment with entrectinib and larotractinib. Both treatments are approved by EM NTRk merged NSclC, based on basket trial. Entrectinib was studied in the Phases 1 and 2 basket studies ALKA-372, STARTRK-1 and STARTRk-2 and update data from these studies were published in 2022 (61)[2b]. Out of 121 enrolled patients, 22 NSClC. The ORR was 64% with mDOR of 19.9 months and mPFS of 14.9 months. Entrectinib was effectively intracranial with ORR of 63,6% in patients with CNS metastases at baseline (mixed diagnosis). Larotractinib was investigated in NTRG fusioned NScloC at pooled results from 2 phase 1/2 basket intracranial (20 patients) (62)[22b] at baseline. Patients with active other rare EGFR variants and PS 0-2 can be offered 1st-line treatment with osimertinib (B) Literature and evidence review Ad. recommendation 10 Patients with rare EGFr variants can be provided 1st line osimateinib according to ESMO and NCCN guidelines. Aflatinib is also recommended by the two guidelines, but is not available in DK without prior application by the Medicines Agency. The rare EGFER variants represent 10-14% of all EGFR variations. The most frequent of the rare EGFS variants are EGFR exon 20 insertion (5%) (see separate recommendation 9), EGFR Exon 18 G719X, EGFRexon 20 S768I and EGFR EXON 21 L861Q. Cirka 14% of the Rare EGFR variant is co-administered with another concurrent EGFR version (63) without any impact on the efficacy of osimertinib. There are 3 Phase II studies that investigate the efficacy and efficacy of the EGFR patients. The single-arm phase II studies (64, 65) [2b] investigated the efficacy of osimertinib to 17 and 37 patients with EGFR variants: EGFR exon 18 G719X, EGFR EXON 20 S768I and EGFR Exon 21 L861Q. The studies also showed the following efficacy data: ORR 47-50%, PFS 8.2-10.5 months, DOR 8,7-11,2 months, and OS 13.8 months. The UNICERN study is also a phase II (66) [2 b], single- arm study that examined the efficacy for 40 patients with rare EGFR variant with similar effect, ORR 55%, PFSS 9.4 months and DOR 22.7 months. A fourth patient had cerebral metastases: Intra-cranial ORR: 100%. The effect is described depending on the EGFR version: G7-19: PFS 5,1 months and DOR 22,7 months. The post-hoc analysis showed for patients with rare variants (EGFR exon 18 G719X, EGFR exon 20 S768I and EGFR Exon 21 L861Q) ORR 56%-100%, PFS 10.7 months and OS 19.4 months. Patients with activating classical EGFR mutations and performance status 0-2 and systemic progression (after re- biopsy) can be offered 2nd-line treatment with platinum-based chemotherapy (A) Litteratur and evidence progression Ad. recommendation 11 All patients with EGFR mutated lung cancer will develop resistance to 1st-line patients on the basis of resistance to the disease. Conversely, selected patients may continue to have clinical efficacy of osimertinib despite photodiagnostic progression (treatment beyond progression). ASYMPTOMATIC PROGRESSION As in ESMO and NCCN guidelines it is recommended to continue osimitinib under close monitoring. OLIGOPROGRESSION One fifth of patients experience progression in individual metastases (≤3) during osimertinib -oligo progression According to ESMO or NCCN guidelines, consideration can be given to providing patients with local treatment for oligoprogregating sites under osimateinib. SYSTEMIC PROGRESION Well half of patients with systemic progression experience systemic progression (>3 progression metastases) (69). The resistance mechanisms under osimetinib are many. It is recommended that selected patients (relevant residual life, AT and performance status) with systemic progress experience of a re-map (grediating metastasis) (66). In particular, patients with co-mutations in TP53 and RB1 are at increased risk of this transformation (67)[3a]. The treatment will in this case be carboplatin and etoposide. For histologic transformation to squamous cellular carcinoma, the patient is treated according to usual first line guidelines for this patient group.",
      "start_page": 18,
      "end_page": 22
    },
    {
      "heading": "Clinical guideline • Requirement DLCG b. Targetable resistance mechanisms",
      "text": "Patients with acquired resistance variants should be offered inclusion in post-EGFR-TKI protocols if possible. By far the majority of patients with systemic progression should be provided platinum-based chemotherapy. If re-biopsy contains targetable resistance mechanisms, consideration may be given to treating the resistance mechanisms as monotherapy or under continued osimertinib (combination TKI). On the basis of the limited evidence (see below) for efficacy, this treatment cannot be recommended outside clinical trials. The resistance mechanisms under osimitinib are summarised in 3 review articles from 2023 (67-69) and also examined in the AURA 3 study (70)[1b]. The most frequent targetible variants associated with resistance development under osimatetinib are off-target variants, i.e. genetic changes for proteins outside the EGFR signal pathway. In this recommendation, only variants are described in clinical studies. MET amplification as resistance mechanism has been best studied. See also under recommendation 18 (HER2/ERBB2). MET amplification for proteins beyond the EGF signal path. (14 patients with MET amplification): ORR 67% vs 43%, PFS 16.6 months versus 4.2 months and OS 37.3 months vs. 13.1 months The most frequently reported grade 3 or above adverse events were: Diare (8.3%) and amylase/liposis elevation (33.3%). TATTON study (phase 1b study) (72) [3b] studied the effect of the combination osimertinib plus MET inhibitor savolitinib in the same patient population (B1: patients in progression of 3rd generation TKI) and showed ORR of 33%, PFSS of 5.5 months and DOR 9.5 months. Over half of patients experienced grade ≥ 3 adverse events. The most frequent adverse reactions (all degrees) were nausea (52%) and peripheral oedema (36%). Savolitimatinib is not EMA approved. MD Andersson Cancer Center published, in 2023, an overall case report for patients receiving MET directed treatment (crizotinib, capmatinib, savolitinib or tempoinib) were reported in patients with placebo. In this study, acceptable toxicity was retrospectively reported, however, an increased awareness of pneumonitis was reported especially in patients who have previously received immunotherapy. Real-world data of Danish patients (case series) show that the combination of EGFR-TKI with Crizotinib can result in PFS between 3-19 months depending on other molecular co-alterations (74) [4]. The MARIPOSA-2 study (75) [1b] is a phase III, 3-arm study examining the efficacy of amivantamab (bispecific antibody directed against both EGFR and MET) plus lazertinib (EGFR inhibitor) plus platinum chemotherapy.",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "Clinical guideline • Require DLCG versus chemotherapy alone or chemotherapy plus amivantamab, 2nd line treatment after osimertinib.",
      "text": "The same was true for both PFS (6,3/8,2 months versus 4,2 months) and CNS PFS (12,8/12,5 months vs 8,3 months). Several adverse reactions were seen in the amifantamab arms compared to chemotherapy: SAE (all) 32-52% vs 20%. Adverse reactions ≥ 3: 72-92% vs 48%. The most frequent adverse events were bone marrow effects. An increased risk of VTE was observed for the amivantamb arms 10%-22% vs 5%. Treatment ceased in 10-22% vs 4% of patients. Combination therapy amiquantamab/chemotherapy is not approved. Amivantanamab monotherapy has not been approved by the EMA, for classical EGFR variants or MET variants (limited evidence) and therefore cannot be recommended as second line treatment for the classic EGFR flavors outside controlled trials. c. The study showed no improvement in PFS or OS by combination. Untreated patients with EGFR exon 19 deletion or L858R were randomised 1:1 in an open-label phase 3 study between standard osimertinib versus osimitinib plus platinum chemotherapy plus pemetrexed. Osimertinib in combination with chemotherapy 1st line is significantly better for PFS (25.5 months versus 16.7 months) and DOR (25.5 months vs 15.3 months). The most frequent adverse events were bone marrow effects: 71% (co-op arm) vs 24% (osimertinib arm). There was no difference in the degree of pneumonitis between the two arms (3-4%). An ESMO expert concensus report from 2022 (2) [5] recommends the combination osimertinib plus chemotherapy for patients with extra-cranial progression below osimertinib and concomitant stable asymptomatic cerebral metastases. The combination Osimertinib plus Chemotherapy is not EMA approved. At the DoLG meeting on 11/6 2024, the addition of chemotherapy to osimateinib in association with progression during osimitinib was discussed. It was decided, based on lack of evidence, not to recommend the combination as second line therapy. Therefore, it is not recommended to continue osimpinib in addition to chemotherapy, by",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Clinical guideline • Require DLCG progression on osimertinib. Dolg recommends, according to the NCCN guidelines, for selected patients who",
      "text": "immunotherapy in combination with EGFR TKI or sequentially (EGFR TKI after immunotherapy) results in serious adverse reactions, especially interstitial lung disease and liver involvement. Therefore, immunotherapy is not recommended in combination or as monotherapy to EGFR mutated NSCLC as the next line treatment after osimertinib. Immunotherapy combined with chemotherapy in combination, nor as the second line therapy for EGFR Muted NSclC, is available. Immune therapy combined with Chemotherapy is available with chemotherapy in 4 phase III studies investigating the efficacy of chemotherapy combined with PD-L1 inhibitor, 2nd line therapy after progression under EGFR TO: IMpower 150, Orient-31, CheckMate 722 and Keynote-789. No studies have shown a significantly improved ORR, PFS or OS by versus immunotherapy with versus versus placebo. In a subgroup analysis for 124 patients (78 patients, a history of EGFRTKI) with EGFR variants, no difference was found between athezolizumab plus platinum-dublet (AP) versus bevazizumab plus Platinum-dblet (BP). The study did not have power for these subgroup analyses. The combination ABP is recommended for chemotherapy alone or chemotherapy, but not for NCCN guidelines. Orient-31 (78) [1b] is a Chinese phase III, 3-armed study examining the efficacy of VEGF inhibitor plus PD-1 inhibitor plus chemotherapy for chemotherapy alone, but is not recommended by NCCN guideline. The study showed no significant difference in ORR (31% versus 27%), PFS (5.6 months versus 5.4 months) or OS (19.4 months  vs 15.9 months). Keynote-798 (LBA ASCO 2023) [1b] is a phase III, 2-arm study that examined the efficacy of pembrolizumab in combination with platinum-dubled chemotherapy against platinum-duplicated chemotherapy alone. The study's results were presented on ASCO 2023 for 492 patients. The trial found no significant differences in ORRS, PFS or OSS. The absence of efficacy was independent of PD-L1 status. Immunotherapy combined with EGFR TKI combination EGFR TDI plus immunotherapy has been studied in a series of Phase I/II studies (80-85) [3b]. All studies reported significant adverse events, especially interstitial lung disease/pneumoniatis, hepatic and gastrointestinal failure to therapy. Therefore, it is not recommended to combine immunotherapy with TKIs. Immunotherapy monotherapy for patients with EGFR TKI resistance is generally not recommended due to lack of evidence of efficacy. A Phase II study (86) [2b], studied the efficacy of pembrolizumab to TKI naïve patients with advanced EGFR mutated NSCLC, PD-L1 ≥ 1% (≥ 50 percent in 74% of patients). The study stopped early due to non-response. A randomised phase II study (87) [2b ] examined the effect of nivolumab against platinum-dubled chemotherapy in patients resistant to EGFR TDI. Hundred-two patients were included and the study showed significant improvement of PFS in favor of the chemotherapy arm (PFS 1.7 months (nivo) versus 5.6 months (chemo) independent of PD- L1 status. There was no difference in OS. IMMONOTARGET (39) [2a] study is a retrospective balance of immunotherapy monotherotherapy for patient with patients with locoprabongrabon. In patients with EGFR mutation, 3.5% PD-L1 ≥ 50% were associated with PD- L1 status: PD-l1 ≥ 1%: 2.8 months versus PD-P1< 1%: 1.7 months. Patients with ALK translocation and performance status 0-2(3) and systemic progression (after re-biopsy) may be offered 2rd to 3rd line treatment with lorlatinib or chemotherapy (A/B) Literature and evidence review Ad. Recommendation 12 All patients will in the long term develop resistance to ALK TKI (21) [1a]. The resistance mechanisms are classified according to whether they are due to a change in the ALK gene itself (on-target) or whether they result from a change of genes associated with the signal pathways independent of ALK (off-target), oravous transformation (88)[2b]. By progression of 3rd generation ALK-TKI at the same time, the same reservations should be taken as with progression under EGFR-TOK, see also for market abuse. SYSTEMIC PROGRESSION On-target resistance mechanisms On- target resistance mechanisms arise as both single mutations and as multiple mutations developed simultaneously (compound mutations) in the ALK gene. These acquired mutations are distinct for each ALK-TKI, also within the same generation of ALK‐TKI. Therefore, in selected cases, it can make sense of switching between the same-generation ALK/TKI in relation to resistance development (e.g. between brigatinib and alectinib (2nd generation TKI). However, it is essential to make a new genetic profiling of progressive metastases (alternative ctDNA) to identify resistance variants (21, 91)[1a, 2b]. Lorlatinib was developed to overcome the most frequent ALK resistance variants occurring during 1-2 generation ALKK-TI. On-target resistance mechanisms developed under lorlatinib are often characterised by the presence of multiple mutations (compundum variants) in ALK12. Therefore, patients should be offered inclusion in clinical trials (if available) or platinum-dubled chemotherapy (21)[2a]. at progression below lorlatinib. Off-target resistance mechanisms Good half of patients who develop resistance to 2nd generation ALK-TKI have no novel ALK variants in progression biopsy. Multiple off-target Resistance mechanisms that activate ALK independent signal pathways under ALK -TKI are described. Cases of response are available by adding crizotinib to continued lorlatinib at acquired MET amplification (21, 89)[1a, 2b]. Several studies investigating the effect of combined TKI are on the way. TKI patients may not be recommended outside clinical trials before further evidence is obtained. Histologic transformation Histological transformation Histhological transformation into small cell lung cancer and squamous carcinoma has been reported in both combination TKI. IMMUNTERAPI MONOTERAPI As for patients with EGFR mutations, there is no safe data to support the use of immunotherapy in patients with ALK fusion (92)[2b]. In a retrospective study of 42 incurable patients with NSCLC and ALK translocation who received immunotherapy without prior ALK-TKI, a very short PFS (2.3 months) was shown. In patients who received immune therapy without prior AlK-TI, it was 3.9 months, and in patients who were receiving immunotherapy after an ALK‐TKI it was 1.5 months (93)[2 b]. For most patients in the study there was no effect of immunotherapy monotherapy. REPOTRECTINIB Repotrectinib is a ROS1 directed treatment that is not yet EMA approved. In the phase 2 part of the TRIDENT-1 study, for patients with ROS1, the ORR was not previously treated with ROs1 TKI, 79% and mPFS was 35.7 months (94)[2b]. For patients treated with ROSE TKI previously, ORR 38% and mMFS was 9.0 months Intra-cranial ORR, for the previously treated patients, was 38%. Twenty-nine percent of patients experienced grade ≥ 3 AEs, the most frequent were anaemia (4%) and elevated creatine kinase (4%). The conclusion of the study was that repotrectedinib had an effect on ROS 1 translocated NSCLC independent of prior treatment with RO SOS1 TKI and independent of cerebral metastasisation. 14. Patients with RET translocation and performance status-1 (2) can be offered 2nd line with opinion.",
      "start_page": 25,
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "end_page": 28
    },
    {
      "heading": "SELPERCATINIB",
<<<<<<< HEAD
      "text": "I fase 1/2 studiet LIBRETTO-001 (95) [2b] blev selpercatinib undersøgt i 2. linje efter platinbaseret kemoterapi.\nHer blev der fundet en ORR på 64% og en median DOR på 17,5 mdr.\nSelpercatinib er, i en interim analyse af fase 3 studiet LIBRETTO-431, vurderet overfor platinbaseret\nkemoterapi +/- pembrolizumab i 1. linje hos patienter med avanceret RET-fusions aktiveret NSCLC (38)[1b].\nStudiet viser PFS: 24,8 mdr. versus 11,2 mdr. for selpercatnib versus platinbaseret kemoterapi +/-\npembrolizumab. ORR: 84% (selpercatinib) versus 65% (kemoterapi). Den intrakranielle ORR var 82%\n(selpercatinib) versus 58% (kemoterapi+/-immunterapi). Mere end en tredjedel af patienterne opnår komplet\nrespons, intrakranielt.\nDe hyppigste RET fusionspartnere var KIF5B (45% af patienterne) og CCDC6 (10% af patienterne). Den\nforlængede PFS ved selpercatinib sammenlignet med kemoterapi var uafhængig af fusionspartner.\nBivirkninger\nDe hyppigste bivirkninger ved selpercatinib var forhøjet ASAT/ALAT, hypertension, diarré, ødem, mundtørhed,\nforhøjet bilirubin og forlænget QTc interval. Alvorlig og livstruende pneumonitis kan forekomme. Hyppigheden\naf grad 2+ bivirkninger var hyppigere for selpercatinib end for kemoterapi (70% vs 57%).\nPRALSETINIB\nPralsetinib (96, 97)[2b] i anden linje efter svigt af platin-baseret kemoterapi betragtes foreløbigt som ligestillet\nmed selpercatinib i MR. Pralsetinib er undersøgt i fase 1/2 ARROW studiet med en ORR på 59% i anden linje\nefter platinbaseret kemoterapi. DOR var 22,3 måneder og PFS 13 måneder. Den intrakranielle responsrate var\nDe hyppigste bivirkninger var neutropeni (18%), hypertension (10%), øget kreatininkinase (9%) og lymfopeni\nPatienter ≥65 år\nBehandling med selpercatinib har vist effekt uafhængigt af alder og er generelt veltolereret hos patienter ≥65\når. Frekvensen af rapporterede bivirkninger er dog højere for stigende aldersgrupper; ≥65-74 år (58.0%), 75-\n84 år (62.5%) og ≥85 år (100.0%). Der er begrænsede data for patienter ≥75 år.\nPatienter med PS ≥ 2\nTil patienter med PS ≥ 2 anbefaler ESMO og NCCN guidelines, RET TKI. Det er vurderet, at data, fra EGFR\nog ALK studier, der har vist høj ORR, håndterbare bivirkninger og bedring af PS, kan extrapoleres til andre\nonkogene drivere (13)[5].\nPatienter i PS 0-2 blev inkluderet i LIBRETTO-001 og LIBRETTO-431 studierne, men meget få patienter var\nPS 2. Der foreligger ikke oplysninger om hvorvidt disse patienter har oplevet flere SAE.\nMedicinrådets anbefaling er kun til patienter med PS 0-1. DOLG har anmodet MR om at udvide indikation til\nogså at gælde patienter med PS 2.\n15. Patienter med aktiverende BRAF V600E og performance status 0-2(3) og tidligere\nbehandlet med platinbaseret kemoterapi og immunterapi (hvor relevant) kan\ntilbydes 2. (3.) linje behandling med dabrafenib plus trametinib, alternativt\nencorafenib plus binimetinib efter godkendelse af afdelingsledelsen / regionale\nmedicinudvalg (B)\nLitteratur og evidensgennemgang\nAd. anbefaling 15\nPatienter med aktiverende BRAF V600E tidligere behandlet med platinbaseret kemoterapi +/- immunterapi,\nkan tilbydes behandling med dabrafenib plus trametinib. Alternativt encorafenib plus binimetinib efter\ngodkendelse af afdelingsledelsen / regionale medicinudvalg.\nDabrafenib/Trametinib\nEffekten af dabrafenib plus trametinib i BRAF V600E muterede NSCLC patienter, der har modtaget tidligere\nminimum 1. linje behandling med platinbaseret kemoterapi, blev undersøgt i et fase 2 studie (kohorte B)\n(40)[2b]. ORR i studiet var 78,9% og DOR var 9,0 mdr. PFS var 9,7 mdr. Data for OS var endnu ikke modne.\nDe hyppigste grad 3-4 AEs var neutropeni (9%), hyponatriæmi (7%) og anæmi (5%).\nI en opdateret 5-års opgørelse (41)[2b] var 5-års PFS 10,2 mdr. og OS 18,2 mdr. for denne kohorte af\npatienter.\nÆldre patienter\nTil ældre patienter over 65 år kan ifølge produktresumeer startes behandling uden justering af dosis.\nPatienter med PS ≥ 2\nTil patienter med PS ≥ 2 anbefaler ESMO og NCCN guidelines, BRAF/MEK TKI. Det er vurderet, at data fra\nEGFR og ALK studier, der har vist høj ORR, håndterbare bivirkninger og bedring af PS, og kan derfor\nextrapoleres til andre onkogene drivere (13)[5].\n16. Patienter med aktiverende MET exon 14 skipping mutation eller MET\namplifikation og performance status 0-2 og tidligere behandlet med platinbaseret\nkemoterapi +/- immunterapi kan tilbydes 2. (3.) linje behandling med capmatinib\neller tepotenib efter godkendelse i det regionale medicinudvalg, alternativt\ncrizotinib (B /C)\nLitteratur og evidensgennemgang\nAd. anbefaling 16\nPatienter med patogene varianter i exon 14 i MET genet kan iht. ESMO-retningslinjer tilbydes platin-baseret\nkemoterapi +/- immunoterapi (13). Immunoterapi i monoterapi ikke anbefales som 1. linje, da der er ingen\nklinisk evidens ej heller i patienter med høj PD-L1 (39, 98, 99)[1a,2b]. Der er også begrænset data vedr.\nkemoterapi i de patienter, men i de enkelte retrospektive studier ORR var 33,3% og denne ligger på det niveau\nsom det elles kan forventes med kemoterapi. I henhold til NCCN Guidelines Version 1.2024 tilbydes\nCapmatinib, Crizotinib eller Tepotinib som første linjer eller senere (4)[1b].\nCrizotinib (FDA breakthrough designation 2018), Capmatinib (FDA 2020 og EMA 2022) og Tepotinib (FDA\n2021 og EMA 2022) er ikke behandlet af MR og der kan ansøges om tilladelse i det regionale medicinudvalg /\nafdelingsledelsen.\nBlandt MET exon14-positive patienter behandlet med Capmatinib i GEOMETRY, fase 2 studiet var ORR 41\n% for 69 forbehandlede patienter og 68 % i 28 behandlings- naive patienter; DOR var henholdsvis 9,7 mdr. og\n12,6 mdr. Intrakraniel ORR var 54%, baseret på 13 patienter med cerebrale metastaser. DOR var 9.7 mdr. og\n11.1 mdr., og PFS var 5.4 og 9.7 mdr., for henholdsvis forbehandlede patienter og behandlingsnaïve patienter\n(100)[1b].\nResultaterne fra, fase 2, VISION studiet med Tepotinib viste ORR 51,4%, DOR på 18 mdr., PFS på 11,2 mdr.\nog median OS på 19,6 mdr. For behandlingsnaive patienter var ORR 50.7% - 62.1% vs tidligere behandlede\npatienter ORR 43,4%- 47% . Tepotinib viste aktivitet intrakranielt: ORR >50%. (47, 101)[2b].\nCrizotinib i PROFIL 1001-studiet viste, at 18 NSCLC-patienter med METex14 opnåede ORR 32%, PFS 7,3\nmdr. og OS 20,5 mdr. (102)[2b].\nBivirkninger\nVISION studiet (Tepotinib) rapporterede bivirkninger, grad 3 eller derover, hos 34,8 % af patienterne, -perifer\nødem var den hyppigste (67,1 %).\nI GEOMETRY studiet (Capmatinib) rapporterede bivirkninger, grad 3 eller derover, hos 75% af patienter, -\nperifert ødem var den hyppigste (54% for tidligere behandlede patienter og 75% for behandlingsnaive\npatienter). (103)\nMET amplifikation\nTil patienter med MET amplifikation (CNV >10) kan der overvejes MET-TKI (103, 104).\n17. Patienter med aktiverende KRAS G12C og performance status 0-2 og tidligere\nbehandlet med platinbaseret kemoterapi og immunterapi (hvor relevant) kan\ntilbydes 2 (3). linje behandling med sotorasib eller adagrasib efter godkendelse i\nregionale medicinudvalg (A)\nLitteratur og evidensgennemgang\nAd. anbefaling 17\nBehandling med sotorasib til patienter med KRAS G12C muteret avanceret NSCLC, tidligere behandlet med\nplatinbaseret kemoterapi og immunterapi, blev undersøgt i CodeBreaK 100 studiet (105) [2b]. Fase 2 delen\nviste ORR 37,1%, DOR 11,1 mdr., PFS 6,8 mdr. og OS 12,5 mdr.\nMR har ikke godkendt behandling med sotorasib på baggrund af CodeBreaK 100.\nSotorasib\nI fase 3 studiet CodeBreaK 200 blev patienter med avanceret NSCLC og KRAS G12C mutation tidligere\nbehandlet med platinbaseret kemoterapi og immunterapi randomiseret til sotorasib eller docetaxel (106)[1b].\nORR var 28,1% og DOR 8,6 mdr. til fordel for sotorasib vs henholdsvis 13,2% og 6,8 mdr. for docetaxel. PFS\nvar signifikant øget for sotorasib 5,6 mdr. vs 4,5 mdr for docetaxel. Der var ikke signifikant forskel på OS (10,6\nmdr. vs 11,3 mdr. for hhv. sotorasib og docetaxel). Det kan skyldes at studiet ikke havde styrke til at\nundersøge OS og at 34% af patienterne i docetaxel-armen modtog KRAS G12C rettet behandling\nefterfølgende.\nBivirkninger\nBivirkningsprofilen var mere favorabel for sotorasib. De hyppigste AEs grad 3 eller højere i sotorasib gruppen\nvar diarre (12%), ALAT stigning (8%) og ASAT stigning (5%) vs neutropeni (12%), træthed (6%) og febril\nneutropeni (5%) i docetaxel gruppen.\nAdagrasib\nAdagrasib blev undersøgt i et fase 2 studie, hvor patienter med KRAS G12C muteret NSCLC tidligere\nbehandlet med både kemoterapi og immunterapi blev inkluderet (107)[2b]. ORR var 42,9% og DOR 8,5 mdr.\nPFS var 6,5 mdr og OS 12,6 mdr. De hyppigste AEs grad 3 eller højere var træthed (4,3%), kvalme (4,3%),\nALAT stigning (4,3%) og ASAT stigning (3,4%).\nBehandling med sotorasib er EMA godkendt som 2. (3.) linje behandling og kan overvejes efter godkendelse i\nregionale medicinudvalg.\n18. Patienter med aktiverende EGFR exon20 ins / ERBB2 (HER2) / NTRK variant og\nperformance status 0-1 kan overvejes tilbudt 2. linje behandling i henhold til EMA\ngodkendt behandling af matchet variant (amivantamab / trastuzumab-deruxtecan /\nentrectinib eller larotrectinib efter godkendelse i regionale medicinråd (A/B/B)\nLitteratur og evidensgennemgang\nAd. anbefaling 18\nEGFR exon20 insertion\nEGFR exon 20 insertion er en heterogen gruppe af varienter med varierende effekt af klassisk EGFR rettet TKI\n(55, 56). Samlet set udgør EGFR exon 20 ins 4-12 % af alle EGFR varianter. EGFR exon 20 insertion ændrer\nkinase domænet og begrænser bindingen af de vanlige EGFR TKIer. EGFR exon 20 ins varianterne er derfor\n(specielt near loop aminsyre-ændringerne: p.V769_D770 insX. (24,6%), p.D770_N771 insX (25,5%) og\np.H773_V774 insX (22,6%)) resistente overfor EGFR TKIer. Gruppen af patienter med EGFR exon 20\ninsertion varianter har en ringere prognose end patienter med de klassiske EGFR varianter.\na. EGFR exon 20 p.A763_Y764insX\nVarianten EGFR exon 20 p.A763_Y764insX (4-6% af alle EGFR exon 20 ins varianter) beliggende i helix\nregionen har en lignende funktion som de klassiske EGFR varianter og case rapports har vist effekt af EGFR\nTKIer, også osimertinib (58, 59) [4]. På den baggrund kan man overveje 2. linje osimertinib til denne variant\nunder tæt responsmonitorering, såfremt osimertinib ikke er anvendt i 1. linje.\nb. Øvrige EGFR exon 20 insertions varianter\nTil patienter med de øvrige EGFR exon 20 ins varianter kan man overveje ansøgning om enkelt-patient\ntilladelse i det regionale medicinudvalg til amivantamab efter progression på plan-dublet kemoterapi.\nAmivantamab er godkendt i EMA og anbefalet som 2. linje behandling efter platin-dublet kemoterapi i både\nESMO og NCCN guidelines. Amivantamab er afvist af MR.\nAmivantamab\nAmivantamab er et bispecifikt antistof som targeterer både EGFR og MET. Samtidig har antistoffet en\nimmunstimulerende effekt via Fc domænet og stimulerer rekrutteringen af effektor immunceller.\nAmivantamab er undersøgt som monoterapi i et fase 1 studie (CHRYSALIS) (108)[2b] og i kombination med\nkemoterapi i et fase III studie (PAPILLON) (109)[1b].\nCHRYSALIS studiet undersøgte bl.a. ORR for amivantamab monoterapi til patienter med EGFR exon 20 ins\nefter platin-dublet behandling. Studiet viste ORR 40%, PFS 8,3 måneder og DOR 11,1 måneder. De hyppigste\ngrad ≥ 3 bivirkninger (35%) var hypokaliæmi / udslæt / diare / neutropeni / lungeemboli.\nPAPILLON studiet er et randomiseret fase III studie, 1. linje behandling, der undersøger effekten af\nkombinationen amivantamab plus platin-dublet kemoterapi over for kemoterapi alene hos patienter med\navanceret EGFR exon 20 insertion muteret NSCLC. Overkrydsning til amivantamab monoterapi ved\nprogression var muligt. Studiet viste en signifikant forbedret ORR (73% vs 47%) og PFS (11,4 mdr versus 6,7\nmdr). Interim analysen for median OS viste ingen signifikant forskel (median ej nået versus 24,4 mdr). De\nhyppigste ≥grad 3 bivirkninger var neutropeni (33%) og udslæt 11%.\nHøjdosis osimertinib\nPOSITION20 studiet (110)[2b] er et fase II studie der undersøger effekten af højdosis osimertinib (160 mg) 2-\n3.linje til 25 patienter med EGFR exon 20 ins (exon 20 varianterne p.(A763-L777)). Studiet demonstrerede\nbegrænset effekt: ORR 28%, mPFS 6,8 mdr og mOS 15,2 mdr. Bivirkningerne var at sammenligne med vanlig\ndosis osimertinib.\nERBB2(HER2) mutation\nTil patienter med mutationer i ERBB2 genet kan man overveje ansøgning om enkelt-patient tilladelse i det\nregionale medicinudvalg til trastuzumab-deruxtecan (T-Dxd) efter progression på plan-dublet kemoterapi. T-\nDxd er godkendt i EMA og anbefalet som 2. linje behandling efter platin-dublet kemoterapi i både ESMO og\nNCCN guidelines. T-Dxd er endnu ikke behandlet af MR.\nERBB2 varianterne hos patienter med NSCLC, specielt adenocarcinomer, er associeret med en ringere\nprognose (60). ERBB2 varianterne består af 1) ERBB2 mutationer (1-3%), 2) ERBB2 amplifikation (2-22%)\neller 3) HER2 receptor overekspression (8-23%). Disse 3 grupper af varianter opstår sjældent sammen og\nHER2 overekspressionen er ikke associeret med ERBB2 amplifikationen. Derfor tyder meget på, at der ligger\nseparate molekylærbiologiske mekanismer bag overstående 3 grupper af varianter og skal dermed formentlig\nbehandles forskelligt (60). ERBB2 mutationer (1%) og ERBB2 amplifikationer (2%) er velkendte\nresistensmekanismer under behandlingen med EGFR TKI til patienter med EGFR muteret NSCLC. Der er set\nbegrænset effekt af HER2-rettede antistoffer (ORR 13%) til patienter med NSCLC og HER2 overekspression\nog kan derfor ikke sammenlignes med behandlingen af brystkræftpatienter med HER2 overekspression.\nPå baggrund af sparsom evidens vil denne anbefaling kun gennemgå behandlingsmuligheder for patienter\nmed ERBB2 mutation og kort berøre behandlingen af patienter med ERBB2 amplifikation.\nERBB2 mutation\nVarianterne opstår hyppigst i den intracellulære del af HER2 receptoren, med ERBB2 exon 20 insertion som\nden hyppigste variant (48%). Cerebrale metastaser opstår hos 47% af patienterne enten på\ndiagnosetidspunktet (19%) eller under behandlingsforløbet (28%) (60). Det er derfor vigtigt at udviklingen af\nnye behandlinger er med fokus på blod-hjerne barrieren og at patienterne screenes / monitoreres for udvikling\naf cerebrale metastaser.\nHER2 rettede antistoffer\nTo nyere fase II studier har undersøgt effekten af HER2 dobbelt antistof blokade (trastuzumab plus\npertuzumab) (111, 112) [2b] til patienter med HER2 muteret NSCLC.\nDet ene studie undersøgte effekten af HER2 dobbelt blokade til patienter med ERBB2 mutation eller\namplifikation og ingen yderligere behandlingsmuligheder. Der blev inkluderet 28 patienter og studiet viste\nrespons (defineret som PR plus SD>16 uger) på 11%. Det andet studie (112)[2b] undersøge affekten af HER2\ndobbelt blokade plus docetaxel til patienter NSCLC HER 2 muteret, 2.-3.- linje og PS 0-2. Der blev inkluderet\n45 patienter og studiet viste ORR 29%, DOR 11 mdr. og PFS 6,8 mdr. end velkendt for docetaxel monoterapi\n(ORR 7-10%) og PFS 2,3 mdr. Bivirkningerne grad ≥3: 64%, hyppigst neutropeni (33%) og diare (13%).\nHER2 receptor dobbelt-blokade har begrænset evidens for effekt og bør kun tilbydes i kliniske forsøg, hvis\noverhovedet.\nAntibody-drug conjugates (ADC)\nADCer er antistoffer rettet mod et overflade protein (receptor) som ofte er overudtrykt på kræftceller. Antistoffet\n(HER2 rettet) er tilkoblet kemoterapi (deruxtecan eller emtansine). Når antistoffet bindes til proteinet\ninternaliseret antistoffet og den tilkoblede kemoterapi frigives inde i cellen. På denne måde bliver\nkemoterapien målrettet de celler der udtrykker det protein som det anvendte antistof er rettet i mod.\nTrastuzumab-deruxtecan (T-Dxd)\nT-Dxd til patienter med HER2 muteret NSCLC er undersøgt i Destiny-Lung 01 og 02, fase II, studierne. I\nDestiny-Lung 01 studiet (113) [2b] blev der inkluderet 91 patienter med ERBB2 muteret NSCLC uden\nyderligere behandlingsmuligheder (tungt behandlede). Studiet viste: ORR 55%, DOR 9,3 mdr., PFS 8,2 mdr.\nog OS 17;8 mdr. Bivirkningerne grad ≥3 sås hos 46% af patienterne. To patienterne døde af interstitiel\nlungesygdom. Destiny-Lung 02 studiet [2b] undersøgte effekten og bivirkningerne under to forskellige doser af\nT-Dxd. Der blev inkluderet 152 patienter i studiet og det viste sammenlignelig effekt for de 2 dosisniveauer og\nfærre bivirkninger for det laveste dosisniveau (5,4 mg/kg); ORR 49% og DOR 16,8 mdr. Antallet af patienter\nder udviklede ≥ 3 grad bivirkninger var 38,6%. Interstitiel lungesygdom blev set hos 12,9% af patienterne (≥3,\nDer blev også set en effekt, dog mindre, hos patienter med HER2 overekspression; ORR 24,5% og PFS 5,4\nmdr.\nTrastuzumab-emtansine (T-DM1)\nDer er begrænset evidens for T-DM1 til patienter med NSCLC. Et fase II, basket studie (114)[2b] undersøgte\nT-DM1 til tidligere behandlede patienter med ERBB2 muteret og/eller amplificeret NSCLC. Der blev inkluderet\n49 patienter. ORR var 50% og 55% for henholdsvis ERBB2 muteret og amplificeret NSCLC. PFS var 5\nmåneder. Seks af patienterne havde tidligere modtaget EGFR TKI på baggrund af EGFR mutation plus\nERBB2 amplifikation. En tredjedel af disse patienter responderede på T-DM1 monoterapi. Bivirkningerne\n≥grad3: anæmi (2%) og trombocytopeni (2%) og febril neutropeni (2%).\nHER2-rettet TKI\nEn række studier har undersøgt / undersøger effekten af pan-HER2 TKIer: Afatinib (115), dacomitinib,\npoziotinib (116-118) og pyrotinib. Ingen af TKIerne er EMA godkendte til indikationen.\nAfatinib og pyrotinib studierne har vist begrænset effekt.\nZENITH20 studierne (116-118)[2b] undersøgte effekten af poziotinib til henholdsvis tidligere behandlede og\nikke-tidligere behandlede patienter med ERBB2 exon 20 insertion NSCLC. Studierne viste ORR 27% - 39%,\nDOR 5,5 mdr. og PFS 5,5 mdr. Exon 20 insertion varianten: G778_P780dupGSP så ud til at en bedre effekt i\n1. linje studiet (ORR 71%) (116)[2b].\nNTRK-fusion\nPatienter med NTRK-fusion kan tilbydes entrectinib eller larotrectinib i 2. linje efter progression på platinholdig\nkemoterapi efter godkendelse i det regionale medicinråd. Da NTRK-fusioner er sjældne er entrectinib og\nlarotrectinib undersøgt i basket trials inkluderende få patienter med NSCLC.\nEntrectinib\nEntrectinib er undersøgt i fase 1 og 2 basket-studierne ALKA-372, STARTRK-1 og STARTRK-2 og opdaterede\ndata fra disse studier er publiceret i 2022 (61)[2a]. Ud af 121 inkluderede patienter, havde 22 NSCLC. Af disse\nhavde 59,1% hjernemetastaser ved baseline. ORR var 64% med DOR på 19,9 mdr. og PFS på 14,9 mdr.\nDe hyppigste bivirkninger var smagsændringer (35,2%), diarre (31,1%), træthed (27,5%) og vægtøgning\nLarotrectinib\nLarotrectinib er undersøgt i NTRK-fusioneret NSCLC ved poolede resultater fra 2 fase 1/2 basket trials (20\npatienter) (62)[2a]. ORR var 73%, DOR var 33,9 mdr., PFS 35,4 mdr. og OS 40,7 mdr. 10/20 patienter havde\ncerebrale metastaser ved baseline og hos disse patienter var den intrakranielle ORR 63%.\nLarotrectinib beskrives generelt veltolereret og de fleste bivirkninger var grad 1-2. De hyppigste bivirkninger\nvar muskelsmerter (50%), svimmelhed (20%), ALAT/ASAT forhøjelse (15-20%), forstoppelse og kvalme\n(15%), samt vægtøgning (15%).\nÆldre patienter\nTKI behandling med entrectinib og larotrectinib har vist effekt uafhængigt af alder og er generelt veltolereret\nhos ældre patienter.\n19. Patienter med aktiverende øvrige sjældne EGFR varianter og performance status 0-2\nog systemisk progression og ingen øvrige targeterbare varianter kan tilbydes 2.\nlinje behandling med platin-baseret kemoterapi +/- immunterapi (D)\nLitteratur og evidensgennemgang\nAd. anbefaling 19\nDer findes ingen studier der omhandler håndteringen af progression under osimertinib til patienter med de\nøvrige sjældne varianter. Generelt skal man være opmærksom på at effekten af osimertinib til de sjældne\nEGFR varianter er begrænset i forhold til behandlingen af de klassiske EGFR varianter. Man bør derfor\noverveje at skifte behandling ved progression, uafhængigt af typen af progression, til platin-dublet kemoterapi\neller platin-dublet kemoterapi plus immunterapi i henhold til ESMO og NCCN guidelines. Monoterapi\nimmunterapi kan som hovedregel ikke anbefales, se under anbefaling 11.\nPatientværdier og – præferencer\nDer forventes ikke stor variation i patienternes præferencer da de anbefalede lægemidler har en bedre effekt\nog færre bivirkninger end kemoterapi.\nRationale\nAnbefalingernes ordlyd:\n\"Bør\": Anvendes når anbefalingen afspejler MR behandlingsvejledning.\n\"Overvej\": Anvendes når anbefalingen ikke afspejler MR behandlingsvejledning, men afspejler EMA's\nguidelines.\nBemærkninger og overvejelser\nDele af retningslinjens anbefalinger kan kun opnås ved forudgående godkendelse i regionernes\nmedicinudvalg. I DOLG er der oplevet en forskel i medicinudvalgenes vurderinger på tværs af regionerne.\nDesuden er der forskel mellem de enkelte afdelingers ressourcer til at gennemføre en ansøgningsproces.\nNedenstående guide (se bilag 2) og selve retningslinjen, i sin form, er et forsøg på at lette arbejdet for den\nenkelte behandlende læge/afdeling i ansøgningsprocessen og dermed sikre ens behandling af patienterne på\ntværs af regionerne.\nEnkelte anbefalinger omhandler MR ikke-godkendt medicin. Det vil, samlet set, årligt dreje sig om ganske få\npatienter da de patientgrupper som vil blive berørt af anbefalingen kun udgør 1-2% af den samlede population\naf lungekræftpatienter. Desuden vil tilbuddet om disse behandlinger foregå via en vurdering / tilladelse i de\nenkelte regioners medicinudvalg.",
=======
      "text": "In the Phase 1/2 study LIBERTTO-001 (95) [2b], selfpercatinib was studied in the 2nd line following platinum-based chemotherapy. Here, an ORR of 64% and a median DOR of 17.5 months was found in an interim analysis of Phase 3 study LIBRETTO-431, as assessed against platinum- based chemotherapy +/- pembrolizumab in the 1st line in patients with advanced RET fusion activated NSCLC (38)[1b]. The study shows PFS: 24.8 months versus 11.2 months for Selpercatnib versus platinum-borne chemotherapy+/pembolizumab. ORR: 84% (selpercatimatinib) versus 65% (chemotherapy). The intracranial ORR was 82% (sel Percatinib) vs 58% (chemotherapy+/immunotherapy). More than one third of patients achieve complete response, intracranial. The most frequent RETe fusion partners were KIF5B (45% of patients) compared to filgravefafabrifabris alone. The frequency of grade 2+ adverse events was considered provisionally equivalent to selfpercatinib in MR. Pralsetinib was studied in the phase 1/2 ARROW study with an ORR of 59% in the second line after platinum-based chemotherapy. DOR was 22.3 months and PFS 13 months. The intracranial response rate was the most frequent adverse events were neutropenia (18%), hypertension (10%), increased creatinine kinase (9%) and lymphopenia patients ≥ 65 years of age. Treatment with selfpercateinib has shown independent of age and is generally well tolerated in patients ≥65 years. Frequency of reported adverse reactions ≥ 75 years ≥ 75 < 75 years; ≥ 75. Patients with PS ≥ 2 For patients with PS > 2 recommend ESMO and NCCN guidelines, RET TKI. Data from EGFR and ALK studies that have demonstrated high ORR, manageable adverse reactions and improvement of PS can be estimated to be extrapolated to other oncogenic drivers (13)[5]. Patients in PS 0-2 were included in the LIBRETTO-001 and LIBERTTO-431 studies, but very few patients were PS 2. Patients with active BRAF V600E and performance status 0-2(3) and previously treated with platinum-based chemotherapy and immunotherapy (where applicable) are only available 2. (3.) line treatment with dabrafenib plus trametinib, alternatively encorafenib plus binimetinib after approval of the reserve management of the arm. The efficacy of dabrafenib plus trametinib in BRAF V600E mutated NSCLC patients who received prior minimum first line therapy with platinum-based chemotherapy was studied in a phase 2 study (cohorte B) (40)[2b]. ORR in the study was 78.9% and DOR was 9.0 months PFS was 9.7 months. Data for OS were not yet mature. The most frequent grade 3-4 AEs were neutropenia (9%), hyponatraemia (7%) and anaemia (5%). In an updated 5-year inventory (41)[2,b], 5-year PFS were 10.2 months and OS 18.2 months for this cohort of patients. Elderly patients For elderly patients over 65 years, according to product summaries, treatment without dose adjustment can be started. Patients with PS ≥ 2 For PS ≥ 2, patients with PS < 2 recommend ESMO and NCCN rev. Patients with activated MET exon 14 skipping mutation or MET amplification and performance status 0-2 and previously treated with platinum-based chemotherapy +/- immunotherapy can be offered 2. (3.) line treatment with capmatinib or tepotenib after approval in the regional medicine committee, alternatively crizotinib (B/C) literature and evidence review Ad. recommendation 16 Patients with pathogenic variants in exon14 in the MET gene can be provided with platinum based chemotherapy+/ immunotherapy (13). Immunotherapy in monotherapy is not recommended as first line, as there is no clinical evidence nor in patients with high PD-L1 (39, 98, 99)[1a,2b]. According to the NCCN Guidelines Version 1,2024, Capmatinib, Crizotinib, or Tepotinib are offered as first line or later (4)[1b]. Crizoninib (FDA breakthrough designation 2018), Capmataparin (Fda 2020 and EMA 2022) and Tepotinib ( FDA 2021 and ema 2022) are not treated by MR and permission can be applied for in the regional medical committee/ department management. Among MET exon14-positive patients treated with Capmatimatinib in GEOMETRY, Phase 2 the study was ORR 41 % for 69 pre-treated patients and 68 % for 28 treatment-naïve patients; DOR was 9.7 months and 12.6 months respectively, Intracranial ORR was 54%, based on 13 patients with cerebral metastases. DOR were 9.7 month and 11.1 months, and PFS was 5.4 months, respectively, for treated patients and treatment naïve subjects (100)[1b ]. Crizotinib in the PROFIL 1001 study showed that 18 NSCLC patients with METEX14 achieved ORR 32%, PFS 7.3 months and OS 20.5 months (102)[2b]. Adverse reactions The VISION study (Tepotinib) reported adverse reactions, grade 3 or above, in 34.8 percent of patients, peripheric oedema was the most common (67.1 %). In the GEOMETRY study (Capmatinib) reported adverse reactions grade 3 and above, 75% of patients with peripheral oedema were the most frequent (54% for previously treated patients and 75% for treatment-naïve patients). (103) MET amplification In patients with met amplification (CNV >10), MET-TKI (103, 104) can be considered. The phase 2 mutated advanced NSCLC, previously treated with platinum-based chemotherapy and immunotherapy, was studied in the CodeBreaK 100 study (105) [2b]. Phase 2 showed ORR 37,1%, DOR 11,1 months, PFS 6,8 months and OS 12,5 months MRI did not approve treatment with sotorasib based on CodeBreak 100. Sotorasub In Phase 3 the study CodeBraK 200 patients with advanced NsCLC and KRAS G12C mutation were previously treated by platinum-borne chemotherapy or immunotherapy randomised to sotoraseib or docetaxel (106)[1b]; ORR was 28.1% and DOR 8.6 months in favour of sotorasasib vs 13.2% and 6.8 months respectively for docetaxel. PFS was significantly increased for sotorarib 5.6 months vs 4.5 months for doceoxime. There was no significant difference between OS (10,6 months vs. vs. The most common AE grade 3 or higher in the sotorasib group were diarrhoea (12%), ALT increase (8%) and AST increase (5%) vs neutropenia (12%), fatigue (6%) and febrile neutropenic (5%) in the docetaxel group. Adarrasib Adarasib was studied in a phase 2 study where patients with KRAS G12C mutated NSCLC previously treated with both chemotherapy and immunotherapy were included (107)[2b]. ORR was 42.9% and DOR 8.5 months PFS was 6.5 months and OS 12.6 months. The most frequent AE grade three or higher were fatigue (4.3%), nausea (4.3%, ALT rise (4.3%) and AST (3.4%). 18. Patients with activating EGFR exon20 ins/ERBB2 (HER2) / NTRK variant and performance status 0-1 may be considered offered 2nd line treatment according to EMA approved treatment of matched variant (amivantamab / trastuzumab-deruxtecan / entrectinib or larotractinib after approval by Regional Medical Council (A/B/B) Literature and evidence review Ad. Recommendation 18 EGFRexon20 insertion EGFR Exon 20 insertion changes the kinase domain and limits the binding of the usual EGFR TKI (55.56). Overall, EGFR EXon 20 ins is 4-12 % of all EGFR variants. EGFR excellent 20 insertion alters the creatinine domain and reduces the bindings of the habitual EGFR TOR. The group of patients with EGFR exon 20 insertion variants has a lower prognosis than patients with the classic EGFR variants. a. EGFR Exon 20 p.A763_Y764insX Varianten EGFRexon 20 pp.A763_Y764insx (4-6% of all EGFR EXON 20 ins variants) located in the helix region have a similar function to the classic fondR variants and case reports have shown the effect of EGFR TKIer, also osimertinib (58.59) [4]. Against this background, the second line osimateinib for this variant can be considered during close response monitoring if osimertinib is not used in the first line. b. Other EGFR exit 20 insertions variants For patients with other EGFR examon 20 inns variants one can consider application for single-patient permission in the regional medicine committee for amiquantamab after progression on plan-dubled chemotherapy. Amifantamab is approved in EMA and recommended as second line treatment after platin-dive antivirabilities in both the reserve. The study showed 40%, PFS 8.3 months and DOR 11.1 months. The most common grade ≥ 3 adverse events (35%) was hypokalaemia / diarrhoea / neutropenia / pulmonary embolism. The PAPILLOON study is a randomised phase III study, 1st line treatment that examines the efficacy of the combination of amivanamab plus platinum-dubled chemotherapy for chemotherapy alone in patients with advanced EGFR exon 20 induction mutated NSCLCopeni. Crossing to amiquantamab monotherapy by progression was shown to be significantly improved (see section 4.4). The most frequent ≥ degree 3 adverse events were neutropenia (33%) and rash 11%. High dose osimertinib (exon 20 variants p.(A763-L777)) is a phase II study that examines the effect of high dose osimitinib (160 mg) 2- 3rd line to 25 patients with EGFR exon 20 ins (exone 20 variants pp. ((A763-L77/7)). The study demonstrated limited efficacy: ORR 28%, mPFS 6.8 months and mOS 15.2 months. Adverse reactions were compared to usual dose osumertinib. ERBB2(HER2) mutation For patients with mutations in the ERBB 2 gene, application for single-patent treatment after the platinum-duble chemotherapy in both trasuzumab-deruxtecan (T-Dxd) after progression on plan-double chemotherapy can be considered. The ERBB2 variant consists of 1) ERBB 2 mutations (1-3%), 2) ERBB2, amplification (2-22%) or 3) HER2 receptor overexpression (8-23%). These three groups of variants rarely occur together and HER2 overexpress is not associated with the ERBB2. Therefore, there is much evidence that separate molecular biological mechanisms exist behind superior 3 groups of variations and are therefore likely to have to be treated differently (60). ERBB2-mutations (1%) and ERBB2) amplifications (2%) are well known mechanisms of resistance during treatment with EGFR TKI in patients with EGFS mutated NSCLC. On the basis of sparsome evidence, this recommendation will only undergo treatment options for patients with ERBB1 mutation and briefly affect the treatment of patients with Erb2 augmentation. ErBB2 mutation Varians are most frequently developing in the intracellular part of the patient population. It is therefore important that the development of new phase II treatments is focused on the blood brain barrier and that patients are screened / monitored for development of cerebral metastases. HER2 directed antibodies Two newer phase II studies have examined the efficacy of HER2 double antibody blockade (traszumab plus perzumab) (111, 112) [2b] for patients with HER2 mutated NSCLC. One study examined the effect of HER2, double blockade in patients with ERBB2 mutation or amplification and no additional treatment options. 28 patients were included and the study showed responses (defined as PR plus SD>16 weeks) of 11%. 45 patients and the trial showed ORR 29%, DOR 11 months and PFS 6,8 months than well known for docetaxel monotherapy (OR 7-10%) and PFSS 2,3 months of evidence (less evidence ≥ 3 years) were included. The antibody is bound to the protein internalised antibody and the associated chemotherapy is released inside the cell. In this way, chemotherapy targets the cells expressing the protein in which the antibody used is directed. Traszumab-deruxtecan (T-Dxd) T-DXd for patients with HER2 mutated NSCLC has been studied in Destiny-Lung 01 and 02, Phase II, studies. In the Destiny- Lung 01 study (113) [2b], 91 patients with ERBB2 muted NSclC were included without further treatment (heavy treated). The study showed: ORR 55%, DOR 9.3 months, PFS 8.2 months and OS 17;8 months. The adverse reactions ≥ 3 were seen in 46% of patients. Two patients died from interstitial lung disease. Destininy-Lungs 02 studies [2b ] examined the efficacy and adverse reactions under two doses of TRR-2. The number of patients who developed ≥ 3 degree adverse events was 38.6%. Interstitial lung disease was seen in 12.9% of patients (≥ 3, An effect was also seen, however, less, in patients with HER2 overexpression; ORR 24.5% and PFS 5.4 months Traszumab emtansine (T-DM1) There was also limited evidence of T-DM1 in subjects with NSCLC. A phase II basket study (114)[2b] studied T-DM1 in previously treated patients with ERBB2 mutated and/or amplified NSclC. 49 patients were included. ORR was 50% and 55% for ERBB2, mutated, and augmented NS. PFS was 5 months respectively. Six patients had previously received EGFR TKI based on EGFR mutation plus ERBB2. The ZENITH20 studies (116-118)[2b] investigated the efficacy of poziotinib in previously treated and non-pre-treated patients with ERBB2 exon 20 induction NSCLC. The studies showed ORR 27% - 39%, DOR 5.5 months and PFS 5.5 months respectively. Exon 20 insertion variant: G778_P780dupGSP appeared to have a better effect in the first line study (ORR 71%) (116)[1b]. NTRK fusion Patients with NTRK fusion may be offered entrectinib or larotractinib in the second line after progression of platinum-containing chemotherapy after approval in the regional drug council. Since NTRCHK fusions are rare are entrectimatinib and larotinib studied in basket trials including few patients with NSclC. Entrectinib Entrecinib is studied in Phase 1 and 2 studies in Phase 2 years. Of these, 59.1% had brain metastases at baseline. ORR was 64% with DOR of 19.9 months and PFS of 14.9 months. The most frequent adverse reactions were taste changes (35.2%), diarrhoea (31.1%), fatigue (27,5%) and weight gain Larotrectinib Larotractinib was studied in NTRK-fused NSCLC by pooled results from 2 phase 1/2 basket trials (20 patients) (62)[2a]. ORR was 73%, DOR was 33.9 months, PFS 35.4 months and OS 40.7 months 10/20 patients had cerebral metastasis at baseline, and in these patients the intracranial ORR 63%. Larotractinib was generally well tolerated and most adverse events were Grade 1-2. In addition, treatment with platinum-based chemotherapy +/- immunotherapy (D) Literature and evidence review Ad. recommendation 19 There are no studies on the management of progression during osimertinib in patients with the other rare variants. In general, the effect of osimitinib in rare EGFR variants is limited in relation to the treatment of the classical EGFR variant. Therefore, it should be considered to change therapy at progression, regardless of the type of progression, to platinum-dubled chemotherapy or platinum-duplicated chemotherapy plus immunotherapy according to ESMO and NCCN guidelines. Monotherapy immunotherapy is not recommended as a rule, see under Recommendation 11. Patient values and preferences No significant variation in patients' preferences is expected as the recommended medicinal products have a better effect and less adverse effects than chemotherapy. Rationale recommendations: \"should be used when the recommendation reflects MR treatment guidance.\" A few recommendations deal with MRI non-approved medications.",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 28,
      "end_page": 36
    },
    {
<<<<<<< HEAD
      "heading": "4. Referencer",
      "text": "with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401. Oncologist. 2020;25(4):306-\ne618.\n67. Blaquier JB, Ortiz-Cuaran S, Ricciuti B, Mezquita L, Cardona AF, Recondo G. Tackling Osimertinib\nResistance in EGFR-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2023;29(18):3579-91.",
      "start_page": 39,
=======
      "heading": "4. References",
      "text": "67. Blaquier JB, Ortiz-Cuaran S, Ricciuti B, Mezquita L, Cardona AF, Recondo G. Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2023.29(18):3579-91.",
      "start_page": 41,
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "end_page": 41
    },
    {
      "heading": "5. Metode",
<<<<<<< HEAD
      "text": "Litteratursøgning\nLitteratursøgningen til denne kliniske retningslinje er foretaget 22 og 23 november 2023.\nDer er foretaget systematiske søgninger efter primærstudier på PubMed.\nDer blev søgt efter engelsksproget litteratur publiceret fra 2010 og frem til tidspunkt for selve søgn\nSøgeprotokoller og søgestrenge er blevet udfærdiget i samråd med RKKP.\nSøgeprotokoller med detaljeret søgestrategi kan findes i Bilag 1.\nLitteraturgennemgang\nAlle referencer udkommet af søgestrengene er gennemgået af forfatterne og sorteret på abstract-\nden prædefinerede patientgruppe og niveauet af evidens.\nESMO guidelines referencelister blev ligeledes gennemgået for at sikre at denne retningslinje som\nindeholdt ESMO guidelines referencer.\nFormulering af anbefalinger\nFormuleringen af anbefalingerne er blevet til i et samarbejde mellem de kliniske eksperter i\nretningslinjegruppen. Retningslinjegruppen har drøftet retningslinjen på et 2-dages internat og efte\npå flere virtuelle møder. Der har ikke været de store uenigheder i gruppen. Retningslinjen beskrive\neksisterende konsensus om behandlingsvalg for onkogen-dreven NSCLC i Danmark.\nInteressentinvolvering\nPatienter har ikke været involveret i udarbejdelsen af retningslinjen.\nInteressenter uden for DMCG'er har ikke været involveret i udarbejdelsen.\nHøring\nRetningslinjen har været i høring i DOLG og DALUPA. Retningslinjen blev rettet til ud fra høringen\ntilbagemeldinger.\nGodkendelse\nRetningslinjen er blevet reviewet af Overlæge Marianne Knap, Kræftafdelingen, AUH\nFaglig godkendelse: Retningslinjen er fagligt godkendt af DOLGs retningslinjeudvalg.\nAdministrativ godkendelse:\n1. juli 2024.\nningen\n-nivea\nm min\nerfølg\ner en\nns\nn.\nau efter\nnimum\ngende\nAnbefalinger, der udløser betydelig merudgift\nAnbefalingerne udløser ingen betydelig merudgift.\nForfattere og habilitet\nRetningslinjen er forfattet i tæt samarbejde mellem alle deltager af gruppen. Alle i gruppen har bidraget.\nNedenstående lister medlemmerne af gruppen og angiver ikke forfatterskabsrækkefølgen\n• Trine Heide Øllegaard (ingen interessekonflikter), onkologi, overlæge, Kræftafdelingen, Regionshospitalet\nGødstrup\n• Edyta Maria Urbanska (ingen interessekonflikter), onkologi, afdelingslæge, Kræftafdelingen, Rigshospitalet\n• Line Brøndum (ingen interessekonflikter), onkologi, afdelingslæge, Kræftafdelingen, Regionshospitalet\nGødstrup\n• Filippa Birte Gade Sundbye (ingen interessekonflikter), onkologi, H-læge, Klinisk Onkologisk Afdeling,\nSjællands Universitetshospital\nJf. Habilitetspolitikken henvises til deklaration via Lægemiddelstyrelsens hjemmeside for detaljerede\nsamarbejdsrelationer:\nvirksomheder/lister-over-tilknytning-til-virksomheder/apotekere,-laeger,-sygeplejersker-og-tandlaeger\nSamlet vurdering af habilitet for forfattergruppen: Hovedparten af forfatterne til denne retningslinje har haft\nsamarbejde med medicinalfirmaer i 2023. Samarbejdet omfatter forsøgsprotokoller, undervisning, rejser og\ndeltagelse i ekspertmøder i forskellige sammenhænge og med forskellige medicinalfirmaer. Det er formandens\nopfattelse og vurdering, at ovenstående samarbejdsrelationer ikke har indflydelse på retningslinjearbejdet.\nPlan for opdatering\nRetningslinjen vil blive opdateret en gang årligt. Opdateringen primo 2025 vil foregå i samarbejde mellem\novenstående medlemmer af gruppen.\nVersion af retningslinjeskabelon\nRetningslinjen er udarbejdet i version 9.3 af skabelonen.",
=======
      "text": "Literature search The literature search for this clinical guideline has been conducted 22 and 23 November 2023. Systematic searches for primary studies have been conducted in PubMed. Search protocols with detailed search strategy are available in Appendix 1. Literary review All references published by the search strings have been reviewed by the authors and sorted on the abstract pre-defined patient group and the level of evidence. The ESMO guideline reference lists were also reviewed to ensure that this guideline, which contained the ESMO guidelines, has not been the subject of major disagreements within the group. The Guideline describes the existing consensus on treatment choices for the onkogen drive NSCLC in Denmark. The guideline group has discussed the guideline at a 2-day international and efte at several virtual meetings. The approval guideline has been reviewed by the Chief Medical Officer Marianne Knap, the Cancer Department, AUH Professional approval: The guideline is technically approved by the DOLG Guideline Committee. Administrative approval: 1 July 2024. The cooperation includes experimental protocols, teaching, travel and participation in meetings of experts in different contexts and with various pharmaceutical companies. It is the President's view and assessment that the above cooperation relations do not affect the directional work. Plan for updating the guideline will be updated once a year. The update will take place at the beginning of 2025 in cooperation between the above members of the group. Version of the guideline template is prepared in version 9.3 of the template.",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 45,
      "end_page": 46
    },
    {
<<<<<<< HEAD
      "heading": "6. Monitorering",
      "text": "Udvikling af kvaliteten på dette område understøttes af viden fra Dansk Lunge Cancer Register (DLCR) i regi\naf Regionernes Kliniske Kvalitetsudviklingsprogram (RKKP), idet indikatorerne i databasen belyser de\nrelevante kliniske retningslinjer (indsæt fodnote til BEK).\nDen kliniske kvalitetsdatabases styregruppe har mandatet til at beslutte databasens indikatorsæt, herunder\nhvilke specifikke processer og resultater der monitoreres i databasen.\nDele af retningslinjen anbefaler behandlinger der endnu ikke er blevet vurderet i MR. Det foreslås derfor, at der\nopstilles indikatorer, der tillader dels 1) overvågning af regionernes tilladelser af anbefalingernes behandlinger\nog dels 2) behandlingernes effekt (f.eks. ORR, PFS og DOR).",
=======
      "heading": "6. Monitoring",
      "text": "The development of quality in this field is supported by knowledge from the Danish Lunge Cancer Register (DLCR) under the auspices of the Regional Clinical Quality Development Programme (RKKP), as the indicators in the database illustrate the relevant clinical guidelines (insert footnote to the BEK). The management group of the clinical quality database has the mandate to decide on the database's indicator sets, including which specific processes and results are monitored in the data base. Parts of the guideline recommend treatments that have not yet been assessed in MRI. It is therefore suggested that indicators be established that allow 1) monitoring of the regions' permissions for the treatment of recommendations and 2) the effectiveness of the treatments (e.g. ORR, PFS and DOR).",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 47,
      "end_page": 47
    },
    {
<<<<<<< HEAD
      "heading": "Bilag 1 – Søgestrategi",
      "text": "Titel (på retningslinje) (Pallierende onkologisk behandling ALK-dreven NSCLC )",
=======
      "heading": "Annex 1 • Search strategy",
      "text": "Title (on Guideline) (Palliende oncological treatment ALK-driven NSCLC)",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "DMCG",
<<<<<<< HEAD
      "text": "DOLG\nKontakt med metodespecialist Retningslinjesekretariatet",
=======
      "text": "DOLG Contact with methodological specialist Guideline Secretariat",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 48,
      "end_page": 48
    },
    {
<<<<<<< HEAD
      "heading": "Senest udfyldt",
      "text": "Afgrænsning af emne\nBaggrund Pallierende onkologisk behandling af ALK-dreven NSCLC –\ntargeteret behandling vs. platinbaseret kemoterapi eller vs. første\ngenerations TKI; er der forskel på effekt og forekomst af bivirkninger\nPublikationsdato (periode): 2010 til dags dato\nInklusions- og\nSprog: engelsk\neksklusionskriterier\nPublikationstype: Primærlitteratur, herunder RCT'er og kohortestudier\nhar interesse\nEmneord Populationen1 Intervention1 Sammenlignings Outcomes1\nintervention1\nEngelsk Lung cancer Platinum-based Overall response\nAlle tænkelige Thoracic cancer Alectinib Chemotherapy rate\nsøgeord bør Lung adenocarcinoma Brigatinib Best supportive Care Outcomes\nindsættes. Non-small-cell lung Lorlatinib Crizotinib Duration of\ncancer Crizotinib response\nNSCLC Ceritinib Overall survival\nStage IV Progression free\nOncogen-driven lung survival\ncancer Adverse events\nOncogen-addicted Side effects\nlung cancer Serious adverse\nLung tumor events\nMetastatic\nThoracic\nALK\n1 Se vejledning for Valg af tema for yderligere eksempler og beskrivelse af 'Population', 'Intervention',\n'Sammenlignings intervention' og 'Outcome'.\ne\nSøgning efter primærlitteratur (fx randomiserede kontrollerede forsøg)\nDato for søgning Ansvarlig for søgningen\nDatabaser (primær litteratur)\n(dd/mm/åååå) (navn(e))\nPubMed 23.11.2023 Hrønn",
=======
      "heading": "Last Completed",
      "text": "For example, if there is a difference in the effect and incidence of adverse reactions, then the date of publication (period): 2010 to day date Inclusion and Language: English exclusion criteria Publication type: Primary literature, including RCTs and cohort studies are of interest Subjects Population1 Intervention1 Comparisons Outcomes1 intervention1 English Lung cancer Platinum-based Overall response All imaginable Thoracic cancer Alectinib Chemotherapy rate keywords should be Lung adenocarcinoma Brigatinib Best supportive Care Outcomes inserted. Non-small-cell lung Lorlatinib Crizotinib Duration of cancer Crizotinib response NSCLC Celitinib Overall survival IV Progression free Oncogen-driven lung cancer Adfixe events after Oncogen-adrivation of the case of HIV-related Sides",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 48,
      "end_page": 49
    },
    {
<<<<<<< HEAD
      "heading": "Søgestrategier (kopieret ind)",
      "text": "For hver database der søges i, kopieres selve søgningen ind herunder.\nMedline (antal hits=78)\nSearch Add to builder Query Items found\n#5 Add 78\n#4 Add 298.212\n#3 Add 147.142\n#2 Add 88\n#1 Add 85.257\nSent On: Thu Nov 23 04:50:11 2023\nSearch: ((((Lung cancer OR Thoracic cancer OR Lung adenocarcinoma OR Non-small-cell lung cancer OR\nNSCLC OR Stage IV OR Oncogen-driven lung cancer OR Oncogen-addicted lung cancer OR Lung tumor OR\nMetastatic OR Thoracic OR ALK) AND ((observationalstudy[Filter] OR randomizedcontrolledtrial[Filter]) AND\n(2010/1/1:3000/12/12[pdat]) AND (english[Filter]))) AND ((Alectinib OR Brigatinib OR Lorlatinib OR Crizotinib\nOR Ceritinib) AND ((observationalstudy[Filter] OR randomizedcontrolledtrial[Filter]) AND\n(2010/1/1:3000/12/12[pdat]) AND (english[Filter]))) AND ((Platinum-based OR Chemotherapy OR Best\nsupportive Care OR Crizotinib) AND ((observationalstudy[Filter] OR randomizedcontrolledtrial[Filter]) AND\n(2010/1/1:3000/12/12[pdat]) AND (english[Filter]))) AND ((Overall response rate OR Outcomes OR Duration of\nresponse OR Overall survival OR Progression free survival OR Adverse events OR Side effects OR Serious\nadverse events) AND ((observationalstudy[Filter] OR randomizedcontrolledtrial[Filter]) AND\n(2010/1/1:3000/12/12[pdat]) AND (english[Filter])))) AND ((observationalstudy[Filter] OR\nrandomizedcontrolledtrial[Filter]) AND (2010/1/1:3000/12/12[pdat]) AND (english[Filter]))) Filters: Observational\nStudy, Randomized Controlled Trial, English, from 2010/1/1 - 3000/12/12\nKlinisk Retningsli\nTitel (på retnings",
=======
      "heading": "Search Strategies (Copied In)",
      "text": "(English[Piler])) AND (NSmal cell lung cancer OR NSCLC OR Stage IV OR ONCogen-driven lung cancer OR ONCOG-added lung cancer or Lung cancer OR Lung tumour OR Lungs adenocarccinoma OR Non-smal-cell lung cancer Or NSCLL C OR OR Stage III OR OR ONCEGEN-driven baby cancer  OR ONCA-add-addicated lung cancer AND OR Lung tum OR OR Metastatic OR Thoracic OR ALK) AND AND ((se observational study[Filer ] OR OR RRomizedcontrolledtrial[Filder]) AND OR OR OR OF ONCogenic-driven driving lung cancer O OR OR Wung cancer , lung cancer (2010/1/1:3000/12/12/12[pdat]) and (english or ALK OR ALC OR OR (( observational studio[Ftiler] OR OR OR OR OR OR Onogen-driving) AND AND (( Observation studio[FI] AND (Fil] ORF brand (AR still still still Still)), and still still! (! (R on).).). (!!! (HH===RR on! (P/!).).) (!) (P (PR)) (R) (S brand brand brand (P) (G!).)).). brand brandG!!). (P brand brand! (S) (B) (T) (H)) [!!)) (\"!!, (!).!!;) () (.).).!). brand) (and!! even even even) (). (SSS) [G//!!/! (G) (In))) SS) and/// (!/ (Stil).).),) (on!)).)) (English[Filter])) AND ((Overall response rate OR Outputs OR Duration of response OR Overall survival OR Progression free survival OR Reverse events OR Side effects OR Serious adverse events AND (Íobservationalstudy[Fileter] OR randomizedcontrolledtrial[Filitter]) AND [2010/1/1:3000/12/12[pdat]] AND (ENGLISH[FILTER]) AND ((observationstudy[Filder] OR marginalizedcontroledtrial[Filder]) And (2010/1/1/12/12 [pdatt]) MAN (english [Filters]) Filters: Observational Study, Randomized Controlled Trial, English, from 2010/1/1 to 3000/12 Clinical Correction Title (on directions])",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 49,
      "end_page": 50
    },
    {
      "heading": "DMCG",
<<<<<<< HEAD
      "text": "Kontakt med me",
=======
      "text": "Contact with me",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 50,
      "end_page": 50
    },
    {
<<<<<<< HEAD
      "heading": "Senest udfyldt",
      "text": "Baggrund\nInklusions- og\neksklusionskrite\nEmneord\nEngelsk\nAlle tænkelige\nsøgeord bør\nindsættes.\ninje │Kræft\nslinje) Pallieren\nDOLG\netodespecialist Retning\nAfg\nPalliere\ntargeter\ngenerat\nPublik\nSprog: e\nerier\nPublikat\nPopulationen2\nLung cancer OR\nThoracic cancer OR\nLung\nadenocarcinoma OR\nNon-small-cell lung\ncancer OR\nNSCLC OR\nStage IV OR\nOncogen-driven lun\ncancer OR\nOncogen-addicted\nlung cancer OR\nLung tumor OR\nMetastatic OR\nThoracic OR\nEGFR\nDLCG\nnde onkologisk behandling EGFR-dreven NSCLC\ngslinjesekretariatet\ngrænsning af emne\nende onkologisk behandling af EGFR-dreven NSCLC –\nret behandling vs. platinbaseret kemoterapi eller vs. første\ntions TKI; er der forskel på effekt og forekomst af bivirkninger\nkationsdato (periode): 2010 til dags dato\nengelsk\ntionstype: Primærlitteratur, herunder RCT'er\nIntervention Sammenlignings Outcomes1\nintervention\nOsimertinib Platinum-based OR Overall respons\nR OR Chemotherapy OR rate OR\nErlotinib OR Erlotinib OR Outcomes OR\nR Amivantama Afatinib OR Duration of\nb OR Gefitinib OR response OR\nGefitinib OR Best supportive Overall survival\nAfatinib OR Care OR\nMobocertinib Progression free\nng OR survival OR\nCheckpoint- Adverse events\ninhibitor OR OR\nPembrolizu Side effects OR\nmab OR Serious adverse\nAtezolizuma events\nb\nse\nl\ne\ns\nR\ne\nSøgning efter primærlitteratur (fx randomiserede kontrollerede forsøg)\nDato for søgning Ansvarlig for søgningen\nDatabaser (primær litteratur)\n(dd/mm/åååå) (navn(e))\nPubMed 22.11.2023 Hrønn\nSøgestrategier (kopieret ind)\nPubMed (antal hits=794)\nAdd to Items found\nSearch Query\nbuilder\n#5 Add 794\n#4 Add 298.212\n#3 Add 147.148\n#2 Add 1.238\n#1 Add 88.089\nSent On: Wed Nov 22 06:59:43 2023\nSearch: ((((Lung cancer OR Thoracic cancer OR Lung adenocarcinoma OR Non-small-cell lung cancer OR\nNSCLC OR Stage IV OR Oncogen-driven lung cancer OR Oncogen-addicted lung cancer * OR Lung tumor\nOR Metastatic OR Thoracic OR EGFR) AND ((randomizedcontrolledtrial[Filter]) AND\n(2010/1/1:3000/12/12[pdat]) AND (english[Filter]))) AND ((Platinum-based OR Chemotherapy OR Erlotinib OR\nAfatinib OR Gefitinib OR Best supportive Care) AND ((randomizedcontrolledtrial[Filter]) AND\n(2010/1/1:3000/12/12[pdat]) AND (english[Filter]))) AND ((Overall response rate OR Outcomes OR Duration of\nresponse OR Overall survival OR Progression free survival OR Adverse events OR Side effects OR Serious\nadverse events) AND ((randomizedcontrolledtrial[Filter]) AND (2010/1/1:3000/12/12[pdat]) AND\n(english[Filter]))) AND ((Osimertinib OR Erlotinib OR Amivantamab OR Gefitinib OR Afatinib OR Mobocertinib\nOR Checkpoint-inhibitor OR Pembrolizumab OR Atezolizumab) AND ((randomizedcontrolledtrial[Filter]) AND\n(2010/1/1:3000/12/12[pdat]) AND (english[Filter])))) AND ((randomizedcontrolledtrial[Filter]) AND\n(2010/1/1:3000/12/12[pdat]) AND (english[Filter])))\nTitel (på retningslinje) Pallierende onkologisk behandling RET-dreven NSCLC",
=======
      "heading": "Last Completed",
      "text": "HAR'OR OVER OUR OUR FA SURE FA OUR SURE OR OR SURE HAR SURE SURE BAR' OUR HOR' URE HOR OUR WAR' SURE COUR OR WOR' HIR' OR RIG SURE A SURE SA OUR RIGHT Lung cancer OR Thorac cancer OR Lung adenocarcinoma OR Non-small cell lung cancer OR NSCLC OR Stage IV OR Oncogen-driven Lun cancer or Oncogenic-addicated lung cancer or Lung tumour OR Metastatic OR Thoracic OR EGFR DDLCG-driven oncological treatment EGFR-driven NSclC Gsline classification of subject matter end oncologic treatment of EGFR drive NSLOR NS C Rung cancer OR Lung lung cancer  OR Lungs cancer OR Long lung cancer Or Lung Tung tum OR OR Thorlac OR OR SON lung cancer DLOC OR DLC OR DLCG-drive oncology treatment The H OR DLL-D R' drive NSG-DR drive RS- drive On On Oncology line line line definition substance substance substance Serious opposite (Serift) GAR/AR) Search for primary literature (e.g. randomised controlled trials) Date of search Responsible for searching Databases (primary literature) (dd/mm/yyyy) (name (e)) PubM 22.11.20223 Høn Search strategies (copied in) PubliM (number of hits=794) Add to items found Search Query builder #5 Add 794 #4 Add 298.212 #3 Add 147.184 #2 Add 1.238 #1 Add 88.089 Lung adenocarcinoma OR Non-small cell lung cancer OR NSCLC OR Stage IV OR OR Ocogen-driven lung cancer OR Ocogen driver lung cancer or OR Ocogenic-addic cancer cancer Or Lung cancer or Thorac cancer OR Lung can cancer  OR Lungs adenoccinoma OR Non-mal cell Lung Cancer OR NNSCLC or Sent On: Wed Nov 22 06:59 Nov 22 6:59 20:49 20:59 Lung-driving lung lung lung cancer R OR OR OR On-green lung lung life lung lung Lung lung cancer lung cancer cancer OR OR Inc lung lung organs cancer OR Oct cancer OR O O OO On On On OR Duration of response OR Overall survival OR Progression free survival OR Reverse events OR Side effects OR Serious adverse events AND ((randomizedcontrolledtrial[Filter]) AND (2010/1/3000/12/12[pdat] AND (English[Filiter]), AND (ÍOsimertinib OR Erlotinib OR Amivantamab OR Gefitinib OR Aflatinib OR Mobocertinib OR Checkpoint inhibitor OR Pembrolizumab OR Atezolizumab) AND [(randomizedcontroledtrial[Filder]) AND (2010/1/1:3000/12/12[pdate]) And (Eglish[Filer])) AND",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 50,
      "end_page": 51
    },
    {
      "heading": "DOLG",
<<<<<<< HEAD
      "text": "Klinisk Retningsli\nKontakt med me",
=======
      "text": "Clinical Directionli Contact with me",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 52,
      "end_page": 52
    },
    {
<<<<<<< HEAD
      "heading": "Senest udfyldt",
      "text": "Baggrund\nInklusions- og\neksklusionskrite\nEmneord\nEngelsk\nAlle tænkelige\nsøgeord bør\nindsættes.\nSøgning efter prim\n3 Se vejledning for\n'Sammenlignings in\ninje │Kræft\netodespecialist Retnings\nAfg\nPalliere\ntargeter\ngenerat\nPublik\nSprog: e\nerier\nPublikat\nhar inte\nPopulationen3\nLung cancer OR\nThoracic cancer OR\nLung adenocarcinoma\nOR\nNon-small-cell lung\ncancer OR\nNSCLC OR\nStage IV OR\nOncogen-driven lung\ncancer OR\nOncogen-addicted\nlung cancer OR\nLung tumor OR\nMetastatic OR\nThoracic OR\nRET\nmærlitteratur (fx randomisere\nValg af tema for yderligere\nntervention' og 'Outcome'.\nDLCG\nslinjesekretariatet\ngrænsning af emne\nende onkologisk behandling af RET-dreven NSCLC –\nret behandling vs. platinbaseret kemoterapi eller vs. første\ntions TKI; er der forskel på effekt og forekomst af bivirkninger\nkationsdato (periode): 2010 til dags dato\nengelsk\ntionstype: Primærlitteratur, herunder RCT'er og kohortestudier\neresse\nIntervention1 Sammenlignings Outcomes1\nintervention1\nPlatinum-based Overall response\nSelpercatinib Chemotherapy OR rate OR\na OR Best supportive Care Outcomes OR\nPralsetinib OR Duration of\nOR response OR\nCheckpoint- Overall survival\ninhibitor OR OR\nPembrolizum Progression free\nab OR survival OR\nAtezolizumab Adverse events\nOR\nSide effects OR\nSerious adverse\nevents\nede kontrollerede forsøg)\ne eksempler og beskrivelse af 'Population', 'Intervention',\ne\nDato for søgning Ansvarlig for søgningen\nDatabaser (primær litteratur)\n(dd/mm/åååå) (navn(e))\nPubMed 23.11.2023 Hrønn",
=======
      "heading": "Last Completed",
      "text": "Background Inclusion and exclusion criteria Subjects English All possible keywords should be inserted. Searching for prime 3 See guidance for 'Comparison inje Lung cancer OR Lung tumor OR Metastatic OR Thoracic OR RET literature (e.g. randomize Selection of theme for further tranvention and 'Outcome'. DLCG line Secretariat definition of topic end oncological treatment of RET-driven NSCLC • right treatment vs. platinum-based chemotherapy or vs. firsttions TKI; there is a difference in efficacy and incidence of adverse reactions (period): 2010 to day English type of treatment: Primary literature, including RCTs and cohort studies areesse Intervention1 Comparisons Outcomes1 Intervention1 Platinum-based Overall response Selpercatinib Chemperapy OR rate OR a OR Best supportive Care Outcome OR Pransetinib OR Duration OR Response OR Checkpoint- Overall survival inhibitor OR OR Pemønizum Progression free AB OR 20",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 52,
      "end_page": 53
    },
    {
<<<<<<< HEAD
      "heading": "Søgestrategier (kopieret ind)",
      "text": "PubMed (antal hits=59)\nItems found\nSearch Add to builder Query\n#5 Add 59\n#4 Add 298.212\n#3 Add 3.306\n#2 Add 638\n#1 Add 85.189\nThis message contains search results from the National Center for Biotechnology Information (NCBI) at the\nU.S. National Library of Medicine (NLM). Do not reply directly to this message\nSent On: Thu Nov 23 05:22:37 2023\nSearch: ((((Lung cancer OR Thoracic cancer OR Lung adenocarcinoma OR Non-small-cell lung cancer OR\nNSCLC OR Stage IV OR Oncogen-driven lung cancer OR Oncogen-addicted lung cancer OR Lung tumor OR\nMetastatic OR Thoracic OR RET) AND ((observationalstudy[Filter] OR randomizedcontrolledtrial[Filter]) AND\n(2010/1/1:3000/12/12[pdat]) AND (english[Filter]))) AND ((Selpercatinib OR Pralsetinib OR Checkpoint-\ninhibitor OR Pembrolizumab OR Atezolizumab) AND ((observationalstudy[Filter] OR\nrandomizedcontrolledtrial[Filter]) AND (2010/1/1:3000/12/12[pdat]) AND (english[Filter]))) AND ((Platinum-\nbased Chemotherapy OR Best supportive Care) AND ((observationalstudy[Filter] OR\nrandomizedcontrolledtrial[Filter]) AND (2010/1/1:3000/12/12[pdat]) AND (english[Filter]))) AND ((Overall\nresponse rate OR Outcomes OR Duration of response OR Overall survival OR Progression free survival OR\nAdverse events OR Side effects OR Serious adverse events) AND ((observationalstudy[Filter] OR\nrandomizedcontrolledtrial[Filter]) AND (2010/1/1:3000/12/12[pdat]) AND (english[Filter])))) AND\n((observationalstudy[Filter] OR randomizedcontrolledtrial[Filter]) AND (2010/1/1:3000/12/12[pdat]) AND\n(english[Filter]))) Filters: Observational Study, Randomized Controlled Trial, English, from 2010/1/1 -\nTitel (på retningslinje) Pallierende onkologisk behandling ROS1-dreven NSCLC",
=======
      "heading": "Search Strategies (Copied In)",
      "text": "PubMed (number of hits=59) Items found Search Add to builder Query #5 Add 59 #4 Add 298.212 #3 Add 3.306 #2 Add 638 #1 Add 85.189 This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). (Selpercatinib OR Prasetinib OR Checkpointin inhibitor OR Pemmin-addiced lung cancer OR Lung tumour or Lung tumor or Metastatic or Thoracacic OR RET) AND AND ((Selservable testy [Filter] OR OR randomizedcontrolled trial[Filer]) AND (2010/1/1/1/1/03/12/12/12[pdat]) AND (ÍSelevercatinib OR Pralsetinib OR Crockpointinstoror Or Pembrolizumab OR Atezolihost] AND (English[Filder])) AND OR OR REMOomizedcontroled trial[Filder] AND OR Pemppointinstouror OR P embroli lift OR Atezollizumab OR Ate level; 12/12/12 [pdatt]) and (Eglish[Fitter])). AND ( ((InSel Perercatinib oror OR Cher OR CheckPointinsororor OR OR OROR OR OROr OR OR Or OR OR or OR OR OR OR OrOROROR OROROR WOR OR OOR OR A PembBBB BOROR OROROrOROR or OROR orOROR OrOR OR ROR OR AT We We WeBororOR OR ANORORororOroror or OR Or O OR Ateboutonoror Or Or OR Atembelboror OR or Or Or OOR  OR A Atezonor OR A We We Atezizonor or Or Atezbolonononor  OR Atevon or OR Ates!!!' OR P P P Am OR A A Atemon or OR A Ateb!! ON Atez!!; OR!! OR - OR A at!!?!! II OR ON ON ON A Ates to OR) AND OR W Atez;) AND!!);) AND;) and OR), AND OGon on On On On OR, AND/!!) AND/ or OR AND!;) OG or OR AT!!onon!!.!! and OG AND!! or OR AND AND ON ON AND) AND);) and OR AND AND; or OR free survival OR Advise events OR Side effects OR Serious adverse events AND ((observational study [Filter] OR randomizedcontrolledtrial[Filtter]) AND (2010/1/1/3000/12/12[pdat])AND (English[Filiter]) And ((Observational Study[Fileter] or randomizedcontrolledtrial[Fitter] AND ( 2010/1/1/1 - Title (on guideline) Palliende oncological treatment ROS1 drive NSCLC",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "DMCG",
<<<<<<< HEAD
      "text": "DOLG\nKontakt med metodespecialist Retningslinjesekretariatet\nKlinisk Retningsli",
=======
      "text": "DOLG Contact with method specialist Guideline Secretariat Clinical direction",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 53,
      "end_page": 54
    },
    {
<<<<<<< HEAD
      "heading": "Senest udfyldt",
      "text": "Baggrund\nInklusions- og\neksklusionskrite\nEmneord\nEngelsk\nAlle tænkelige\nsøgeord bør\nindsættes.\nSøgning efter prim\nDatabaser (prim\nPubMed\nSøgestrategier (kop\n4 Se vejledning for\n'Sammenlignings in\ninje │Kræft\nAfg\nPalliere\ntargeter\ngenerat\nPublik\nSprog: e\nerier\nPublikat\nhar inte\nPopulationen4\nLung cancer OR\nThoracic cancer OR\nLung adenocarcinoma\nOR\nNon-small-cell lung\ncancer OR\nNSCLC OR\nStage IV OR\nOncogen-driven lung\ncancer OR\nOncogen-addicted\nlung cancer OR\nLung tumor OR\nMetastatic OR\nThoracic OR\nROS1 OR\nmærlitteratur (fx randomisere\nmær litteratur)\npieret ind)\nValg af tema for yderligere\nntervention' og 'Outcome'.\nDLCG\ngrænsning af emne\nende onkologisk behandling af ROS1-dreven NSCLC –\nret behandling vs. platinbaseret kemoterapi eller vs. første\ntions TKI; er der forskel på effekt og forekomst af bivirkninger\nkationsdato (periode): 2010 til dags dato\nengelsk\ntionstype: Primærlitteratur, herunder RCT'er og kohortestudier\neresse\nIntervention1 Sammenlignings Outcomes1\nintervention1\nPlatinum-based Overall response\nEntrectinib Chemotherapy OR rate OR\na OR Best supportive Care Outcomes OR\nCrizotinib OR OR Duration of\nRepotrectinib Crizotinib response OR\nOR Overall survival\nCeritinib OR OR\nLorlatinib OR Progression free\nCheckpoint- survival OR\ninhibitor OR Adverse events\nPembrolizum OR\nab OR Side effects OR\nAtezolizumab Serious adverse\nevents\nede kontrollerede forsøg)\nDato for søgning Ansvarlig for søgningen\n(dd/mm/åååå) (navn(e))\n23.11.2023 Hrønn\ne eksempler og beskrivelse af 'Population', 'Intervention',\ne\nFor hver database der søges i, kopieres selve søgningen ind herunder.",
=======
      "heading": "Last Completed",
      "text": "Background Inclusion and exclusion criteria Subjects English All possible keywords should be inserted. Searching for prime Databases (prim PubMed Search Strategies (cop 4 See Guide for 'Comparison inje DLCG definition of subject end oncologic treatment of ROS1-driven NSCLC • right treatment vs. platinum-based chemotherapy or vs. first readings TKI; there is a difference between effect and incidence of adverse reactions Contractinib Chemotherapy or rate OR a OR Best supportive Care Outcomes OR Crizotinib OR OR Duration of Repotrectinib Crizotinib Crizotinib response OR OR OR Overall survival Cerizotamine or OR OR Overall survival Cerapy OR OR Or Overall Cereapy Or rate OR OR A OR Best supported Care Outcomes OR CRTs and cohort studies Intervention1 Comparison of Outcome1 intervention1 Platinum-based Overall response Overall response Entrectinib Chemootherappy or rate OR A OR OR Best-supported Care Outcomes OR Criszotimat OR OR Or Corr Duration of ReporrepotrECinib Cribinib 1 Platum-founded based Overall response Over all survival Critinib OR Or Or Overall survival ceremon OR OR OR Lor Lor à a AB AB AB above above above A apart apart apart A above above ab Β  tomorrow ably  tomorrow'  tomorrow in â' , â company company company site site site , gar in H H Save Save Save company company Fair Fair Fair company company H H H R R R , '? H H IN IN IN , and Fin Fair Fair in H R • Market Market Market site site/ Fin???!!!??",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 54,
      "end_page": 55
    },
    {
<<<<<<< HEAD
      "heading": "PubMed (antal hits=129)",
      "text": "Items found\nSearch Add to builder Query\n#5 Add 129\n#4 Add 298.212\n#3 Add 3.371\n#2 Add 716\n#1 Add 85.082\nSent On: Thu Nov 23 04:14:35 2023\nSearch: ((((Lung cancer OR Thoracic cancer OR Lung adenocarcinoma OR Non-small-cell lung cancer OR\nNSCLC OR Stage IV OR Oncogen-driven lung cancer OR Oncogen-addicted lung cancer OR Lung tumor OR\nMetastatic OR Thoracic OR ROS1 OR) AND ((observationalstudy[Filter] OR randomizedcontrolledtrial[Filter])\nAND (2010/1/1:3000/12/12[pdat]) AND (english[Filter]))) AND ((Entrectinib OR Crizotinib OR Repotrectinib OR\nCeritinib OR Lorlatinib OR Checkpoint-inhibitor OR Pembrolizumab OR Atezolizumab) AND\n((observationalstudy[Filter] OR randomizedcontrolledtrial[Filter]) AND (2010/1/1:3000/12/12[pdat]) AND\n(english[Filter]))) AND ((Platinum-based Chemotherapy OR Best supportive Care OR Crizotinib) AND\n((observationalstudy[Filter] OR randomizedcontrolledtrial[Filter]) AND (2010/1/1:3000/12/12[pdat]) AND\n(english[Filter]))) AND ((Overall response rate OR Outcomes OR Duration of response OR Overall survival OR\nProgression free survival OR Adverse events OR Side effects OR Serious adverse events) AND\n((observationalstudy[Filter] OR randomizedcontrolledtrial[Filter]) AND (2010/1/1:3000/12/12[pdat]) AND\n(english[Filter])))) AND ((observationalstudy[Filter] OR randomizedcontrolledtrial[Filter]) AND\n(2010/1/1:3000/12/12[pdat]) AND (english[Filter]))) Filters: Observational Study, Randomized Controlled Trial,\nEnglish, from 2010/1/1 - 3000/12/12",
=======
      "heading": "PubMed (number of hits=129)",
      "text": "Items found Searchorect rent (Add to builder Query #5 Add 129 #4 Add 298.212 #3 Add 3.371 #2 Add 716 #1 Add 85.082 Lent On: Thu Nov 23 04:14:35 2023 Search: ((((LiLiLiLung cancer or Thoracic cancer or Tor Thorac cancer or Lung adenocarcinoma or Non-smal-cell lung cancer OR NSCLC OR Stage IV OR Oncogen-driven lung cancer or Oncogenic-addicated lung cancer  OR Lung cancer OR Lung tumor OR Metastatic OR Thoracacic OR ROS1 OR) AND ((observ observation study[Filer]) AND OR randomizedcontrolledtrial[Filder] OR OR OR (2010/1/1:3000/12/12[pdat]) AND (2010/1/1/12/12 [pdatt] AND (English [Filter]) and (([Ftiler]), AND ( ((Entrectet] OR] OR [F/12, brand brand brand H2 brand brand). Still Still Still! Re brand brand Still Still Saturday Saturday Saturday Bur brand brand Pursu brand brand! brand brand (\"! Saturday Saturday rent rent rent Saturday Saturday! rent rent! brand organisation!!! rent!! brand; brand brand [F to rent rent) Still! brand) Still Still) Still to brand brand (F to build) Still; brand;! brand (E brand brand;; brand)) Still [i!! [...]! brand!!;!!, brand; Still;!;;;! to build); brand brand);!! to buildings) Still) brand brand market!!) Still (F) Stil!! (F [...]!; brand);;!,!!G!!);;; to build), brand brand), brand) brand););; brand!))) brand;, brand!; industry;;,! brand); brand; (F brand brand/!! even) Still);! brand, brand (S brand brand) Organisation; brand (B!!.!!/!,.,!;,;; (E;!) (F!!), brand;., brand,!, etc;;.!; (S!!). brand brand to build; brand), manufacture;;) (2010/1/1:3000/12[pdat]) AND (English[Filter])) AND [Overall response rate OR Outputs OR Duration of response OR Overall survival OR Progression free survival OR Reverse events OR Side effects OR Serious adverse events AND ((observational study[FILTER] OR randomizedcontrolled trial[Fileter]]) AND (2010/1/1/3000/12/12[dat ]) AND AND (english [Filtter]) And ((Observational Study[Filitter] OR randomisedcontrolledtrial[Filder])AND ( 2010/1/3000/12 [pdatt]) MAN (ENGLISH[Filler]) Filters: Observational Study, Randomized Controlled Trial, English, 2010/1/12",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 55,
      "end_page": 55
    },
    {
<<<<<<< HEAD
      "heading": "Bilag 2 - Forkortelser og forklaringer",
      "text": "AE. Adverse events (bivirkninger).\nALK: Receptor der aktiverer JAK-STAT, RAS-MAPK, PI3K-mTOR and JUN signalvejene\nAmplifikation: En forøgelse i antallet af et gen, dvs. flere kopier af et gen i forhold til centromer. Det kan (men\nikke altid) medføre en forøgelse af det protein genet/DNA sekvensen koder for.\nBRAF: Intracellulært protein i MAPK signalvejen\nCNA: Copy number alterations: Variation i antallet af gener / sekvenser af DNA'et (der kan være flere eller\nfærre af de samme sekvenser / gener)\nDLCG/DLCR: Dansk lunge cancer gruppe (Reregister)\nDNA: Deoxyribonukleinsyre. Vores arvemasse. Et makromolekyle (2 meter langt hvis vi snor det ud),\ndobbeltstrenget kæde af nucleotider.\nDOLG: Dansk onkologisk lungekræft gruppe\nDOR: Duration of respons (median)\nEBUS: Endobronchial-ultrasound, altså ultralydsvejledt bronkoskopisk biopsi\nEGFR: En transmembran receptor (ERBB1), medlem af ERBB familen af receptor tyrosine kinaser der\naktiverer en række signalveje bl.a. MAPK and PI3K/AKT/mTOR signalvejene.\nEML4: Echinoderm microtubule-associated protein-like 4\nERBB2 (HER 2): En transmembran receptor, medlem af ERBB familen af receptor tyrosine kinaser,\ninkluderende EGFR, ERBB3, and ERBB4. Proteinet er associeret med aktivering af en række intracellulære\nsignalveje bl.a. MAPK and PI3K/AKT/mTOR signalvejene.\nExon: De dele af DNAet som er koder for proteiner Inkurabel: Ej muligt at behandle med kurativ intendenderet\nkirurgi eller kombineret kemoterapi-strålebehandling\nGNB: Grovnåls biopsi\nKRAS: Medlem af RAS familien af små GTPaser. De er involveret i MAPK and PI3K signalvejene.\nMdr.: Måneder\nMET: Receptor tyrosine kinase, også kaldet c-MET or hepatocyte growth factor (HGF) receptor. Receptoren er\ninvolveret i en række intracellulære signalveje bl.a. PI3K/AKT and RAS/RAF/MEK signalvejene.\nMR: Medicinrådet\nMutation: En hændelse i arvemassen som medfører en vedvarende ændring af et gen (en hændelse der\nmedfører at der opstår en variant af genet)\nNGS: Next Generation Sequencing. Med denne metode er det muligt at sekventere -kortlægge (læse) hele det\nmenneskelige genom på en gang.\nKlinisk Retningslinje │Kræft\nNSCLC: Non-small-cell-lungcancer\nORR: Overall response rate\nOS: Overall survival (median)\nPD: Progressive disease\nPFS: Progressionsfri overlevelse (median)\nRET: Receptor tyrosine kinase involveret i en række intracell\nsignalvejene.\nROS1:Ttransmembrane protein med intracellular tyrosin kina\nRNA: Ribonukleinsyre. Et stort molekyle som består af kæde\nTKI: Tyrosinkinase inhibitor\nVariant: Et gen der er ændret fra det \"normale\" gen\nlulære sign\nase aktivite\ner af nukleo\nnalveje bl.a\net.\notider, enke\na. PI3K\neltstre\nDLCG\nK/AKT og M\nenget.\nMAPK\nK\nBilag 3 - Vejledning i ansøgning om enkelt-patient ibrugtagning af\nEMA (og evt. FDA) godkendte (og tilgængelig i DK) dyre\nlægemidler som enten er afvist af eller ikke-vurderet i MR:\nFolketinget har opstillet 7 principper for prioritering på området for sygehuslægemidler. Det 7. princip handler\nom lægers ordinationsret, mulighed for at afvige fra MR afgørelser og mulighed for at for at tage højde for\npatienters individuelle behov. Læger har via \"det 7. princip\" mulighed for at tilbyde ikke-MR-godkendt\nbehandling, som lægen anser for den bedste, til den enkelte patient. Ibrugtagning af dyr sygehusmedicin skal\nofte godkendes af regionens medicinudvalg/lægemiddelkomite for at få refusion af udgiften.\nAfdelingsledelserne har ofte fastsat et max. beløb som grænse for hvornår udgifterne betales af afdelingen og\ndet regionale medicinudvalgt dermed ikke skal ansøges for refusion.\nRegionerne har hver især formuleret en vejledning til udøvelse af det 7. princip (kan findes på regionernes\nhjemmeside:\nlaegemidler-som-ikke-har-vaeret-behandlet-i-medicinraadet.pdf. Spørg evt. klinisk farmakologisk afdeling.\nStepvis overordnet procedure for disse ansøgninger\n1. Beslutning om ansøgning godkendes af afdelingsledelsen (og af patient) / task force (RH)\n2. Kontakt evt. Klinisk Farmakologisk Afdeling og søg hjælp til ansøgningen.\n3. Ansøgningsskema (findes på regionens hjemmeside) udfyldes (RH: Task force udfylder).\n4. I ansøgningen skal der lægges vægt på, hvorfor netop denne patient skal tilbydes behandlingen\n(effektdata / ingen yderligere behandlingsmuligheder / mindre bivirkningstung behandling / CNS\nmetastaser med bedre chance for effekt / komorbiditeter der vanskeliggør standardbehandling).\nEvidensen skal beskrives og beskriv gerne anbefalingen i ESMOs guidelines / EMA godkendelsen.\nAnsøgningen skal ikke begrundes med en uenighed med MR, men MR evt. vurdering af lægemidlet\nskal ofte anføres.\n5. Regionernes medicinudvalg mødes typisk en gang om ugen (kan variere mellem regioner)\n6. Send en mail til forpersonen for retningslinjeudvalget for at blive registret i DOLGs database for\nansøgninger om ibrugtagning af dyr sygehusmedicin. Mailen skal indeholde: 1) Hvilket præparat, 2)\nHvilken region 3) Ansøgning imødekommet ja/nej. 4) Begrundelse for afvisning (kort)",
=======
      "heading": "Annex 2 - Abbreviations and explanations",
      "text": "AE. Advertise events (side effects). ALK: Receptor that activates JAK-STAT, RAS-MAPK, PI3K-mTOR and JUN signal pathways Amplification: An increase in the number of a gene, i.e. several copies of a gen compared to centromer. It can (but not always) result in an increase of the protein gene/DNA sequence codes for. BRAF: Intracellular protein in the MAPK signal path CNA: Copy number altars: Variation in the numbers of genes/sequences of DNA (there may be several or fewer of the same sequences / genes) DLCG/DLCR: Danish lung cancer group (Reregister) DNA: Deoxyribonucleic acid. Our genetic mass. A macromolecule (2 meter long if we string it out), double-string chain of nuclotides. DOLG: Danish oncologic lung cancer Group DOR: Duration of response (median) EBUS: Endobronchial-ultrasabras, ie. MAPK and PI3K/AKT/mTOR signal paths. EML4: Echinoderm microtubule-associated protein-like 4 ERBB2 (HER 2): A transmembrane receptor, member of the ERBB family of receptor tyrosine kinases, including EGFR, ERBB3, and ERBB4. The protein is associated with activation of a number of intracellular signal pathways, including MAPK and PIP3K /AKTOR signal pathways. Exon: The parts of the DNA that are codes for proteins Incurable: Ej possible to treat with curative intended surgery or combined chemotherapy radiation therapy GNB: Grovenåls biopsy KRAS: Member of the RAS family of small GTPases. They are involved in Mapk and Pl3K signal routes. Mdr.: Months MET: Receptor tyrosinee kinasee, also called c-MET or hepatocyculate growth factor. With this method, it is possible to sequence -map (read) the whole human genome at once. Clinical Counselling NSCLC: Non-small-cell-lung cancer ORR: Overall response rate OS: Overall survival (median) PD: Progressive disease PFS: Progression-free survival (Median) RET: Receptor tyrosine kinase involved in a number of intracell signal pathways. ROS1: Transmembrane protein with intracellular tyrosine kina RNA: Ribonucleic acid. A large molecule consisting of chain TKI: Tyrosine kinase inhibitor Variant: A gene modified from the \"normal\" releaze signase activite is of nucleo nalveje e. e.g. an otider, enke a. PI3Keltstre DLCG K/ACT and M enget. MAPKKK K Patient Annex 3 - Instructions in application for single-pathisation of EMA (and possibly FDA) approved patients (a. Doctors need to be informed about the use of the standard form of medicine. Through the 7th principle, doctors have the option of offering non-MR-approved treatment which the doctor considers to be the best for the individual patient. The use of expensive hospital medicine must often be approved by the medical committee of the region to obtain reimbursement of the cost. The department managers have often set a maximum amount as a limit for when the costs are paid by the department and the regional medicine committee are therefore not to be claimed for reimbursement. The regions have each formulated a guide for the exercise of the 7rd principle (available on the regional website: Ask clinical pharmacological section if any. Stepvis's overall procedure for these applications is completed). 4. In the application, emphasis must be placed on why this particular patient should be offered the treatment (effect data / no additional treatment/smaller side effect) / CNS metastases with better chance of efficacy / comorbities which are needed to improve the quality of the medicine. The medical committees of the regions typically meet once a week (may vary between regions) 6. Send an email to the person in charge of the guideline committee to be registered in the Dolg database for applications for animal hospital medicine.",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 56,
      "end_page": 58
    },
    {
<<<<<<< HEAD
      "heading": "Vejledning i ansøgning om NPP/PAA/EAP",
      "text": "Lægemidler som ikke er tilgængelige i Danmark (kan ikke slås op i ProMedicin) kan i enkelte tilfælde være\ntilgængelige via de medicinalfirmaer som har udviklet lægemidlet (f.eks. repotrectinib) i såkaldte \"named-\npatient-programmer (NPP) / \"early-access-programmer\" (EAP) / Pre-Approval Access (PAA). Programmerne\ner ofte åbne i perioden fra et studie har vist lovende resultater til det er markedsført i den enkelte land (ofte i\nforbindelse med godkendelse af EMA). Hvis patienten inkluderes dækker firmaerne ofte udgifterne for\npatientens medicin, indtil det bliver markedsført.\nStepvis overordet procedure for disse ansøgninger\n1. Kontakt til medicinalfirmaet: På medicinalfirmaernes hjemmesider er der beskrevet de tilgængelige\npre-approval access programmer (PAA). Her er ansøgningsprocessen også beskrevet og links til\nrelevante kontaktpersoner.\n2. Overordnet beskrivelse af patient (efter accept fra patient) i henhold til studiets in- og\neksklusionskriterier sendes til firmaets kontaktperson.\n3. Firmaet godkender og initierer en ansøgningsproces\n4. Ansøgningen skal godkendes af din afdelingsledelse\n5. Der sendes ansøgning til firma via en formular udgivet af medicinalfirmaet (se deres hjemmeside)\n(Firmaernes responstid er kort –få dage). Det er en overkommelig opgave.\n6. Samtidig sendes ansøgning til lægemiddelstyrelsen (LMS) om udleveringstilladelse af lægemidlet til\npatienten, via formular på LMS hjemmeside (LMS responstid er meget kort, inden for 1-2 døgn). Det\ner en meget overkommelig opgave.\n7. Såfremt ansøgningen godkendes af medicinalfirma skal der indgås en kontrakt med medicinalfirmaet\n–den skal underskrives af dig og din afdelingsledelse. Kontrakten bør drøftes med regionens jurister –\nregionen har ofte et fast-track for disse kontrakter.)\n8. Kontakt hospitalets apotek som skal stå for modtagelse og håndtering af medicinen\n9. Udfærdig et behandlingsskema i sammenråd med medicinalfirma og apotek\n10. Regionerne har ofte udfærdiget en formular for skriftlig samtykke, som skal underskrives af patient og\nbehandlende læge.\n11. Vær opmærksom på skærpet indberetningspligt af bivirkninger til både firma og LMS\nOvenstående procedurer (fra initiering af processen og indtil patienten modtager medicinen) kan vare mellem\n2-4 uger, hvor flaskehalsene kan være udfærdigelse af behandlingsskema og fragt af medicin.",
=======
      "heading": "Guide to application for NPP/PAA/EAP",
      "text": "Medicines that are not available in Denmark (can not be posted in ProMedicin) may in some cases be available via the pharmaceutical companies that have developed the medicine (e.g. repotrectinib) in so-called \"named patient programs (NPP) / \"early-access programs\" (EAP) / Pre-Approval Access (PAA). The programs are often open during the period from one study have shown promising results until they are marketed in each country (often in connection with approval of EMA). If the patient is included, the company often covers the cost of the patient's medications until it is marketed. Stepwise superior procedure for these applications 1. Contact to the pharmaceutical firm: The pre-approval access programs (PAAs) are described on the websites of the pharmaceutical firms. Here, the application process is also described and links to relevant contact persons. 2. Overall description of the patients (after acceptance from patient) according to the study's inclusion criteria are sent to the company's contact person. 3. The company approves the drug agency's website. At the same time, an application is sent to the Danish Medicines Agency (LMS) for the dispensation of the medicinal product to the patient via the form on the LMS website (LMs response time is very short, within 1-2 days). It is a very affordable task. 7. If the application is approved by the pharmaceutical company, a contract must be signed with the pharmaceutical firm and your department management. The contract should be discussed with the region's lawyers. The region often has a fixed-track for these contracts.) 8. Contact the hospital's pharmacy which must be responsible for the reception and handling of the medicine 9. Complete a treatment form in consultation with pharmaceutical company and pharmacy 10. The regions have often drawn up a form of written consent to be signed by the patient and the treating doctor. 11. Pay attention to tightened reporting of adverse reactions to both the company and LMS Above procedures (from initiation of the process until the patient receives the medicine) may last between 2-4 weeks, where the bottlenecks may be the completion of treatment form and the shipment of medicines.",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 58,
      "end_page": 59
    },
    {
<<<<<<< HEAD
      "heading": "8. Om denne kliniske retningslinje",
      "text": "Denne kliniske retningslinje er udarbejdet i et samarbejde mellem Danske Multidisciplinære Cancer Grupper\n(DMCG.dk) og Regionernes Kliniske Kvalitetsudviklingsprogram (RKKP). Indsatsen med retningslinjer er\nforstærket i forbindelse med Kræftplan IV og har til formål at understøtte en evidensbaseret kræftindsats af høj\nog ensartet kvalitet i Danmark. Det faglige indhold er udformet og godkendt af den for sygdommen relevante\nDMCG. Sekretariatet for Kliniske Retningslinjer på Kræftområdet har foretaget en administrativ godkendelse af\nindholdet. Yderligere information om kliniske retningslinjer på kræftområdet kan findes på:\nRetningslinjen er målrettet klinisk arbejdende sundhedsprofessionelle i det danske sundhedsvæsen og\nindeholder systematisk udarbejdede udsagn, der kan bruges som beslutningsstøtte af fagpersoner og\npatienter, når de skal træffe beslutning om passende og korrekt sundhedsfaglig ydelse i specifikke kliniske\nsituationer.\nDe kliniske retningslinjer på kræftområdet har karakter af faglig rådgivning. Retningslinjerne er ikke juridisk\nbindende, og det vil altid være det faglige skøn i den konkrete kliniske situation, der er afgørende for\nbeslutningen om passende og korrekt sundhedsfaglig ydelse. Der er ingen garanti for et succesfuldt\nbehandlingsresultat, selvom sundhedspersoner følger anbefalingerne. I visse tilfælde kan en\nbehandlingsmetode med lavere evidensstyrke være at foretrække, fordi den passer bedre til patientens\nsituation.\nRetningslinjen indeholder, ud over de centrale anbefalinger (kapitel 1 – quick guide), en beskrivelse af\ngrundlaget for anbefalingerne – herunder den tilgrundliggende evidens (kapitel 3), referencer (kapitel 4) og\nanvendte metoder (kapitel 5).\nAnbefalinger mærket A baserer sig på stærkeste evidens og anbefalinger mærket D baserer sig på svageste\nevidens. Yderligere information om styrke- og evidensvurderingen, der er udarbejdet efter ”Oxford Centre for\nEvidence-Based Medicine Levels of Evidence and Grades of Recommendations”, findes her:\nGenerelle oplysninger om bl.a. patientpopulationen (kapitel 2) og retningslinjens tilblivelse (kapitel 5) er også\nbeskrevet i retningslinjen. Se indholdsfortegnelsen for sidehenvisning til de ønskede kapitler.\nRetningslinjeskabelonen er udarbejdet på baggrund af internationale kvalitetskrav til udvikling af kliniske\nretningslinjer som beskrevet af både AGREE II, GRADE og RIGHT.\nFor information om Sundhedsstyrelsens kræftpakker – beskrivelse af hele standardpatientforløbet med\nangivelse af krav til tidspunkter og indhold – se for det relevante sygdomsområde:\nDenne retningslinje er udarbejdet med økonomisk støtte fra Sundhedsstyrelsen (Kræftplan IV) og RKKP.",
=======
      "heading": "8. About this clinical guideline",
      "text": "This clinical guideline is based on a collaboration between Danish Multidisciplinary Cancer Groups (DMCG.dk) and the Regional Clinical Quality Development Programme (RKP). Recommendations marked A are based on strongest evidence and recommendations marked D based on weakest evidence. For further information on the strength and evidence assessment prepared after the Evidence-Based Medicine Levels of Evidence and Grades of Recommendations, see: General information on, inter alia, the patient population (Chapter 2) and the origin of the guideline (Chapter 5) is also described in the guideline. See the table of contents for page reference to the requested chapters. The guideline template has been prepared on the basis of international quality requirements for the development of clinical guidelines as described by both AGREE II, GRADE and RIGHT. For information about the Danish Health Authority's cancer packages, the description of the entire standard patient cycle, specifying the timing and content of the relevant disease area: This guideline has been drawn up with financial support from the Health Authority (Kreftplan IV) and RKP.",
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
      "start_page": 60,
      "end_page": 60
    },
    {
<<<<<<< HEAD
      "heading": "table under heading <5. Metode> (from previous page)",
      "text": "Row 1: Retningslinjen vil blive opdateret en gang årligt. Opdateringen primo 2025 vil foregå i samarbejde mellem\nRow 2: ovenstående medlemmer af gruppen.",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Titel (på retningslinje)|(Pallierende onkologisk behandling ALK-dreven NSCLC )\nRow 2: DMCG|DOLG\nRow 3: Kontakt med metodespecialist|Retningslinjesekretariatet\nRow 4: Senest udfyldt|",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Afgrænsning af emne|\nRow 2: Baggrund|Pallierende onkologisk behandling af ALK-dreven NSCLC – targeteret behandling vs. platinbaseret kemoterapi eller vs. første generations TKI; er der forskel på effekt og forekomst af bivirkninger\nRow 3: Inklusions- og eksklusionskriterier|Publikationsdato (periode): 2010 til dags dato Sprog: engelsk Publikationstype: Primærlitteratur, herunder RCT'er og kohortestudier har interesse",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Emneord|Populationen1|||Intervention1||Sammenlignings||Outcomes1\nRow 2: ||||||intervention1||\nRow 3: Engelsk Alle tænkelige søgeord bør indsættes.||Lung cancer||Alectinib Brigatinib Lorlatinib Crizotinib Ceritinib|Platinum-based Chemotherapy Best supportive Care Crizotinib|Platinum-based||Overall response rate Outcomes Duration of response Overall survival Progression free survival Adverse events Side effects Serious adverse events\nRow 4: ||Thoracic cancer||||Chemotherapy||\nRow 5: ||Lung adenocarcinoma||||Best supportive Care||\nRow 6: ||Non-small-cell lung||||Crizotinib||\nRow 7: ||cancer||||||\nRow 8: ||NSCLC||||||\nRow 9: ||Stage IV||||||\nRow 10: ||Oncogen-driven lung||||||\nRow 11: ||cancer||||||\nRow 12: ||Oncogen-addicted||||||\nRow 13: ||lung cancer||||||\nRow 14: ||Lung tumor||||||\nRow 15: ||Metastatic||||||\nRow 16: ||Thoracic||||||\nRow 17: ||ALK||||||\nRow 18: ||||||||",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: \nRow 2: Alectinib\nRow 3: Brigatinib\nRow 4: Lorlatinib\nRow 5: Crizotinib\nRow 6: Ceritinib\nRow 7: \nRow 8: ",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Overall response\nRow 2: rate\nRow 3: Outcomes\nRow 4: Duration of\nRow 5: response\nRow 6: Overall survival\nRow 7: Progression free\nRow 8: survival\nRow 9: Adverse events\nRow 10: Side effects\nRow 11: Serious adverse\nRow 12: events",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "table under heading <Senest udfyldt> (column 1)",
      "text": "Row 1: Titel (på retningslinje)\nRow 2: DMCG\nRow 3: Kontakt med metodespecialist\nRow 4: Senest udfyldt",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "table under heading <Senest udfyldt> (column 1)",
      "text": "Row 1: Baggrund\nRow 2: Inklusions- og eksklusionskriterier",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "table under heading <Senest udfyldt> (column 1)",
      "text": "Row 1: Emneord|Populationen1|||Intervention1||Sammenlignings||Outcomes1|Outcomes1\nRow 2: ||||||intervention1|||\nRow 3: Engelsk Alle tænkelige søgeord bør indsættes.||Lung cancer||Alectinib Brigatinib Lorlatinib Crizotinib Ceritinib|Platinum-based Chemotherapy Best supportive Care Crizotinib|Platinum-based||Overall response rate Outcomes Duration of response Overall survival Progression free survival Adverse events Side effects Serious adverse events|Overall response\nRow 4: ||Thoracic cancer||||Chemotherapy|||rate\nRow 5: ||Lung adenocarcinoma||||Best supportive Care|||Outcomes\nRow 6: ||Non-small-cell lung||||Crizotinib|||Duration of\nRow 7: ||cancer|||||||response\nRow 8: ||NSCLC|||||||Overall survival\nRow 9: ||Stage IV|||||||Progression free\nRow 10: ||Oncogen-driven lung|||||||survival\nRow 11: ||cancer|||||||Adverse events\nRow 12: ||Oncogen-addicted|||||||Side effects\nRow 13: ||lung cancer|||||||Serious adverse\nRow 14: ||Lung tumor|||||||events\nRow 15: ||Metastatic|||||||\nRow 16: ||Thoracic|||||||\nRow 17: ||ALK|||||||\nRow 18: |||||||||",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "table under heading <Senest udfyldt> (column 2)",
      "text": "Row 1: \nRow 2: \nRow 3: \nRow 4: \nRow 5: \nRow 6: \nRow 7: \nRow 8: \nRow 9: \nRow 10: \nRow 11: \nRow 12: ",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "table under heading <Søgestrategier (kopieret ind)>",
      "text": "Row 1: ||||||",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "table under heading <Søgestrategier (kopieret ind)>",
      "text": "Row 1: Databaser (primær litteratur)|Dato for søgning (dd/mm/åååå)|Ansvarlig for søgningen (navn(e))\nRow 2: PubMed|23.11.2023|Hrønn",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "table under heading <Søgestrategier (kopieret ind)>",
      "text": "Row 1: Search|Add to builder|Query|Items found\nRow 2: #5|Add||78\nRow 3: #4|Add||298.212\nRow 4: #3|Add||147.142\nRow 5: #2|Add||88\nRow 6: #1|Add||85.257",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Titel (på retningslinje)|Pallierende onkologisk behandling EGFR-dreven NSCLC\nRow 2: DMCG|DOLG\nRow 3: Kontakt med metodespecialist|Retningslinjesekretariatet\nRow 4: Senest udfyldt|",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Afgrænsning af emne|\nRow 2: Baggrund|Pallierende onkologisk behandling af EGFR-dreven NSCLC – targeteret behandling vs. platinbaseret kemoterapi eller vs. første generations TKI; er der forskel på effekt og forekomst af bivirkninger\nRow 3: Inklusions- og eksklusionskriterier|Publikationsdato (periode): 2010 til dags dato Sprog: engelsk Publikationstype: Primærlitteratur, herunder RCT'er",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Emneord|Populationen2|||Intervention||||Sammenlignings||Outcomes1\nRow 2: ||||||||intervention||\nRow 3: Engelsk Alle tænkelige søgeord bør indsættes.||Lung cancer OR|||Osimertinib||Platinum-based OR Chemotherapy OR Erlotinib OR Afatinib OR Gefitinib OR Best supportive Care|Platinum-based OR||Overall response rate OR Outcomes OR Duration of response OR Overall survival OR Progression free survival OR Adverse events OR Side effects OR Serious adverse events\nRow 4: ||Thoracic cancer OR|||OR|||Chemotherapy OR||\nRow 5: ||Lung|||Erlotinib OR|||Erlotinib OR||\nRow 6: ||adenocarcinoma OR|||Amivantama|||Afatinib OR||\nRow 7: ||Non-small-cell lung|||b OR|||Gefitinib OR||\nRow 8: ||cancer OR|||Gefitinib OR|||Best supportive||\nRow 9: ||NSCLC OR|||Afatinib OR|||Care||\nRow 10: ||Stage IV OR|||Mobocertinib|||||\nRow 11: ||Oncogen-driven lung|||OR|||||\nRow 12: ||cancer OR|||Checkpoint-|||||\nRow 13: ||Oncogen-addicted|||inhibitor OR|||||\nRow 14: ||lung cancer OR|||Pembrolizu|||||\nRow 15: ||Lung tumor OR|||mab OR|||||\nRow 16: ||Metastatic OR|||Atezolizuma|||||\nRow 17: ||Thoracic OR|||b|||||\nRow 18: ||EGFR||||||||\nRow 19: ||||||||||\nRow 20: ||||||||||",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Overall response\nRow 2: rate OR\nRow 3: Outcomes OR\nRow 4: Duration of\nRow 5: response OR\nRow 6: Overall survival\nRow 7: OR\nRow 8: Progression free\nRow 9: survival OR\nRow 10: Adverse events\nRow 11: OR\nRow 12: Side effects OR\nRow 13: Serious adverse\nRow 14: events",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "table under heading <Senest udfyldt> (column 2)",
      "text": "Row 1: Populationen2|Populationen2\nRow 2: |Lung cancer OR\nRow 3: |Thoracic cancer OR\nRow 4: |Lung\nRow 5: |adenocarcinoma OR\nRow 6: |Non-small-cell lung\nRow 7: |cancer OR\nRow 8: |NSCLC OR\nRow 9: |Stage IV OR\nRow 10: |Oncogen-driven lun\nRow 11: |cancer OR\nRow 12: |Oncogen-addicted\nRow 13: |lung cancer OR\nRow 14: |Lung tumor OR\nRow 15: |Metastatic OR\nRow 16: |Thoracic OR\nRow 17: |EGFR\nRow 18: |\nRow 19: |",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "table under heading <Senest udfyldt> (column 3)",
      "text": "Row 1: ||Intervention||||Sammenlignings||Outcomes1|Outcomes1\nRow 2: ||||||intervention|||\nRow 3: |||Osimertinib||Platinum-based OR Chemotherapy OR Erlotinib OR Afatinib OR Gefitinib OR Best supportive Care|Platinum-based OR||Overall respons rate OR Outcomes OR Duration of response OR Overall survival OR Progression free survival OR Adverse events OR Side effects OR Serious adverse events|Overall respons\nRow 4: R|||OR|||Chemotherapy OR|||rate OR\nRow 5: |||Erlotinib OR|||Erlotinib OR|||Outcomes OR\nRow 6: R|||Amivantama|||Afatinib OR|||Duration of\nRow 7: |||b OR|||Gefitinib OR|||response OR\nRow 8: |||Gefitinib OR|||Best supportive|||Overall survival\nRow 9: |||Afatinib OR|||Care|||OR\nRow 10: |||Mobocertinib||||||Progression free\nRow 11: ng|||OR||||||survival OR\nRow 12: |||Checkpoint-||||||Adverse events\nRow 13: |||inhibitor OR||||||OR\nRow 14: |||Pembrolizu||||||Side effects OR\nRow 15: |||mab OR||||||Serious adverse\nRow 16: |||Atezolizuma||||||events\nRow 17: |||b||||||\nRow 18: |||||||||\nRow 19: |||||||||\nRow 20: |||||||||",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "table under heading <Senest udfyldt> (column 4)",
      "text": "Row 1: e\nRow 2: \nRow 3: \nRow 4: \nRow 5: \nRow 6: \nRow 7: \nRow 8: e\nRow 9: \nRow 10: \nRow 11: \nRow 12: \nRow 13: e\nRow 14: ",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "table under heading <DOLG>",
      "text": "Row 1: Databaser (primær litteratur)|Dato for søgning (dd/mm/åååå)|Ansvarlig for søgningen (navn(e))\nRow 2: PubMed|22.11.2023|Hrønn",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "table under heading <DOLG>",
      "text": "Row 1: Search||Add to||Query||Items found\nRow 2: ||builder||||\nRow 3: #5|Add||||794|\nRow 4: #4|Add||||298.212|\nRow 5: #3|Add||||147.148|\nRow 6: #2|Add||||1.238|\nRow 7: #1|Add||||88.089|",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "table under heading <DOLG>",
      "text": "Row 1: Titel (på retningslinje)|Pallierende onkologisk behandling RET-dreven NSCLC\nRow 2: DMCG|DOLG",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Kontakt med metodespecialist|Retningslinjesekretariatet\nRow 2: Senest udfyldt|",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Afgrænsning af emne|\nRow 2: Baggrund|Pallierende onkologisk behandling af RET-dreven NSCLC – targeteret behandling vs. platinbaseret kemoterapi eller vs. første generations TKI; er der forskel på effekt og forekomst af bivirkninger\nRow 3: Inklusions- og eksklusionskriterier|Publikationsdato (periode): 2010 til dags dato Sprog: engelsk Publikationstype: Primærlitteratur, herunder RCT'er og kohortestudier har interesse",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Emneord|Populationen3|||Intervention1||Sammenlignings||Outcomes1\nRow 2: ||||||intervention1||\nRow 3: Engelsk Alle tænkelige søgeord bør indsættes.||Lung cancer OR||Selpercatinib OR Pralsetinib OR Checkpoint- inhibitor OR Pembrolizum ab OR Atezolizumab|Platinum-based Chemotherapy OR Best supportive Care OR|Platinum-based||Overall response rate OR Outcomes OR Duration of response OR Overall survival OR Progression free survival OR Adverse events OR Side effects OR Serious adverse events\nRow 4: ||Thoracic cancer OR||||Chemotherapy OR||\nRow 5: ||Lung adenocarcinoma||||Best supportive Care||\nRow 6: ||OR||||OR||\nRow 7: ||Non-small-cell lung||||||\nRow 8: ||cancer OR||||||\nRow 9: ||NSCLC OR||||||\nRow 10: ||Stage IV OR||||||\nRow 11: ||Oncogen-driven lung||||||\nRow 12: ||cancer OR||||||\nRow 13: ||Oncogen-addicted||||||\nRow 14: ||lung cancer OR||||||\nRow 15: ||Lung tumor OR||||||\nRow 16: ||Metastatic OR||||||\nRow 17: ||Thoracic OR||||||\nRow 18: ||RET||||||\nRow 19: ||||||||",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: \nRow 2: Selpercatinib\nRow 3: OR\nRow 4: Pralsetinib\nRow 5: OR\nRow 6: Checkpoint-\nRow 7: inhibitor OR\nRow 8: Pembrolizum\nRow 9: ab OR\nRow 10: Atezolizumab\nRow 11: \nRow 12: \nRow 13: \nRow 14: \nRow 15: ",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Overall response\nRow 2: rate OR\nRow 3: Outcomes OR\nRow 4: Duration of\nRow 5: response OR\nRow 6: Overall survival\nRow 7: OR\nRow 8: Progression free\nRow 9: survival OR\nRow 10: Adverse events\nRow 11: OR\nRow 12: Side effects OR\nRow 13: Serious adverse\nRow 14: events",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <Senest udfyldt> (column 2)",
      "text": "Row 1: Populationen3|Populationen3\nRow 2: |Lung cancer OR\nRow 3: |Thoracic cancer OR\nRow 4: |Lung adenocarcinoma\nRow 5: |OR\nRow 6: |Non-small-cell lung\nRow 7: |cancer OR\nRow 8: |NSCLC OR\nRow 9: |Stage IV OR\nRow 10: |Oncogen-driven lung\nRow 11: |cancer OR\nRow 12: |Oncogen-addicted\nRow 13: |lung cancer OR\nRow 14: |Lung tumor OR\nRow 15: |Metastatic OR\nRow 16: |Thoracic OR\nRow 17: |RET\nRow 18: |",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <Senest udfyldt> (column 3)",
      "text": "Row 1: ||Intervention1||Sammenlignings||Outcomes1|Outcomes1\nRow 2: ||||intervention1|||\nRow 3: ||Selpercatinib OR Pralsetinib OR Checkpoint- inhibitor OR Pembrolizum ab OR Atezolizumab|Platinum-based Chemotherapy OR Best supportive Care OR|Platinum-based||Overall response rate OR Outcomes OR Duration of response OR Overall survival OR Progression free survival OR Adverse events OR Side effects OR Serious adverse events|Overall response\nRow 4: ||||Chemotherapy OR|||rate OR\nRow 5: a||||Best supportive Care|||Outcomes OR\nRow 6: ||||OR|||Duration of\nRow 7: |||||||response OR\nRow 8: |||||||Overall survival\nRow 9: |||||||OR\nRow 10: |||||||Progression free\nRow 11: |||||||survival OR\nRow 12: |||||||Adverse events\nRow 13: |||||||OR\nRow 14: |||||||Side effects OR\nRow 15: |||||||Serious adverse\nRow 16: |||||||events\nRow 17: |||||||\nRow 18: |||||||\nRow 19: |||||||",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <Senest udfyldt> (column 4)",
      "text": "Row 1: \nRow 2: \nRow 3: \nRow 4: \nRow 5: \nRow 6: \nRow 7: \nRow 8: \nRow 9: \nRow 10: \nRow 11: \nRow 12: \nRow 13: \nRow 14: ",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "table under heading <DMCG>",
      "text": "Row 1: Databaser (primær litteratur)|Dato for søgning (dd/mm/åååå)|Ansvarlig for søgningen (navn(e))\nRow 2: PubMed|23.11.2023|Hrønn",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "table under heading <DMCG>",
      "text": "Row 1: Search|Add to builder|Query||Items found|\nRow 2: #5|Add||59||\nRow 3: #4|Add||298.212||\nRow 4: #3|Add||3.306||\nRow 5: #2|Add||638||\nRow 6: #1|Add||85.189||",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "table under heading <DMCG>",
      "text": "Row 1: Titel (på retningslinje)|Pallierende onkologisk behandling ROS1-dreven NSCLC\nRow 2: DMCG|DOLG\nRow 3: Kontakt med metodespecialist|Retningslinjesekretariatet",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Senest udfyldt|",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Afgrænsning af emne|\nRow 2: Baggrund|Pallierende onkologisk behandling af ROS1-dreven NSCLC – targeteret behandling vs. platinbaseret kemoterapi eller vs. første generations TKI; er der forskel på effekt og forekomst af bivirkninger\nRow 3: Inklusions- og eksklusionskriterier|Publikationsdato (periode): 2010 til dags dato Sprog: engelsk Publikationstype: Primærlitteratur, herunder RCT'er og kohortestudier har interesse",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Emneord|Populationen4|||Intervention1||Sammenlignings||Outcomes1\nRow 2: ||||||intervention1||\nRow 3: Engelsk Alle tænkelige søgeord bør indsættes.||Lung cancer OR||Entrectinib OR Crizotinib OR Repotrectinib OR Ceritinib OR Lorlatinib OR Checkpoint- inhibitor OR Pembrolizum ab OR Atezolizumab|Platinum-based Chemotherapy OR Best supportive Care OR Crizotinib|Platinum-based||Overall response rate OR Outcomes OR Duration of response OR Overall survival OR Progression free survival OR Adverse events OR Side effects OR Serious adverse events\nRow 4: ||Thoracic cancer OR||||Chemotherapy OR||\nRow 5: ||Lung adenocarcinoma||||Best supportive Care||\nRow 6: ||OR||||OR||\nRow 7: ||Non-small-cell lung||||Crizotinib||\nRow 8: ||cancer OR||||||\nRow 9: ||NSCLC OR||||||\nRow 10: ||Stage IV OR||||||\nRow 11: ||Oncogen-driven lung||||||\nRow 12: ||cancer OR||||||\nRow 13: ||Oncogen-addicted||||||\nRow 14: ||lung cancer OR||||||\nRow 15: ||Lung tumor OR||||||\nRow 16: ||Metastatic OR||||||\nRow 17: ||Thoracic OR||||||\nRow 18: ||ROS1 OR||||||\nRow 19: ||||||||",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: \nRow 2: Entrectinib\nRow 3: OR\nRow 4: Crizotinib OR\nRow 5: Repotrectinib\nRow 6: OR\nRow 7: Ceritinib OR\nRow 8: Lorlatinib OR\nRow 9: Checkpoint-\nRow 10: inhibitor OR\nRow 11: Pembrolizum\nRow 12: ab OR\nRow 13: Atezolizumab\nRow 14: \nRow 15: \nRow 16: ",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Overall response\nRow 2: rate OR\nRow 3: Outcomes OR\nRow 4: Duration of\nRow 5: response OR\nRow 6: Overall survival\nRow 7: OR\nRow 8: Progression free\nRow 9: survival OR\nRow 10: Adverse events\nRow 11: OR\nRow 12: Side effects OR\nRow 13: Serious adverse\nRow 14: events",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <Senest udfyldt>",
      "text": "Row 1: Databaser (primær litteratur)|Dato for søgning (dd/mm/åååå)|Ansvarlig for søgningen (navn(e))\nRow 2: PubMed|23.11.2023|Hrønn",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <Senest udfyldt> (column 2)",
      "text": "Row 1: Populationen4|Populationen4\nRow 2: |Lung cancer OR\nRow 3: |Thoracic cancer OR\nRow 4: |Lung adenocarcinoma\nRow 5: |OR\nRow 6: |Non-small-cell lung\nRow 7: |cancer OR\nRow 8: |NSCLC OR\nRow 9: |Stage IV OR\nRow 10: |Oncogen-driven lung\nRow 11: |cancer OR\nRow 12: |Oncogen-addicted\nRow 13: |lung cancer OR\nRow 14: |Lung tumor OR\nRow 15: |Metastatic OR\nRow 16: |Thoracic OR\nRow 17: |ROS1 OR\nRow 18: |",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <Senest udfyldt> (column 3)",
      "text": "Row 1: ||Intervention1||Sammenlignings||Outcomes1|Outcomes1\nRow 2: ||||intervention1|||\nRow 3: ||Entrectinib OR Crizotinib OR Repotrectinib OR Ceritinib OR Lorlatinib OR Checkpoint- inhibitor OR Pembrolizum ab OR Atezolizumab|Platinum-based Chemotherapy OR Best supportive Care OR Crizotinib|Platinum-based||Overall response rate OR Outcomes OR Duration of response OR Overall survival OR Progression free survival OR Adverse events OR Side effects OR Serious adverse events|Overall response\nRow 4: ||||Chemotherapy OR|||rate OR\nRow 5: a||||Best supportive Care|||Outcomes OR\nRow 6: ||||OR|||Duration of\nRow 7: ||||Crizotinib|||response OR\nRow 8: |||||||Overall survival\nRow 9: |||||||OR\nRow 10: |||||||Progression free\nRow 11: |||||||survival OR\nRow 12: |||||||Adverse events\nRow 13: |||||||OR\nRow 14: |||||||Side effects OR\nRow 15: |||||||Serious adverse\nRow 16: |||||||events\nRow 17: |||||||\nRow 18: |||||||\nRow 19: |||||||",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <Senest udfyldt> (column 3)",
      "text": "Row 1: Dato for søgning (dd/mm/åååå)\nRow 2: 23.11.2023",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <Senest udfyldt> (column 4)",
      "text": "Row 1: \nRow 2: \nRow 3: \nRow 4: \nRow 5: \nRow 6: \nRow 7: \nRow 8: \nRow 9: \nRow 10: \nRow 11: \nRow 12: \nRow 13: \nRow 14: ",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "table under heading <PubMed (antal hits=129)>",
      "text": "Row 1: Search|Add to builder|Query||Items found|\nRow 2: #5|Add||129||\nRow 3: #4|Add||298.212||\nRow 4: #3|Add||3.371||\nRow 5: #2|Add||716||\nRow 6: #1|Add||85.082||",
      "start_page": 55,
      "end_page": 55
    }
  ]
=======
      "heading": "(2010/1/1:3000/12/12[pdat]) AND (english[Filter]))) AND ((Platinum-based OR Chemotherapy OR Best",
      "text": "Table Title: (2010/1/1:3000/12/12[pdat]) AND (English[Filter])) AND, ((Platinum-based OR Chemotherapy OR Best Table contains the following columns: Search, Add to builder, Query, Items found Row 1: Search: #5, Add to buildinger: Add, and Items found: 78 Row 2: Search:#4, Add tobuilder: Ag, and items found: 299.212 Row 3: Search: ~3, Add to buildings: Add., and Points found: 147.142 Row 4: Search:~2, Add to builter: add, and Notes found: 88 Row 5: Search: *1, Add to store: Add; and Itemsfound: 8.5.57",
      "start_page": 49,
      "end_page": 49,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 6,
        "extraction_method": "pass_1_standard",
        "has_title": true,
        "page": 49,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": "(2010/1/1:3000/12/12[pdat]) AND (english[Filter]))) AND ((Platinum-based OR Chemotherapy OR Best",
        "narrative_length": 505
      }
    },
    {
      "heading": "All possible Thoracic cancer OR OR Chemotherapy OR rate OR",
      "text": "Table Title: All imaginable Thoracic cancer OR OR Chemotherapy OR rate OR Row 1 contains: 'Titel (on guideline) ', 'Palliende oncologiske behandling EGFR-driven NSCLC' Row 2 contain: 'DMCG', 'DOLG' Row 3 contains:'Contact with method specialist', \"Rightline secretariat' Row 4: Last completed",
      "start_page": 50,
      "end_page": 50,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 4,
        "extraction_method": "pass_2_relaxed",
        "has_title": true,
        "page": 50,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": "Alle tænkelige Thoracic cancer OR OR Chemotherapy OR rate OR",
        "narrative_length": 302
      }
    },
    {
      "heading": "Table 2 on page 51",
      "text": "Table contains the following columns: Search, Column_2, Add to, Column _4, Query, Column__6, Items found Row 1: Add to: builder Row 2: Search: #5, Column_2: Add, and Column_6: Search:#4, Column_2: 794 Row 3: Search:~4, Column__2: Add; and Column__6: 298,212 Row 4: Search:*3, Column_2; Add, & Column_6; 147.148 Row 5: Search; #2, Column_2. Add; And Column_6, 1.238 Row 6: Search.#1, Column_2/Add, and Columm_6",
      "start_page": 51,
      "end_page": 51,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 7,
        "extraction_method": "pass_1_standard",
        "has_title": false,
        "page": 51,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": null,
        "narrative_length": 398
      }
    },
    {
      "heading": "based Chemotherapy OR Best supportive Care) AND ((observationalstudy[Filter] OR",
      "text": "Table Title: based Chemotherapy OR Best supportive Care) AND ((observatory[Filter] OR Table contains the following columns: Search, Add to builder, Query, Column_4, Items found, Column_6 Row 1: Search: #5, Add to buildinger: Add, and Column_4: 59 Row 2: Search:#4, Add tobuilder: Agd, and Columne_4 3: Search: ~3, Add to builter: Ad, and Collumn__4: 3.306 Row 4: Search:~2, Add to Buildinger: Add, and Column_4",
      "start_page": 53,
      "end_page": 53,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 6,
        "extraction_method": "pass_1_standard",
        "has_title": true,
        "page": 53,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": "based Chemotherapy OR Best supportive Care) AND ((observationalstudy[Filter] OR",
        "narrative_length": 492
      }
    },
    {
      "heading": "(English [Filter])) AND ((Platinum-based Chemotherapy OR Best supportive Care OR Crizotinib) AND",
      "text": "Table Title: (English[Filter])) AND ((Platinum-based Chemotherapy OR Best supportive Care OR Crizotinib) AND Table contains the following columns: Search, Add to builder, Query, Column_4, Items found, Column_6 Row 1: Search: #5, Add tobuilder: Add, and Column_4: 129 Row 2: Search:#4, Add to buildinger: Agd, and Columm_4; Search: &amp; Column_4;: 298.212 Row 3: Search: *3, Add to buildings: Add; and Column _4: 3.371 Row 4: Search: #2, Add to builter: add, and Collumn__4: 716 Row 5: Search:~1, Add to storeer: Ad, and Column_4",
      "start_page": 55,
      "end_page": 55,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 6,
        "extraction_method": "pass_1_standard",
        "has_title": true,
        "page": 55,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": "(english[Filter]))) AND ((Platinum-based Chemotherapy OR Best supportive Care OR Crizotinib) AND",
        "narrative_length": 510
      }
    }
  ],
  "_table_detection_summary": {
    "total_tables_found": 5,
    "tables_by_page": {
      "49": [
        {
          "heading": "(2010/1/1:3000/12/12[pdat]) AND (english[Filter]))) AND ((Platinum-based OR Chemotherapy OR Best",
          "narrative_length": 505,
          "extraction_method": "pass_1_standard",
          "original_rows": 6,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ],
      "50": [
        {
          "heading": "Alle tænkelige Thoracic cancer OR OR Chemotherapy OR rate OR",
          "narrative_length": 302,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 4,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ],
      "51": [
        {
          "heading": "Table 2 on page 51",
          "narrative_length": 398,
          "extraction_method": "pass_1_standard",
          "original_rows": 7,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ],
      "53": [
        {
          "heading": "based Chemotherapy OR Best supportive Care) AND ((observationalstudy[Filter] OR",
          "narrative_length": 492,
          "extraction_method": "pass_1_standard",
          "original_rows": 6,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ],
      "55": [
        {
          "heading": "(english[Filter]))) AND ((Platinum-based Chemotherapy OR Best supportive Care OR Crizotinib) AND",
          "narrative_length": 510,
          "extraction_method": "pass_1_standard",
          "original_rows": 6,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ]
    },
    "table_storage_info": "Tables stored as individual chunks with hybrid metadata (narrative + structured)",
    "medical_table_insights": {
      "pricing_tables": 0,
      "dosage_tables": 0,
      "medication_tables": 0,
      "multi_pass_detection_summary": {
        "pass_1_standard": 4,
        "pass_2_relaxed": 1,
        "pass_3_medical": 0
      }
    }
  },
  "_translation_metadata": {
    "processing_timestamp": "2025-08-05T08:23:00.531935",
    "source_file": "dlcg_pal_onkogen_dreven_nsclc_v.1_admgodk_010724_cleaned.json",
    "detected_language": "da",
    "was_translation_needed": true,
    "tier_attempts": [
      {
        "tier": 1,
        "model_loaded": true,
        "model_name": "Helsinki-NLP/opus-mt-da-en",
        "processing_time_seconds": 217.82037,
        "chunks_found": true,
        "total_chunks": 37,
        "chunks_translated": 65,
        "chunks_english": 8,
        "table_chunks_processed": 7,
        "quality_scores": {
          "overall": 0.850810810810811,
          "english_quality": 0.8810810810810811,
          "length_score": 0.8054054054054054,
          "length_ratio": 0.847490471810664,
          "chunk_count": 37
        }
      }
    ],
    "final_tier_used": 1,
    "final_model_used": "Helsinki-NLP/opus-mt-da-en",
    "retranslation_occurred": false,
    "quality_comparison": {},
    "final_quality_scores": {
      "overall": 0.850810810810811,
      "english_quality": 0.8810810810810811,
      "length_score": 0.8054054054054054,
      "length_ratio": 0.847490471810664,
      "chunk_count": 37
    },
    "chunks_translated": 57,
    "chunks_preserved_english": 16,
    "table_chunks_processed": 7,
    "total_processing_time_seconds": 229.181186,
    "translation_strategy": "tier_1_first_with_conservative_chunking",
    "max_input_tokens": 512,
    "target_chunk_tokens": 350,
    "overlap_tokens": 50,
    "length_ratio_threshold": 0.7,
    "table_content_detected": 7,
    "tier_1_available": true,
    "tier_2_available": true,
    "translation_decision": "tier_1_sufficient",
    "processing_completed_timestamp": "2025-08-05T08:26:49.713126"
  }
>>>>>>> 3ec1c54ab451af6dd1a75ebf329c4080ff38dff7
}